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Mucins are high molecular weight glycoproteins and have critical functions in 
protecting epithelial cells from a myriad of cellular stress. However, mucins are 
expressed aberrantly under cancer conditions that allow tumors to progress and 
metastasize. Among many mucins, Mucin 4 (MUC4) serves as one of the top-
differentially expressed proteins in pancreatic cancer (PC), however, the precise 
mechanism responsible for its aberrant expression is still not clear. The evolving view of 
cancer as an energetic and growing ecosystem underlines an intricate interplay between 
cancer and its microenvironment. In spite of being recognized as one of the most critical 
oncogenic proteins in PC, MUC4 regulation in terms of micro-environmental stress has 
not been determined. In my dissertation research, I have investigated the role of PC 
microenvironment in the regulation of MUC4. From my studies, I have demonstrated that 
MUC4 stability is significantly reduced due to hypoxia-mediated induction of reactive 
oxygen species (ROS), which promotes autophagy by inhibiting pAkt/mTORC1 pathway. 
Hypoxia-mediated degradation of MUC4 provides necessary metabolites to ensure the 
survival of highly stressed PC cells.  
The longstanding model of cancer development involves that presence of 
cytokines can trigger chronic inflammation and impact tumor development, including PC. 
In addition to cytokines, bile acids (BA) facilitated chronic inflammation has shown to 
induce intestinal metaplasia, but their role in PC is still elusive. Elevated levels of BA 
(p<0.05) and its receptor were observed in pre-clinical and clinical serum samples from 
human and mouse models. Further, their significantly higher levels were also observed 
in pancreatic juice obtained from PC patients in comparison to controls, establishing the 
direct involvement of BA in PC pathobiology. It prompted us to hypothesize that BA have 
tumor promoting functions in PC. Mechanistically, the tumorigenic functions of BA were 
explained by BA-mediated upregulation of mRNA expression of MUC4, which, in turn, is 
primarily dependent on FXR-mediated activation of FAK. Activation of FXR further leads 
to an increase in the expression of c-Jun that binds to AP-1 motifs present on MUC4 
distal promoter region resulting in transcriptional upregulation of MUC4.  
In addition to the regulation, I have pinpointed the novel functional roles of MUC4 
in determining the fate of receptor tyrosine kinases (RTKs) in PC. Multiple studies have 
associated MUC4 overexpression with increased stability of RTKs for sustained 
proliferation; however, no studies have so far highlighted the implicated mechanism. I 
have demonstrated that the presence of MUC4 leads to increased internalization and 
recycling of EGFR and HER2 to the plasma membrane compared to MUC4 silenced PC 
cells. Mechanistically, the impact of MUC4 on RTKs trafficking is associated with its 
ability to regulate the activity of RAB5A, which is known to catalyze the rate-limiting step 
in receptor internalization. Lastly, I have detected the presence of MUC4 in pancreatic 
cancer associated stellate cells (PaSC). This was an unexpected finding given that 
MUC4 is normally expressed in the epithelial cells. These results indicate towards the 
involvement of MUC4 expression in determining the activation status of PaSC and 
provide us an additional strong rationale to therapeutically target MUC4. 
Altogether, in my dissertation research, I have elucidated the novel regulatory 
mechanisms and functions of MUC4 in PC condition. 
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CHAPTER I 
 
 INTRODUCTION 
 
CHAPTER IA: Regulation of Mucins by the microenvironmental stress of 
pancreatic cancer microenvironment 
CHAPTER IB: Regulation of MUC4 by the Bile acids (BA) in PC condition 
CHAPTER IC: Novel mechanism implicated in MUC4-mediated increase in the 
stability of EGFR-family members in PC 
 Parts of this chapter are driven from: 
1. Joshi S, Kumar S, Bafna S, Rachagani S, Jain M, Wagner KU et al. Genetically-
Engineered Mucins Mouse Models for Inflammation and Cancer. Cancer Metastasis 
Rev. 2015; 34(4): 593-609.  
 
2. Joshi S, Kumar S, Choudhary A, Ponnusamy MP, Batra SK. Altered Mucins (MUC) 
Trafficking in Benign and Malignant Conditions. Oncotarget. 2014; 5(17): 7272-84.  
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CHAPTER IA: Regulation of Mucins by the microenvironmental stress of 
pancreatic cancer microenvironment 
1A.1 An outline of mucins 
Mucins comprise a complex family of high molecular weight, membrane-bound or 
secreted O-glycoproteins which are produced by glandular and ductal epithelial cells. 
Mucins play critical roles in lubrication and protection of mucosa, renewal and 
differentiation of the epithelia, cell adhesion, and cellular signaling (Figure 1.A.1) (3-5). 
So far twenty one mucins have been recognized in human; out of them twelve are 
attached to the cell membrane, whereas the others are secreted by the cells [1]. 
Multiple studies have shown the diverse and tissue-specific expression profile of 
mucins. Nonetheless, a single tissue can express number of different mucins (Table 
1A.1). Qualitative and quantitative alterations in mucins have been correlated with the 
inflammatory, pre-neoplastic and neoplastic conditions (6-12). Studies have shown that 
some of the membrane-spanning mucins could serve as cell-surface receptors and 
facilitate signal transduction in response to external stimuli that lead to cell proliferation, 
differentiation, apoptosis, migration, and invasion of cancer cells (Figure 1A.1) (3, 13-
18). Despite ongoing research efforts, the structure and function of various mucins and 
mucin-mediated molecular mechanisms under normal and pathological conditions 
remain poorly understood. Moreover, the awry molecular and cellular mechanisms 
which lead to the aberrant expression and upregulation of various mucins under 
different disease conditions have not been completely comprehended (19).  
  
3 
 
Figures and Figure Legends 
Figure 1A.1. Illustration of the various physiological outcomes of aberrant mucin 
expression under normal and pathological conditions: A) Under normal 
physiological condition, mucins provide lubrication and protection to the epithelial 
surface by providing a physical barrier from a hostile environment. Mucins shield the 
epithelium against the action of various pathogens ( ), enzymes, gastric and bile 
acids.(20). Mucins are involved in the cellular differentiation of epithelial and immune 
cells. The expression of mucins in BM progenitors and mature immune cells are involved 
in hematopoiesis. B) Under pathological conditions, mucins are aberrantly expressed 
and undergo differential post-translational modifications. The mucous layer sequesters 
many molecules involved in inflammation, cellular migration and healing processes [1]. 
Mucins help transformed cells to avoid immune surveillance by masking epitopes of 
tumor antigens on the cell surface. Loss of apical-basolateral polarity allows interaction 
between membrane bound mucins (MBMs) and growth factor receptors such as receptor 
tyrosine kinases ( ), leading to sustained proliferative signaling cascades. Furthermore, 
the overexpression of mucins promotes cells motility, invasiveness and induces 
resistance to chemotherapeutic agents. Interestingly, the aberrant expression of 
secretory mucins (SMs) occasionally facilitates pathogenic infection, though the exact 
mechanism is still not understood. 
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Table 1A.1 Specific expression patterns of different mucins in the human body 
 
Mucin 
 
Normal Expression Pattern (3, 5, 12, 21) 
MUC1 
Expressed in the epithelial surfaces of the respiratory, female 
reproductive and gastrointestinal tracts as well as in the middle 
ear, salivary and mammary glands. 
MUC2 Expressed in the intestinal and colonic goblet cells. 
MUC3 
MUC3 is the product of two genes, MUC3A and MUC3B that are 
both present in the gastrointestinal epithelium. 
MUC4 
Mainly expressed by the epithelial surfaces of the eye, oral cavity, 
middle ear, lachrymal glands, salivary glands, mammary gland, 
prostate gland, stomach, colon, lung, trachea, and female 
reproductive tract. 
MUC5 
MUC5 is the product of two genes, MUC5AC and MUC5B. 
MUC5AC is primarily expressed in the tracheobronchial goblet 
cells and in the gastric epithelial cells, whereas MUC5B is present 
in the salivary, tracheobronchial and esophageal mucous glands 
as well as in the pancreatobiliary and endocervical epithelial cells. 
MUC6 
Detected in the gastric and duodenal mucous glands, 
pancreatobiliary and endocervical epithelial cells. 
MUC7 
Expressed in the oral cavity epithelial cells, minor salivary gland, 
and possibly in the respiratory tract. Its expression is also 
detected in the pancreas and bladder. 
MUC8 
Expressed in the airway and middle ear epithelial cells and male 
and female reproductive tracts. 
MUC10 
The expression pattern of MUC10 has not been determined to 
date. 
MUC11 
The MUC11 sequence is part of the very large VNTR domain of 
MUC12 and may represent a differential splice variant, which is 
normally expressed in the colon and stomach. Its expression has 
also been shown in the middle ear and lung epithelium. 
MUC12 Normally expressed by the stomach and colon. 
MUC13 
Highly expressed in the epithelium of the gastrointestinal and 
respiratory tracts. 
MUC15 
Expressed in the lung, mammary gland, hematopoietic tissues, 
gonads, and gastrointestinal tract. 
MUC16 
Expressed in the ocular surface, respiratory tract, and female 
reproductive tract epithelia. 
MUC17 
Expressed in the gastrointestinal tract with the highest expression 
in the duodenum and conjunctival epithelium. 
MUC19 
Mainly expressed in the mucosal cells of major salivary glands 
and the epithelial cells from corneal, conjunctival, lacrimal gland, 
middle ear and trachea. 
MUC20 
Highly expressed in the kidneys and moderately in the placenta, 
colon, lung, prostate, and liver. 
MUC21 
It is a novel transmembrane mucin and normally expressed in the 
lung, large intestine, thymus, and testis. 
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1A.2 Types of mucins 
Mucins consist of multiple domains (Figure 1A.2): Sperm protein enterokinase, and the 
agrin (SEA) domain involved in protein interactions; epidermal growth factor (EGF)-like 
domain that can act as a ligand; cysteine-rich dimerization or D domain (including D1, 
D2, D', D3 similar to vWD domains) for oligomerization; variable number of tandem 
repeats (VNTR or TRs) rich in serine (Ser), threonine (Thr), proline (Pro) (collectively 
known as S/T/P) for O-linked glycosylation; the hydrophobic transmembrane (TM) 
domain for cell surface localization and cytoplasmic tail (CT) to facilitate signal 
transduction (22, 23).  
1A.2.1 Membrane-bound mucins 
Muc1 was the first murine mucin gene identified and characterized (24). The human 
MUC1 gene and its murine ortholog is 87% identical in the non-TR domains and 74% in 
the promoter regions. The VNTR region of human MUC1 consists of 20 amino acid 
repeats, while that of mouse Muc1 has 20 to 21 amino acids each (25). The maximum 
similarity between Muc1 and MUC1 exist in their TM and cytoplasmic domains. The 
tissue-specific expression pattern of the mouse Muc1 is also very similar to that of its 
human counterpart (Table 1A.2). Similarities in the sequence and expression pattern of 
human MUC1 and murine Muc1 are indicative of their similarities in function(s), 
interacting partners, mode of internalization, sub-cellular localization and routing to the 
plasma membrane during their recycling or after their synthesis. 
Muc4, like its human ortholog, is encoded by 25 exons (26). It consists of at least 
20 TRs of 124-126 amino acids each, whereas human MUC4 has 146-500 repeats of 16 
amino acid residues. The Ser/Thr region located upstream of TRs in murine Muc4 is 
significantly different and much smaller in size (63 amino acids) as compared to human 
sequence (951 amino acids) (26). Interestingly, 12 potential N-glycosylation sites, which 
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are downstream of TR region, are perfectly conserved in Muc4 and MUC4 and both 
orthologs exhibit similar expression patterns (26). 
Two large exons of mouse Muc16 at the N terminal region have sequence 
homology to exons 1 and 3 of human MUC16. Murine Muc16 possesses only one SEA 
domain in its extracellular (EC) region, whereas the number of SEA domains in the EC 
region of human MUC16 goes upto 60. Muc16 also shares the similar characteristic 
repeat structure of human MUC16 along with 66% homology in their C-terminus (27). 
The overall expression pattern of Muc16 and MUC16 is similar (Table 1A.2). Both of 
them are expressed by the ovarian surface epithelial cells, though their cellular 
localization is different. Human MUC16 is present on the cell surface and soluble fraction 
due to its shedding from the cell membrane, whereas murine Muc16 has shown to be 
secreted by MOVCAR ovarian cells (28). 
Other membrane-bound murine mucins including Muc13, Muc15, Muc3, Muc20, 
and Muc21 are either partially characterized or have not been characterized yet. The C-
terminus of Muc13 shows 52% identity to the human MUC13 ortholog. However, the N-
terminus of the Muc13 mucins domain shows a significant divergence from the human 
MUC13, as the murine form has a nearly perfect repeat structure in contrast to the 
human form which retains many degenerate repeats (29, 30). The carboxyl terminal of 
MUC17 was found to be 59.6% similar to murine Muc3, while there is only 46.4% amino 
acid sequence similarity between murine and human MUC3. MUC17 has 52% similarity 
with the first EGF domain and 63.5% similarity with the second EGF domain of Muc3. 
Altogether, there is greater similarity between Muc3 and MUC17 compared to Muc3 and 
MUC3, suggesting that MUC17 is the ortholog of Muc3 (31). Comparison of the amino 
acid sequences of human and mouse Muc20 showed 48% overall similarity (32). Both 
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mucins comprise several hydrophobic domains and three mucin-like repeats of 18 amino 
acid residues in their N-terminal regions, and are expressed predominantly in kidney. 
1A.2.2 Gel-forming mucins 
Gel-forming mucins are the main components of mucus and consist of multiple 
“cysteine-rich” vWF C and vWF D domains in the flanking region of the mucin-like 
Thr/Ser-rich repeats and C-terminal cystine knot-like domain (CTCK) (33), which allow 
them to oligomerize by forming intermolecular disulfide bonds. Currently, five gel-forming 
murine mucins have been recognized; Muc2, Muc5ac, Muc5b, Muc6 and Muc19. 
Interestingly, four of these genes (Muc2, Muc5ac, Muc5b and Muc6) are clustered on 
chromosome 7F5 (34), a region that exhibits synteny with the human chromosome 
11p15 (35). The order of clustering of secretory mucin genes is Muc6–Muc2–Muc5ac–
Muc5b, which is conserved in both human and mouse (35). 
Muc2 forms the basic framework for the formation of an intra-luminal mucus gel 
of various gastrointestinal (GI) organs (36). Apart from their 75% homology at the N-
terminus, mouse and human MUC2 promoter regions also exhibit a strong sequence 
similarity which might subject them to similar transcriptional regulation (37). Muc2, like its 
human counterpart, is predominantly expressed in the colon, to a lesser extent in the 
small intestine and undetectable in the stomach (38). 
The TR of Muc5ac contains a 16 amino acid sequence, whereas the human 
MUC5AC has only 8 amino acid residues per repeat (25, 39). The TR domain of Muc5ac 
is followed by a 133 amino acid cysteine-rich non-repetitive region (CRRI), a 63-residue 
non-repetitive Ser/Thr-rich domain and a second cysteine rich region (CRRII) which 
share around 81% and 76% similarity, respectively (40). Despite the lack of sequence 
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similarity between the TR units of the murine and human MUC5AC, their non-repetitive 
regions are nearly identical.  
Alignment of the Muc5b gene with its human orthologue indicated few common 
features. Overall, there is 43% identity between the murine Muc5b and human MUC5B 
which is predominantly contributed by N- and C-terminal regions which are 64% and 
62% similar, respectively (41). However, the expression pattern of Muc5b does not 
match the human MUC5B as the murine form is principally expressed in the laryngeal 
mucous glands and at a low level in the stomach and duodenum, whereas the MUC5B 
gene is expressed in many tissues including the airway, gall bladder, and tongue (41). 
The mouse Muc19 gene is located on chromosome 15, which is homologous to 
human MUC19 on chromosome 12 (33). Like other gel-forming mucins, Muc19 also has 
vWD, vWC and CTCK domains (33). Paired analysis of mouse Muc19 and human 
MUC19 has shown 27% homology (42), mainly at the C-terminus and the putative N-
terminus of the peptide sequences, whereas the central repetitive regions did not show 
any homology (33). Similar to the human MUC19, Muc19 is predominantly expressed in 
the salivary glands. 
The murine Muc6 is composed of 33 exons and comparative analysis suggested 
that the human and mouse Muc6 lack both the cysteine-rich domains and the cysteine-
rich subdomains which are frequently found in the S/T/P-rich regions of other human and 
mouse secretory mucins (MUC2, 5AC, and 5B). The absence of these cysteine-rich 
domains and sub-domains possibly make them resistant to proteolytic degradation (43) 
and could be the reason for their high expression in the stomach in both humans and 
mice. In addition to the stomach, murine Muc6 also exhibits high expression in the 
duodenum, whereas it is expressed at low levels in the salivary glands (34). 
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Figure 1A.2. Representation of the prototype structure of mucins along with the 
characterized and putative roles of their functional domains: MBMs and SMs have 
a TR domain with variable numbers and lengths of the repeats. They are predominantly 
get O-glycosylated and separated by unique sequences. They also have few N-
glycosylation sites with varying localization with different mucins. Most of the MBMs 
possess SEA domains with a potential cleavage site (G/SVVV), except MUC4 where 
GDPH (also present in MUC2 and MUC5ac secretory mucins) is considered to be a 
putative site for cleavage. Mucins have varying lengths of cytoplasmic tails, (MUC4 CT is 
shortest with 22 amino acids) which are believed to facilitate signal transduction due to 
the presence of potential phosphorylation sites such as Ser, Thr and Tyr residues. Other 
domains present in mucins include EGF-like motifs, nidogen and adhesion-associated 
NIDO and AMOP, and vWD domains. SMs are rich in cys-rich domains (D1, D2, D3 and 
D4), which are similar to the D domains of the vWD factor and flank the TR region. 
These domains are important for disulfide cross-linking to allow oligomerization between 
the mucin molecules required for gel-forming network. 
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Table 1A.2. Different human mucin homologues of mice and their genomic 
localization 
 
 
Abbreviations: TM, transmembrane; NP, Not present 
 
(* Muc3 is 46.4% and 59.6% similar to human MUC3 and MUC17, respectively [36, 
37]. Therefore, murine Muc3 is considered as true ortholog of human MUC17) 
 
Human 
Mucins 
Type 
Chromosomal  
Location in Human 
Mouse 
Homologue 
of Human 
Chromosomal
Location in 
Mice 
MUC1 TM 1q21 Muc1 3F1 
MUC2 Gel 11p15 Muc2 7F5 
MUC3A TM 7q22 
Muc3* 5G2 
MUC3B TM 7q22 
MUC4 TM 3q29 Muc4 16B3 
MUC5AC Gel 11p15 Muc5ac 7F5 
MUC5B Gel 11p15 Muc5b 7F5 
MUC6 Gel 11p15.5 - p15.4 Muc6 7F5 
MUC7 Soluble 4q13–q21 Muc7 NP 
MUC8 Gel 12q24.3 Muc8 NP 
MUC10 NP NP Muc10 5qE1+ 
MUC11 TM 7q22 Muc11 NP 
MUC12 TM 7q22 Muc12 NP 
MUC13 TM 3q13.3 Muc13 16B3 
MUC15 TM 11p14.3 Muc15 2E3 
MUC16 TM 19p13.2 Muc16 9A3 
MUC17 TM 7q22 Muc3* 5G2 
MUC19 Gel 12q12 Muc19 15E3 
MUC20 TM 3q29 Muc20 16B3 
MUC21 TM 6p21 Muc21 17B1 
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1A.3 MUC4 and its genomic structure 
In our laboratory, we have extensively studied human MUC4.  The first partial cDNA of 
MUC4 was obtained from a human tracheobronchial library (44), where it was found to 
be localized on chromosome 3q29 (45). The 5′-region of the MUC4 gene is 
characterized by an extremely lengthy exon-2 which is mainly comprised of 48-
bp minimal unit repeated in tandem and encodes for a large Ser/Thr-rich domain (46). 
The tandem repeat could vary from 7 to 19 kb and gives rise to variable number of 
tandem repeat polymorphism (46). On the other hand, the 3′-end region of MUC4 is 
primarily made up of two EGF-like domains, a transmembrane domain, and a short 
cytoplasmic tail (47). Due to the presence of 26 exons having number of repetitive 
sequences, MUC4 extensively generates many splice variants which give rise to a family 
of putative secreted and membrane-associated MUC4 isoforms.  
In situ hybridization studies have detected MUC4 expression on various normal 
tissues such as trachea, lung, stomach, colon, uterus, and prostate, whereas normal 
pancreas, gall bladder, biliary epithelial cells, liver, or intrahepatic bile ducts were 
negative for MUC4 expression (48-50). MUC4 expression appears very early during the 
development of the primitive gut (6.5 weeks of gestation) (51). Expression of MUC4 has 
shown to be developmentally regulated in the pulmonary and GI segments, and was 
associated with cell and tissue differentiation. Remarkably, aberrant expression of MUC4 
has been noticed in multiple human epithelial cancers such as lung and pancreatic 
carcinomas (5, 52). Silencing of MUC4 expression led to noticeable decrease in the 
proliferation, migration and chemo-resistance of PC cells, points out an important role for 
MUC4 in human tumor biology (18). Therefore, understanding of the underlying 
molecular mechanisms responsible for the dysregulation of MUC4 is necessary to 
understand its precise role and contribution during carcinogenesis. Studies have 
highlighted the importance of soluble and insoluble factors in the regulation of MUC4 
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expression. For instance, Gollub et al. have shown that MUC4 expression is induced at 
the transcriptional level upon estrogen and dexamethasone treatment in the endometrial 
Ishikawa epithelial cell line. RA and all-trans-RA have also showed to induce MUC4 at 
the transcriptional level in PC cell lines (53). However, the exact reason that leads to an 
aberrant expression of MUC4 in pancreatic ductal adenocarcinoma (PDAC) is still 
unknown. 
Earlier studies have revealed that rat Muc4 has a TATA less promoter with 2.4 kb 
of size (54, 55). On the other hand, functional studies of the 5′-flanking region of MUC4 
in human PC cells have demonstrated that MUC4 transcription is regulated by two 
regulatory regions (−219/−145 and −2781/−2572) (55). This led to the characterization of 
a classical TATA box flanked by an extremely long 5′-UTR which is generally referred as 
a distal promoter, and the 3′-end of the 5′-UTR is characterized by a GC-rich region that 
serves as a second transcription unit and generally called as proximal promoter (56). 
Due to the presence of two promoters with numerous binding sites for transcription 
factors which gets activated in response to growth factor stimulation, MUC4 regulation is 
somewhat complicated. 
1A.4 PC microenvironment 
The tumor microenvironment is the environment at the cellular and acellular level in 
which cancer cells either interact with each other (homotypic interactions), different cell 
types (heterotypic interactions) and with the extracellular matrix (ECM) (57). This 
interaction is highly critical for the sustained tumor development and growth. Under 
normal and healthy conditions, extracellular signals play a critical role by tightly 
regulating the growth and differentiation programs of epithelial cells. However, defects in 
such signaling pathways may circumvent the normal pathway of epithelial differentiation 
and drives the cells towards malignant transformation (57, 58). As repeatedly mentioned 
in multiple scientific reports, the PC microenvironment is extremely complex and 
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consists of components of the ECM, connective tissues, stromal cells, and polypeptide 
growth factors. The ECM itself is composed of complex components of fibronectins, 
laminins, collagens, glycoaminoglycans and proteoglycans (59). In this 
microenvironment, epithelial cancer cells do not only interact with each other, but also 
interact with mesenchymal cells (which includes, cancer associated fibroblasts and 
stellate cells) and the ECM. These interactions are quite specific. Cell-cell interactions 
are mediated by specific cell-cell adhesion molecules, while cell-matrix interactions are 
mediated by specific integrin receptors for each of the major components of the ECM. It 
has long been recognized that changes in the microenvironment accompany the 
transformation process. This is often indicated by increased activation of cancer 
associated fibroblasts (CAFs) and pancreatic stellate cells (PaSCs), which in turn is 
accompanied by increased proliferation, aberrant expression or overexpression of 
proteins, increased migration and extensive ECM remodeling, particularly in areas where 
cancer cells are found. The tumor stroma, in many aspects, resembles the processes of 
wound healing and inflammatory response. 
Despite of the presence of tremendous amount of literature regarding cellular 
and acellular component of PC tumor microenvironment, there are limited studies which 
has extensively concentrated to link microenviromental stress, such as hypoxia, serum 
starvation and oxidative stress, with PC aggressiveness. Increasing evidence strongly 
emphasizes that hypoxia exerts profound impact on the development and advancement 
of the tumor microenvironment which in turn controls the differentiation of tumor and 
stromal cells (60). In detail, tumor cells and their microenvironment reciprocally regulate 
each other. In the following chapters and section, I am going to present the background 
information in pertinent to the following chapters where I have elucidated the novel 
regulatory mechanisms which are involved in the aberrant overexpression of MUC4 
mucin.  
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1A.5 Hypoxia in PC 
Under cancerous condition, imbalance between cellular supply and consumption of 
oxygen leads to depletion of oxygen (O2), a condition known as hypoxia (61). Ambient 
air is approximately 21% O2 (or 150 mmHg), however, most human organs are exposed 
to 2% to 9% of O2 (average, 40 mmHg) (62) . The levels of oxygen varies among 
organs, however, most experimental studies consider ≤ 2% O2 as hypoxia (62). Hypoxia 
has been acknowledged as one of the distinctive and common feature observed for 
locally advanced solid cancers (63). In multiple cancer models, hypoxia has been 
associated with poor clinical outcomes; including, cancer cell invasion and metastasis. In 
order to adjust with the hypoxic microenvironment, tumor cells have to alter the 
expression of multiple genes, which encodes for metabolic enzymes, vasoactive, and 
proangiogenic molecules and so on. Tumor hypoxia activates multiple signal 
transduction pathways, which produce significant impact on the tumor biology by 
promoting metastasis, angiogenesis and tumor progression (64, 65).   
Koong and colleagues were the first one who demonstrated that PC are 
notoriously hypoxic in nature, where they directly measured intratumoral O2 levels in 
patients undergoing a Whipple procedure (n=7) (66). It was revealed that areas of 
pancreatic carcinoma had a median pO2 level of 0–5.3 mmHg. Contrarily, tumor adjacent 
areas consisting normal pancreatic tissue had median tissue pO2 levels of 24–92.7 
mmHg (66). Such momentous reduced tissue oxygenation has also been noticed in 
chronic pancreatitis, a condition that usually co-exists in PC patients (67). This is already 
known that pancreatic tumors are highly resistant to common therapies (68, 69). It could 
be attributed to the presence of low oxygenation and the extraordinary ability of PC cells 
to withstand and grow aggressively in highly stressed microenvironment (5, 70). These 
reasons are further supported by the studies which have directly associated hypoxic 
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tumor regions with the resistance against chemo- and radiation therapy, both of which 
are clinical hallmarks of human PC (71, 72). Besides therapy resistance, recent studies 
have implicated tumor hypoxia with a variety of growth-modulating effects including 
tumor metastasis. Altogether, hypoxia, a condition when cancer cells are deprived of 
oxygen, has profound effect on its overall growth, development and therapy resistance. 
1A.6 Hypoxia inducible factors (HIFs) in PC 
A crucial component required for the induction of hypoxia-regulated genes is the hypoxia 
inducible factor-1 (HIF-1) complex, which is composed of HIF-1α and HIF-1β subunits 
(73, 74). The HIF-1β subunit (also known as aryl hydrocarbon nuclear translocator, 
ARNT) is constitutively expressed, whereas the HIF-1α subunit is accumulated only 
under hypoxic exposure by evading proteasome-mediated degradation (74). Under 
hypoxic conditions, the active HIF-1α/β heterodimer is translocated to the nucleus and 
binds to a specific cis-acting regulatory sequence referred to as the hypoxia response 
element (HRE) in target genes, which leads to transcriptional activation of their target 
genes. HIF-1α serves as a master regulator of several hypoxia-inducible genes, 
including vascular endothelial growth factor (VEGF), glucose transporter-1 (Glut-1) and 
survivin (75). VEGF plays a central role in the tumor neo-angiogenesis which is a crucial 
step in tumor growth and progression. Glut-1 mediates cellular glucose uptake, and thus 
facilitates anaerobic glycolysis, a prerequisite for cancer cell proliferation under hypoxic 
microenvironment. Survivin, a member of the apoptosis inhibitor protein family, is 
uniquely expressed in various kinds of human malignances but not in normal adult cells 
and its over-expression in cancerous condition has been associated with reduced cell 
death (75). In PDAC condition, immunohistochemistry performed in 58 PDACs and 20 
normal pancreatic tissue samples by Sun HC et al, have clearly demonstrated 
expression of HIF-1α, VEGF, Glut-1 and survivin in 70.7%, 77.6%, 67.2% and 84.5% of 
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the patients with PDACs, respectively, which is substantially higher than in the normal 
controls (75). 
Under chronic hypoxia, stabilized HIF-1 complex binds to HRE2 in 5'flanking 
region of miR-191 in PC cells, which is followed by increased transcription of miR-191 
(76). Expression of miR-191 was significantly higher in pancreatic tumor tissues, 
compared to normal pancreas (76). The overexpression of miR-191 was associated with 
increased tumor size, pTNM stage, lymph node metastasis, perineural invasion and poor 
prognosis of the disease (76). Similar to miR-191, increased HIF-1α expression also 
indicates increased lymph node metastasis and a tendency of larger tumor size as well 
as advanced TNM stage, irrespective of its expression pattern (75). Multiple studies 
have shown that 50-70% of the investigated PDA samples have positive staining for HIF-
1α molecule. HIF-1α expression has shown primarily two patterns depending upon the 
underlying source. For example, lack of oxygen leads to necrosis where HIF-1α exhibits 
prominent focal positive staining, whereas in an oxygen-independent pathway, HIF-1α 
has strong diffused nuclear and/or cytoplasm staining in the tumor cells (75).   
Due to the implicated role of HIF-1 in increasing the expression of genes required 
for increased tumor growth and metastasis, disruption of the HIF-1 pathway could be an 
effective strategy to treat PC. In a study by Chen et al, it has been demonstrated that 
expression of dominant-negative HIF-1α in PC cells leads to reduction in tumorigenicity 
due to interruption of glucose metabolism, which made cancer cells sensitive to 
apoptosis and growth inhibition upon hypoxic condition (77). Taken together, it can be 
concluded that PC patients may noticeably receive clinical advantage from treatments 
targeting HIF-1α, and a routine assessment of these proteins by IHC may expand our 
understanding into improved treatment after surgery. 
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1A.7 Oxidative stress association with PC progression 
 
Around 90% of PC patients have K-ras mutations, implying their critical role in 
the molecular pathogenesis (78), which has been associated with ROS homeostasis 
under cancer condition. Vaquero et al. have recently shown that ROS have pro-survival 
and anti-apoptotic functions in PC (79). They showed that ROS generation by the 
activation of nonmitochondrial NAD(P)H oxidase due to the stimulation of growth factors 
facilitates survival of PC cells, whereas suppression of ROS production leads to PC cell 
death. Therefore, the pro-survival effect of ROS may be an important mechanism which 
is utilized by PC cells to evade therapy response. Further, Santillo et al. have shown that 
in K-ras–transformed mouse fibroblasts, there is elevated ROS levels which leads to the 
activation of signal transduction pathways (80). Not only k-ras, transfection of viral H-ras 
oncogene in mouse fibroblasts also led to increased synthesis of superoxide (O2
−), 
where they execute their cell proliferating functions by plausibly acting as a second 
messenger molecule. In addition to fibroblasts, ras-transformed keratinocytes also 
demonstrated increased generation of O2
-, and this augmented production was 
effectively paused when an adenovirus construct containing the cDNA of the antioxidant 
protein superoxide dismutase was expressed (81). Contrarily, most of the studies have 
encouraged the usage and clinical testing of ROS-inducing small molecules for the 
treatment of PC. For instance, in NAD(P)H:quinone oxidoreductase (NQO1)-
overexpressing pancreatic tumors, administration of ROS inducer β-lapachone leads to 
significant cytotoxicity by tempering PARP, NAD+/ATP levels. It is subsequently followed 
by increased single-stranded DNA breaks, and results in necrosis (82, 83). Another 
small molecule pro-oxidant, imexon, which is an aziridine-derived iminopyrrolidone, has 
shown to induce apoptosis in multiple PC cell lines by increasing ROS levels and 
facilitating cell cycle arrest at G2 phase (84). Considering its effective anti-cancer 
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properties, this drug has been used for phase I and II clinical studies for PC patients 
(85).  
In a recent study, Dhillon and colleagues have investigated the in vitro and in 
vivo effects of the ROS-inducer piperlongumine (PPLGM) on PC cell death (86). PPLGM 
is an bioactive alkaloid found in the fruits of long pepper plants and have potent growth-
inhibitory properties in a variety of cancer cell lines and animal models (86). Though it 
exhibits cytotoxic effects on tumor cells, PPLGM is not at all toxic to its normal 
counterparts. In this study, authors have evaluated the therapeutic potential of PPLGM 
for PC treatment. Similar to other cancer types, PPLGM exhibited growth inhibitory 
effects on PC cells by inducing ROS levels and generating DNA damage (86). The effect 
of PPLGM was found to be ROS-dependent because its effect on cytotoxicity and DNA 
damage was reversed, when PC cells were concomitantly treated with antioxidant. 
These anticancer effects of PPLGM were confirmed in a xenograft mouse model of 
human PC, where they observed significant reduction in tumor size. IHC analysis further 
revealed that PPLGM-treated animals had reduced Ki-67 and increased 8-OHdG 
expression. Taken together, it can be proposed that further studies evaluating the anti-
tumor effects of ROS-inducer on normal and K-ras mutant pancreatic tumors in 
combination with chemotherapy should be encouraged and executed. 
 1A.8 Autophagy status in PC condition 
Autophagy is a highly regulated destructive cellular mechanism in which 
autophagosomes are fused with lysosomes that lyse or recycle the contents (87). 
Therefore, this catabolic process provides building blocks for use within the cell and 
dynamically control and maintain cell function. Particularly, stress conditions, such as 
starvation, are known to induce autophagy which leads to energy redistribution to 
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sustain cell survival; however, if the attempts to sustain viability are failed, autophagy 
facilitates cell death. The dual role of autophagy is also applied to tumorigenesis 
because it can serves both as a guardian for cancer initiation and as a stimulator for 
cancer growth, by providing energy for advanced malignancies (88). For instance, loss 
of Atg5 predisposes mice to develop benign liver adenomas; however, these lesions do 
not headway to form malignant tumors (89). Supportively, upon lung specific 
concomitant loss of Atg5 or Atg7 in conjunction with oncogenic Kras, mice developed 
increased benign lesions (adenomas) which were again failed to progress to malignancy 
(90, 91). 
In PC, the role of autophagy has been examined by different research groups 
and the results are quite interesting. Mukubou and colleagues have investigated the in 
vivo and in vitro effects of gemcitabine and ionizing radiation (IR) upon modulation of 
autophagy (92). Treatment with gemcitabine and/or IR had significant inhibitory effects 
on cellular viability and tumor growth, but addition of autophagy inhibitors ostensibly 
increased the dose requirement of gemcitabine in order to suppress cell viability, 
suggesting that autophagy sensitize PC cells for gemcitabine-mediated cell death (92). 
However, most of the available literature has associated autophagy with increased 
survival, tumorigenicity and aggressiveness of PDAC. Yang and colleagues, for 
instance, have suggested presence of constitutively instigated autophagic pathway in 
PC neoplasm (93). They assessed the autophagic status using both static and flux 
measurements in different cells. Upon comparison, it was revealed that all PDAC cell 
lines showed a significant increase in autophagic activity as well as flux compared to 
non-transformed pancreatic cells, breast and lung cancer cell lines (93). To directly 
relate the induction of autophagy with the survival of PC cells, ATG5 was silenced using 
targeted small interfering RNA (siRNA), which led to 50% reduction in the growth of 
PDAC cell lines compared to the other cancer cell lines. Altogether, their results 
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provided evidence that activation of autophagy is required for the maintenance of PDAC 
(93). Further, clinicopathological study in a cohort of 71 resected PDAC patients 
revealed an association between activated autophagy (high LC3 protein expression) and 
poor outcome of PDAC patients (94).  
Increased basal levels of autophagy has been observed in human cancer cell 
lines bearing activating mutations in H-ras or K-ras, even in a nutrient abundant 
microenvironment, suggesting that autophagy maintains tumor cell survival. Therefore, 
by subduing the expression of proteins required for autophagy, the growth of cancer 
cells was significantly suppressed, indicating that Ras-driven cancers are addicted to 
autophagy, and blocking autophagy in such tumors could be an effective treatment 
approach (95). Interestingly, xenografts obtained from PC patients who contain Kras 
mutation were extraordinarily susceptible for the treatment of anti-autophagy based 
therapies including, chloroquinone derivatives (96). In a recent report, Perera et al. have 
gauged both autophagosomes and lysosomes using IHC and found them significantly 
larger in PDAC cell lines than in controls (97, 98). Additionally, high resolution 
transmission electron microscopy showed that not only the size, numbers of lysosomes 
are also higher in PDAC samples than in normal pancreatic tissues. Mechanistically, the 
authors have associated this increase with an elevated expression of genes involved in 
lysosomal biogenesis (98). It is already known in the literature that MiT/TFE family of 
transcription factors play important role in increased lysosome and autophagosome (99). 
After melanoma and kidney cancer, PDAC had the third highest expression levels for 
MiT/TFE factors; particularly TFE3, TFEB and MITF. Suppression of these MiT/TFE 
factors in PDAC cells led to significant change in lysosomal morphology and 
functionality. Particularly, metabolite profiling in TFE3 kd PC cells revealed a substantial 
reduction in the cellular levels of amino acids and their breakdown products due to 
impaired uptake of extracellular factors through macro-pinocytosis (98). In a parallel 
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experiment, PDAC cells overexpressing TFE3 or MITF exhibited increased clonogenic 
growth compared with controls when cultured in low amino acid, indicating that induction 
of autophagy make PC cells to survive better under nutrient deprived conditions. 
Moreover, MITF overexpression considerably increased the tumorigenicity of mouse 
pancreatic epithelial cells expressing KRAS-G12D when orthotopically injected into 
recipient mice. 
The pro-survival role of autophagy in PDAC progression has been further 
substantiated by using highly defined genetically engineered mouse models (GEMMs) 
(100). For example, pancreas-specific depletion of Atg5 or Atg7 in the presence of 
constitutively active Kras, significantly abrogated the progression of pre-malignant 
lesions to invasive cancer; however, due to the embryonic homozygous p53 deletion in 
the pancreas, these observation might not be physiologically relevant (100). Because 
p53 alterations are mainly loss of heterozygous (LOH) in human PC condition, these 
conclusions derived from p53 homozygous model might not be representative of human 
tumors. Interestingly, Atg5 deletion impairs the progression of pre-malignant PanIN to 
invasive PDAC in the setting of heterozygous deletion of p53 (101). Altogether, it led us 
to conclude that in the physiological setting of p53 loss during tumor progression, 
autophagy seems to be required for optimal development of PC. The intricate and highly 
complexed relationship between autophagy and p53 is of great importance and required 
further studies. To increase the clinical relevance of the study, authors did acute 
inhibition of autophagy by chloroquinone (CQ)-treatment or RNAi approaches, and 
observed significant growth inhibition of murine PDAC cell lines with various p53 
alterations, which is quite consistent with the prior data using p53 harboring human 
PDAC cell lines. Upon treating of patient derived PDAC xenografts that harbor p53 
mutations with hydrochloroquinone (HCQ), significant attenuation in the growth was 
observed (101). Taken together, majority of the evidence indicates that autophagy has 
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oncopromoting functions in PDAC, which makes this process to look appealing as a 
potential target in PC therapy and has prompted multiple anti-autophagy based ongoing 
preclinical and clinical trials.  
1A.9 Role of hypoxia in the regulation of autophagy 
Previous reports have confirmed that hypoxia induces autophagy in a HIF-1α dependent 
manner in both normal and cancer cell lines to promote cell survival, implying that HIF-
1α plays an important role in maintaining and regulating cell autophagy. However, the 
underlying mechanism of hypoxia-induced autophagy has started to get unearthed by 
recent studies. The activation of HIF-1α-dependent autophagy occurs via the induction 
of Bcl-2 (B-cell lymphoma 2)/adenovirus E1B 19 kDa protein-interacting protein 3 
(BNIP3), which has two HRE (HRE-1 and 2) sites on its promoter region. HIF-1 directly 
binds to HRE2 site on BNIP3 promoter and leads to the transcriptional upregulation of 
BNIP3 (102). Due to established role of BNIP3 in disrupting the autophagy inhibitory Bcl-
2: Beclin 1 complex, BNIP3 overexpression under hypoxia led to the release of BECN1, 
which is now free to initiate autophagy by assembling a pre-autophagosomal structure 
(103). 
In addition to HIF-1 dependent pathways, there are HIF-1 independent pathways 
as well, known to regulate autophagy under hypoxic condition. One of such pathway is 
the regulation of the mammalian target of rapamycin (mTOR), which consists of two 
specific mTOR complexes; mTORC1 and mTORC2. Their downstream effectors 
orchestrate several biological processes, including autophagy. mTORC1 has been 
associated with autophagy suppression by inhibiting ATG1 ser/thr protein kinase, which 
is involved in the formation of autophagosomes (104). Under hypoxia, mTORC1 
pathway is suppressed by cancer cells by utilizing multiple pathways; one of them is 
mediated through hypoxic activation of the tuberous sclerosis protein (TSC) complex 
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(104). It is a heterodimeric complex formed by TSC1 and TSC2. Under nutrient deprived 
conditions, there is an increase in AMP/ATP ratio, which is sensed by the heterodimeric 
5′ AMP-activated protein kinase (AMPK) complex, which phosphorylates many 
downstream targets, including TSC2 on serine residues positioned at 1270 and 1388 
(104). Phosphorylation of these sites has inhibitory effect on the activity of the 
TSC1/TSC2 complex. Due to the inactivation of the TSC1/TSC2 complex, Ras homolog 
enriched in brain (RHEB)-dependent activation of mTOR is prevented. Activation of the 
unfolded protein response (UPR), a program which leads to major transcriptional and 
translational alteration due to endoplasmic reticulum (ER) stress with a goal to clear 
misfolded proteins, is an additional HIF-1-independent pathway that activates autophagy 
(105). There are mainly three ER stress sensors which facilitate UPR program: PKR-like 
ER kinase (PERK), ER to nucleus signaling 1 (ERN1), and activating transcription factor 
(ATF). Under hypoxic conditions, autophagy seems to be facilitated by PERK. 
Phosphorylation of the eukaryotic translation initiation factor 2 alpha (elF2α) in a PERK-
dependent manner leads to the activation of ATF4 transcription factor which 
subsequently induce the expression of MAP1LC3B and ATG5 at mRNA level (105). 
1A.10 Role of oxidative stress in autophagy regulation in PC 
Different stress signals or genetic alterations prompt ROS production leading to the 
stimulation of autophagy, which regulates cell death or cell survival pathways. In a 
classical paper by Scherz‐Shouval and colleagues, it has been clearly demonstrated that 
during amino acid starvation, PtdIns3K class III-dependent generation of H2O2 by the 
mitochondria, serves as a local signaling molecule to modulate the activity of the 
cysteine protease Atg4 (106). In their in vitro studies, they have demonstrated that a 
critical cysteine residue near the catalytic site of Atg4 undergo oxidative alteration, which 
inhibits the activity of Atg4, and thus ensures the conjugation of Atg8 to the 
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autophagosomal membrane (106). This could lead to a ROS-dependent accumulation of 
LC3-PE on the autophagosomal membranes in close vicinity, thereby facilitating the first 
steps in autophagosome formation. 
Furthermore, autophagy regulation by intracellular ROS levels during starvation 
has shown to involve p53-inducible protein TP53-induced glycolysis and apoptosis 
regulator (TIGAR). TIGAR functions as a fructose- 2,6-bisphosphatase, and diverts 
glycolytic metabolic intermediates to the oxidative branch of the hexose monophosphate 
pathway, which led to increased cellular production of NADPH, and thereby, lowers 
intracellular ROS levels and the sensitivity of cells to oxidative stress associated 
apoptosis (107). Therefore, suppression of TIGAR expression increases the production 
of ROS and autophagy in hepatocellular cancer cells, independent of mTOR- and p53, 
However, induction of autophagy due to loss of TIGAR is considered to be cytoprotective 
and reduces the apoptotic response by limiting oxidative stress (plausibly by the 
degradation of ROS producing mitochondria) (108).  
The redox-regulation by Akt-mTOR and AMPK signaling systems are other 
critical mechanisms responsible for ROS-mediated induction of autophagy. ROS 
production following growth factor-stimulation results in the inactivation of phosphatase 
and tensin homologue (PTEN) through the formation of a disulfide bridge between a 
cysteine in the catalytic site with a proximal cysteine residue. This PTEN inactivating 
process leads to an increment in the levels of PtdIns(3,4,5)P3, which promotes the 
activation of Akt, a well-known proto-oncogene (109). Furthermore, the selective 
degradation of the H2O2 converting enzyme, catalase, by autophagy can provide an 
auto-stimulatory feedback loop, while the autophagic degradation of mitochondria or 
other ROS-producing organelles alleviates oxidative stress progression and acts as a 
negative feedback loop (110). These results are also consistent with a model in which 
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ROS act as signaling molecules upstream of autophagy, whereas the stimulation of 
autophagy further limits ROS levels by removing ROS-generating mitochondrial 
therapies. 
1A.11 Regulation of mucins by hypoxia in cancer condition 
Accumulating evidence suggests a number of physiological roles and regulatory 
mechanisms for mucins; however, there are limited studies which have demonstrated 
the effects of local microenvironment on mucins regulation. Studies have identified and 
appreciated the involvement of HIF-1α regulated pathway in mucins regulation. The first 
study came back in 1990s, where a molecular link between hypoxia and mucins 
regulation was observed in intestinal epithelial cells. The hypoxia-dependent induction of 
MUC3 signified a novel innate mechanism that may protect the immunologic 
components of the lamina propria from exposure to various insults including, pathogenic 
luminal bacteria, antigens, and toxins under oxygen deficient conditions (111). Of note, 
HRE was not precisely mapped on MUC3 promoter, which could be due to the 
complexity of the flanking region around the HIF-1 consensus sequence (111). Following 
HIF-1 consensus site, the immediate region contains potential binding sites for the 
transcription factors such as, c-rel, NFκB, glucocorticoid receptor, the estrogen receptor, 
and CREB, where some of these transcription factors have been implicated in either 
gene induction or repression under hypoxia. Therefore, MUC3 gene at this site is quite 
complicated and might involve interplay between positive and negative regulatory 
signals. Efforts to better understand MUC3 signaling pathways and to identify other 
hypoxia-elicited protective elements could provide future focus for development of novel 
treatments. 
Polosukhin et al. demonstrated that hypoxia induces metaplasia in goblet cells 
which is followed by increased gel-forming MUC5AC mucin expression in primary 
human bronchial epithelial cell lines (112). Zhou et al validated the presence of HIF-1α 
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transcription factor–binding sites (HREs) on the MUC5AC promoter region (113). The 
expression and secretion of MUC5AC in human bronchial epithelial cells was found to 
be significantly reduced when HIF-1α expression was inhibited using HIF-1α inhibitor 
(YC-1) and HIF-1α small interfering RNA (siRNA).  
Another transmembrane mucin, MUC17, has been reported to be overexpressed 
in pancreatic ductal adenocarcinomas (PDAC) compared with its lack of expression in 
normal pancreas or pancreatitis. Additionally, Hirono et al. also reported that MUC17 is 
an independent prognostic factor associated with lymph node metastasis in PDAC (114). 
MUC17 expression has also been found to be enhanced under hypoxic condition in a 
HIF-1α dependent manner (115). Further investigations revealed that DNA methylation 
of HRE is a key determinant of the hypoxic inducibility of MUC17 in PC (115). Clinically, 
hypomethylation of HRE within the MUC17 promoter is a frequently occurring event in 
the pancreatic tissues of patients with PDAC. In the future, the significance of these 
findings in PC pathogenesis needs to be reconnoitered. 
MUC1 is the most studied mucin in terms of hypoxia under cancerous condition. 
The first study which showed the connection between MUC1 and hypoxia came in 2007, 
where Yin et al. first related MUC1 expression with reduced ROS production which had 
inhibitory effects on the activity of HIF-1α expression (116). According to the report, 
MUC1 overexpression blocks hypoxia-induced apoptosis and necrosis by suppressing 
accumulation of ROS, and therefore, MUC1 expression leads to better survival response 
in response to hypoxic stress (116). The subsequent studies have related HIF-1 
signaling mechanism in MUC1 upregulation, which is the main pathway involved in renal 
carcinogenesis. Hypoxia-derived conditioned media (HCM) from MUC1 kd AsPC1 cells 
demonstrated profound inhibitory effect on the migration and proliferation ability of 
endothelial cells compared to hypoxia-treated control cells, suggesting the potential 
involvement of MUC1 in the process of hypoxia-driven angiogenesis (117). Not only wt-
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MUC1, this study has also shown that hypoxia strongly induced the translocation of 
MUC1-CT to the nucleus as well as HIF1α in AsPC1 cells, but not under normoxic 
culture conditions. In another study, hypoxia-mediated induction of MUC1 has been 
linked with increased glucose uptake and glycolysis by nutrient-deficient PC cells (118). 
The physical interaction of MUC1 with HIF-1α and p300 in a hypoxia-dependent manner 
is ensued by enhanced promoter occupancy of the HIF- 1α and p300 on glycolytic gene 
promoters, which regulates the expression of multiple metabolic genes. This is further 
supported by the observed positive correlation of MUC1 expression with the expression 
of glucose metabolic enzymes such as GLUT1 and LDHA (118). Presence of MUC1 has 
also been associated with enhanced stability by diminishing the levels of 2-oxoglutarate 
in PC cells. Altogether, the interrelationship between MUC1–HIF-1α oncogenic signaling 
networks serves to facilitate tumor growth and metastasis and could present a potential 
therapeutic target for the treatment of malignant diseases that rely upon MUC1 and HIF-
1α.  
In addition to PC and CRC, the association between HIF-1α and MUC1 is also 
established in invasive ductal breast carcinoma (n=243). MUC1 overexpression was 
observed in 37.0% of patients and it correlated positively with estrogen receptor 
(p = 0.0001), progesterone receptor (p = 0.0001), HIF-1α (p = 0.006), VEGF (p = 0.024), 
and p53 (p = 0.025) (119). Here, authors have also demonstrated that MUC1 
overexpression leads to the increased degradation of inhibitor of NF-κB (IκBα). It 
subsequently promotes the nuclear translocation of NF-κB which blocks apoptosis and 
promotes cell survival (119). Moreover, it has been reported that MUC1 has the ability to 
promote autophagy which provides a survival advantage in a low glucose-stressed 
microenvironment by suppressing excessively generated ROS levels in colon cancer 
condition.  
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1B.1 An outline of Bile acids 
Bile acids (BA) are amphiphilic molecules and are the main component of bile along with 
cholesterol, phospholipids, and bilirubin (1). BA are derived from cholesterol and 
synthesized primarily in the liver. They are initially synthesized as primary bile acids, 
namely cholic acid (CA) and chenodeoxycholic acid (CDCA), but get conjugated with 
glycine and taurine (2). Subsequently, these conjugated BA are excreted from the liver 
into the gall bladder, at a concentration of approximately 100 mM, and remains stored, 
until gall bladder receives stimulus (2). Dietary fat is a stimulus for BA secretion into the 
intestine, and the primary function of BA is to facilitate digestion absorption of fats and 
liposoluble vitamins in the intestine throughout the enterocyte barrier (1). It is the same 
region, where approximately 95% of the BA are re-absorbed into ileal columnar 
epithelium cells, by an active apical sodium-dependent BAs transporter ASBT (Apical 
Sodium-Dependent Bile Acid transporter) (3). After uptake into enterocytes of the ileum, 
bile salts are transported to the basolateral domains of the cells for efflux into the portal 
circulation, and mined from portal blood plasma by liver cells. Liver does it job efficiently 
and eliminate BA from the circulation; therefore, the circulatory BA levels in healthy 
individuals are generally maintained at around 0.003 mM. The remaining unabsorbed  
5% of BA pool enters to the colon, where it gets further metabolized by the anaerobic 
bacterial species using two major and a number of minor reactions (4). The first major 
reaction is the process of deconjugation which is followed by the release of free BA, 
whereas the second major reaction is 7-α dihydroxylation, which converts CA and 
CDCA to DCA and lithocholic acid (LCA), respectively (4). Although partially, DCA gets 
reabsorbed in the colon and enters into enterohepatic circulation, where it undergoes 
conjugation in the liver and secreted in the bile. On the other hand, very little amount of 
LCA is reabsorbed in the colon which can be attributed to its fairly insoluble nature. As a 
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result, the circulating BA pool (after undergoing both conjugation and deconjugation 
process) contains about 30–40% each of CA and CDCA, and about 20–30% of DCA, 
with less than 5% of LCA (5). Besides primary and secondary BA, bacterial degradation 
in the colon and alterations in the liver produce tertiary BA, such as ursodeoxycholic 
acid, which is also present in the circulating BA pool (6). It has been noticed that people 
on a high fat diet have substantially elevated levels of both DCA and LCA, in the fecal 
water. Before delivery, BA levels are maximally present in the gallbladder, but after their 
delivery towards small intestine, their maximum levels are present near the Ampulla of 
Vater than any other region of the body.  
1B.2 BA under cancer condition 
The first evidence demonstrating the involvement of BA in cancer development 
came from Cook et al. in 1940, where authors have clearly shown the induction of 
malignant tumors when DCA was injected into the right flank of mice. In another model, 
administration of CDCA to APC (Min/+) mice model has shown to increase number of 
duodenal tumors (7). Administration of BA alone did not lead to the formation of cancer 
in both mice and rat, but their treatment along with carcinogens has shown to 
significantly promote colon carcinogenesis (8).  
Using multiple experimental models of rodents, particularly between 1974 and 
1993, different types of BA have shown to exert their tumor-promoting functions. 
Administration of BA alone was failed to induce colon tumors. However, administration of 
LCA, taurine conjugated and unconjugated DCA had a significant promoting impact on 
colon carcinogenesis in rat after intrarectal instillation of N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG), which is a well-known mutagen (8). Similarly, CA also had a 
promoting effect on colon tumor formation in rats after intrarectal instillation of N-methyl-
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N-nitrosourea (MNU) or sub-cutaneous injection of azoxymethane (9). In addition to 
colon, BA shown enhanced hyperplastic and neoplastic lesions in stomach mucosa, 
when administered in the presence of MNNG (10). Therefore, BA is considered as 
tumor-promoters. However, in spite of all these experimental models and related 
literature, considerable indirect evidence and logical argument supports the view that BA 
are carcinogens in humans. The GI tract of rodents and humans are exposed to BA for 
different duration of time. Most of the discussed experiments establishing the tumor 
promoting roles of BA were conducted for one year or less. However, most of the GI 
cancers in humans are primarily developed at around 60 years of age. Additionally, 
colonic epithelium renews themselves around 365 times during the lifespan of mice and 
rats and 5110 times in human. Due to DNA damaging or mutation inducing ability of BA, 
sustained exposure of BA to human colonic epithelium could have tumor initiating 
actions.  
In addition to colon cancer, significant amount of literature has made it apparent 
that BA is also important in other gastrointestinal (GI) cancers (11). High or abnormal BA 
exposure is associated with increased incidence of cancer in the laryngopharyngeal 
tract, esophagus, stomach, pancreas, the small intestine (near the Ampulla of Vater) and 
the colon. As the local microenvironment (both cellular and acellular) varies from one GI 
organ to another, it can be speculated that both the extent of effect and the underlying 
mechanism involved upon BA exposure, could be different at different organs. 
The involvement of BA in the progression from Barrett's esophagus (BE) to 
esophageal cancers, which is the seventh leading cause of cancer-related death 
worldwide, is well established. Patients with BE disease have an estimated 30–125 fold 
increased risk of developing esophageal cancers (12). BE disease occurs during healing 
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of esophageal mucosal injury typically triggered by gastro-esophageal reflux diseases 
(GERD), in which the exposure of esophagus is significantly increased to acidity from 
stomach and to BA from duodenum. Using surgical models, several studies have shown 
that GERD development is indeed result in esophageal adenocarcinoma (EA) 
development without exogenous carcinogen. Furthermore, feeding mice with zinc 
deficient diet containing DCA led to increased production of ROS with the visible 
appearance of BE-like lesions (13). Moreover, BA induces expression of inflammatory 
mediators (e.g. Interleukin-8 (IL-8), cyclo-oxygenase (COX-2), oxidative stress and DNA 
damage that could be linked to mutational events over a longer period (14), to 
development of resistant apoptotic cells, and ultimately cancer. However, the exact 
molecular pathways involved remain unclear. Few studies have investigated the 
implication of BA receptors in the development of BE disease and adenocarcinoma. 
Several lines of evidence have implicated BA in liver tumorigenesis. Rodent 
models showed prominent appearance of preneoplastic lesions of hepatocellular 
carcinoma upon exogenous administration of DCA. Diet enriched with 0.2% CA has 
shown to intensely enhance N-nitrosodiethylamine-initiated liver carcinogenesis in WT-
mice (15). In addition, children with progressive familial intrahepatic cholestasis type 2 
(PFIC type 2), which is genetic deficiency of the canalicular bile salt export pump BSEP 
or ABCB11, are known to be predisposed to hepatocellular carcinoma (HCC). Similar to 
colon cancer, in vitro studies have indicated that BAs may directly affect hepatocytes by 
inducing ROS production which is followed by DNA damage and apoptosis. For 
example, hydrophobic BAs like DCA, glucuro-CDCA or tauro-CDCA have been reported 
to produce ROS in rat hepatocytes, human hepatoma cell line or primary human 
hepatocytes. Treatment of human hepatocarcinoma cells with DCA leads to the 
transcription of genes that participates in oxidative stress (NF-κB, c-fos) or DNA damage 
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(gadd153, c-fos). Moreover, several studies have also shown that BA induce apoptosis 
in liver cells, which can be reduced by an anti-oxidant treatment like α-tocopherol or β-
carotene, suggesting that increased ROS production due to BA exposure is responsible 
for this cell death event. Even though we know that BA has carcinogenic potential in the 
pathogenesis of liver cancer, the defined mechanisms by which they act is not known 
and involvement of their receptors FXRα and TGR5 are poorly understood. 
1B.3 BA receptors and their role in cancer 
In addition to their mechanical role, BAs have been described as signaling molecules 
binding receptors. So far, four receptors, namely nuclear receptor farnesyl-X-receptor 
(FXRα, NR1H4), vitamin D receptor (VDR), G-protein-coupled receptor TGR5 (GPBAR1, 
G-protein-coupled bile acid receptor) and pregnane X receptor (PXR)/steroid xenobiotic 
receptor (SXR), have been recognized to bind to BA and perform tumorigenic functions. 
FXR is present in high levels in liver, intestine, or kidney and it belongs to nuclear 
receptor superfamily. It acts as a mandatory heterodimer with retinoid X receptor (RXR) 
and binds to specific IR1 (inverted repeat-1) sequences on target gene promoters to 
regulate gene transcription. Using Fxrα gene (Fxrα−/−) mouse model, its involvement in 
regulating BAs biosynthesis and entero-hepatic cycle was highlighted. Fxrα−/− mice 
revealed high BA plasma levels due to abnormal hepatic biosynthesis, as FXRα 
represses the gene expression of cholesterol 7α-hydroxylase (CYP7A1) and sterol 12α-
hydroxylase (CYP8B1), key enzymes involved in BA biosynthesis (16). This is how 
FXRα limits the deleterious effects of accumulated BA. In hepatocytes, FXRα decreases 
BA uptake via repression of Na+-taurocholate co-transporting polypeptide (NTCP), 
organic anion-transporting polypeptide (OATP)-1 and OATP-4 expressions. It also 
promotes BA excretion in bile ducts through transcriptional induction of the specific BA 
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transporter BSEP (Bile salt export pump) in hepatocytes. Due to the involvement of FXR 
on BA homeostasis, significant upregulation was observed for the genes implicated in 
inflammation and cell cycle in aging FXR−/− mice, whereas WT control mice did not 
exhibit such effects. FXR-/- mice showed liver tumor formation between 13 and 15 
months of age, whereas WT mice did not have any tumor formation (15). Interestingly, 
feeding mice with 2% cholestyramine, a bile acid–sequestering resin, to lower BA pool in 
FXR−/− mice had significant negative impact on the formation of malignant lesions, 
establishing the causal relationship between BA and liver tumors (15).   
 The involvement of FXRα in BE disease and adenocarcinoma development has 
been elucidated by several studies. In patients with BE disease, FXRα overexpressed in 
both esophageal squamous epithelium and specialized intestinal BE cells, while almost 
no FXRα was found in healthy squamous epithelium, whereas advanced EA patients 
exhibited loss of FXRα expression (17, 18). FXR expression has shown to be reduced 
remarkably in intestinal tumors developed both in human and mice models. Using two 
mouse models of intestinal tumorigenesis results, it has been demonstrated that loss of 
FXR is related with early death and increased size of small intestine adenocarcinomas, 
indicating that loss of FXR and not merely elevated BA concentrations increases 
susceptibility to tumorigenesis (19). In the absence of FXR, enhanced Wnt signaling is 
observed which is attributed to increased infiltrating immune cells (neutrophils) and 
cytokines (TNFα) production. It is also accompanied with an increased basal proliferative 
compartment both in the ileal portion of small intestine and colon along with 
simultaneous decrease in the apically localized differentiated compartment. This 
scenario leads to increased progression of colon tumors along with early mortality in 
utilized mice model (20). On the other hand, when FXR is activated in the differentiated 
normal enterocytes and in colon cancer cells, there is an induction of apoptosis and 
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removal of genetically altered cells, which may otherwise progress to complete 
transformation (20). Thus, from a therapeutic standpoint, strategies aimed at reactivating 
FXR expression in colon tumors might be useful in the treatment of colon cancer.  
The first established G-protein coupled receptor specific for BA binding is TGR5 
(21). TGR5 expresses ubiquitously both in humans and animals, and it is known to 
activate multiple intracellular signaling cascades upon binding to BA (22). TRG5 
activation has well established functions in the maintenance of metabolic homeostasis 
and energy expenditure. IHC study has shown that TGR5 protein expression is present 
throughout the GI tract (22). Unlike FXRα, significantly high levels of TGR5 was 
observed both at mRNA and protein levels in human EA compared to normal 
esophageal mucosa or Barrett's mucosa (23), suggesting that it might play a central role 
in adenocarcinoma development. Additionally, TGR5 was established as a mediator of 
ROS generation, which leads to increased proliferation of esophageal cancer cells upon 
exposure to BA. Thus, TGR5 activity could be involved in the evolution of Barrett's 
syndrome to adenocarcinoma (23). Additionally, prominent staining for TGR5 has been 
observed in 12% of human intestinal metaplasia, without any detectable expression in 
normal gastric epithelium controls (24). In a recent study, TGR5 overexpression in 
gastric adenocarcinoma has been associated with poor survival (25).  
Vitamin D deficiency has been considered as one of the major risk factors for the 
development of GI malignancies, such as pancreatic and colon cancers (26). Vitamin D 
binding to VDR, activates the receptor which makes it an active nuclear transcription 
factor and leads to the transcriptional induction of the expression of various genes (27). 
This is how vitamin D execute its profound antimitogenic and prodifferentiating effects on 
normal and malignant cells (28). Therefore, inadequacy in the levels of Vitamin D is 
plausibly causing abrupt regulation of cellular functions and growth. Besides these 
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functions, VDR has also been established as a receptor for secondary BAs such as 
LCA, and has a key role in the initiation of pathways which leads to the detoxification of 
LCA (29). Similar to VDR, activated human xenobiotic receptor (SXR) and its mouse 
homolog (PXR) have been associated with the detoxification of BA by activating 
enzymes, involved in BA metabolism (30, 31). Under cancer condition, PXR/SXR 
receptor is considered to be protective against oxidant induced apoptosis. Upon 
progression from normal epithelia to dysplastic lesions, the enteric NR transcriptome has 
been found to be reduced in both mouse and human models of colorectal cancer (20), 
suggesting that these transcription factors could have therapeutic and/or diagnostic 
potential that could be exploited to treat colorectal cancer.   
1B.4 Association between BA and mucins expression 
The first evidence that BA is important in the regulation in mucins secretion was 
provided by Klinkspoor JH et al. in 1995 (32). Hypersecretion of gallbladder mucin has 
been proposed as a pathogenic factor in gallstone formation. Therefore, the primary 
objective of the study was to understand the effect of biliary constituents on mucin 
secretion using normal, well-differentiated dog gallbladder epithelial cells. Interestingly, it 
was observed that alteration in the concentration of cholesterol or phospholipid had no 
effect on the extent of mucin secretion (32). However, TCA showed a dose-dependent 
increase in mucin secretion, signifying that bile salts, one of the major functional 
components of bile, are responsible for these stimulatory effects. Compared to 
hydrophilic BA, hydrophobic bile salts; TCDCA and TCA, showed more increased mucin 
secretion at 0.5 mmol/L (p< 0.01). A shift in the bile salt composition of bile towards 
more hydrophobic bile salts may cause mucin hypersecretion, and thereby participate in 
the initiation of cholesterol gallstone formation (32). Following, another study by Dray-
Charier N and colleagues have implicated the predominant involvement of calcium-
51 
 
dependent signaling pathways, particularly Ca2+/CaM-kinase II and protein kinase C 
(PKC) in BA-mediated hypersecretion by human gallbladder epithelial cells (33). 
Similarly, human colonic epithelial cells demonstrated increased mucin secretion upon 
BA stimulation. Taken together, these reports suggest that bile salts-mediated regulation 
of mucins secretion might be a common mechanism and one of the plausible reasons of 
increased secretion is to protect epithelia against the deleterious detergent action 
of bile salts as an adaptive response throughout the gastrointestinal tract. Later studies 
have apparently shown that BA play crucial role in the increased synthesis of both 
transmembrane and secretory mucins (34, 35). 
Clinically, atypical gastro-oesophageal reflux and BA have been associated with 
the occurrence of BE premalignant lesions, which are linked with an increase in mucin-
producing goblet cells and overexpression of mucins (36, 37). Multiple studies have 
postulated that a pattern of mucin staining in BE patients might be indicative of their 
increased tendency to progress from BE to adenocarcinoma (38). In normal esophagus, 
which has stratified squamous epithelium, there is positive expression for membrane 
bound MUC1 and MUC4 mucins. In the preneoplastic stage or BE, secretory mucins, 
such as MUC2, MUC5AC, MUC5B, MUC6, are expressed with MUC1 and MUC4. In 
high-grade dysplasia and adenocarcinoma of BE, downregulation in secreted mucins 
have been observed, whereas MUC1 and MUC4 mucin expression remain persistently 
high. It is therefore evident that there is a definite order in the appearance and 
subsequent decrease of various mucins in the Barrett's-adenocarcinoma sequence.  
MUC5AC mucin is strongly expressed in almost 100% of BE and in 61.5% of 
tissues obtained from EA (39). MUC5AC mucin has been found to express at high levels 
in BE tissues stimulated by duodenoesophageal in rat reflux model (39). Conjugated BA 
had more impact in the induction of MUC5AC gene expression at the transcriptional 
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level compared to unconjugated BA, by utilizing PI3K/AKT/AP-1 signaling pathway (39). 
Similar to MUC5AC, another secretory mucin, MUC2 also showed transcriptional 
induction in esophageal carcinoma cell lines (40). PKC-dependent activation of nuclear 
factor-κB (NF-κB) was implicated in BA-mediated transcriptional upregulation of MUC2 
in esophageal cancer (40). In addition to esophageal cancer, induction of MUC2 mRNA 
has also been noticed in DCA treated gastric cancer cell lines (41). DCA showed 
inhibitory effects on the invasion and migration of SNU-216 and MKN45 cell lines (41). 
Supportively, increased expression in E-cadherin along with reduced expression of snail 
and MMP-9 was observed upon DCA treatment. Multiple forms of BA have been 
previously identified as potent inducers of MUC4 expression in esophageal 
carcinogenesis associated with bile reflux (34, 42). Mechanistically, PI3K signaling, PKC 
and hepatocyte nuclear factor-1α were attributed to BA-facilitated increase in MUC4 
expression (34, 35). BA also leads to MUC1 upregulation via a PI3K–mediated 
molecular transcriptional mechanism in human esophageal adenocarcinomatous cell 
lines. The biologic consequences of the induction of mucins expression by BA in cancer 
cells are still unknown, but considering the association of both BA and mucins 
overexpression in cancer condition, all this data favors a role of this mode of mucins 
regulation by tumor cells for their progression and metastasis. The development of a 
mouse or rat model of carcinogenesis in which epithelial mucosa is exposed to bile or 
acid reflux or both will be very informative regarding the following: (1) deciphering the 
precise molecular mechanisms activated by BA to induce mucins expression, (2) 
evaluating the consequences of mucins overexpression during the carcinogenetic 
sequence on tumor cell behavior and biologic properties, and (3) demonstrating the 
pivotal role of BA as the main inducer of the expression of both membrane and secreted 
mucins. 
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However, it is still unclear whether this is the primary cause for the persistence of 
the BE in-spite of successful anti-reflux surgery, or if it reflects the genetic instability 
associated with this preneoplastic condition. Further studies in patients undergoing 
surveillance for Barrett's and dysplasia will help answer whether mucin gene expression 
has a diagnostic role in predicting those at risk and does not merely represent an artifact 
of progression. An open question is whether therapeutic manipulation of MUC gene 
expression will decrease the risk of malignancy for patients with BE and dysplasia. 
 
54 
 
1B.5 Reference List 
 (1)  Baptissart M, Vega A, Maqdasy S, Caira F, Baron S, Lobaccaro JM, Volle DH. 
Bile acids: from digestion to cancers. Biochimie 2013;95:504-17. 
 (2)  Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and 
clinical responses to bile acid sequestration. Diabetes Care 2009;32 Suppl 
2:S237-S245. 
 (3)  Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and 
pathophysiological implications. Pharm Res 2007;24:1803-23. 
 (4)  Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid 
receptors in metabolic regulation. Physiol Rev 2009;89:147-91. 
 (5)  Lafleur B, Lee W, Billhiemer D, Lockhart C, Liu J, Merchant N. Statistical 
methods for assays with limits of detection: Serum bile acid as a differentiator 
between patients with normal colons, adenomas, and colorectal cancer. J 
Carcinog 2011;10:12. 
 (6)  Sagar NM, Cree IA, Covington JA, Arasaradnam RP. The interplay of the gut 
microbiome, bile acids, and volatile organic compounds. Gastroenterol Res Pract 
2015;2015:398585. 
 (7)  Mahmoud NN, Dannenberg AJ, Bilinski RT, Mestre JR, Chadburn A, Churchill M, 
Martucci C, Bertagnolli MM. Administration of an unconjugated bile acid 
increases duodenal tumors in a murine model of familial adenomatous polyposis. 
Carcinogenesis 1999;20:299-303. 
 (8)  Narisawa T, Magadia NE, Weisburger JH, Wynder EL. Promoting effect of bile 
acids on colon carcinogenesis after intrarectal instillation of N-methyl-N'-nitro-N-
nitrosoguanidine in rats. J Natl Cancer Inst 1974;53:1093-7. 
 (9)  Cohen BI, Raicht RF, Deschner EE, Takahashi M, Sarwal AN, Fazzini E. Effect 
of cholic acid feeding on N-methyl-N-nitrosourea-induced colon tumors and cell 
kinetics in rats. J Natl Cancer Inst 1980;64:573-8. 
 (10)  Kobori O, Shimizu T, Maeda M, Atomi Y, Watanabe J, Shoji M, Morioka Y. 
Enhancing effect of bile and bile acid on stomach tumorigenesis induced by N-
methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. J Natl Cancer Inst 1984;73:853-
61. 
 (11)  Bernstein H, Bernstein C, Payne CM, Dvorak K. Bile acids as endogenous 
etiologic agents in gastrointestinal cancer. World J Gastroenterol 2009;15:3329-
40. 
 (12)  Hage M, Siersema PD, van DH, Steyerberg EW, Dees J, Kuipers EJ. 
Oesophageal cancer incidence and mortality in patients with long-segment 
Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J 
Gastroenterol 2004;39:1175-9. 
55 
 
 (13)  Guy NC, Garewal H, Holubec H, Bernstein H, Payne CM, Bernstein C, 
Bhattacharyya AK, Dvorak K. A novel dietary-related model of esophagitis and 
Barrett's esophagus, a premalignant lesion. Nutr Cancer 2007;59:217-27. 
 (14)  Payne CM, Bernstein C, Dvorak K, Bernstein H. Hydrophobic bile acids, genomic 
instability, Darwinian selection, and colon carcinogenesis. Clin Exp Gastroenterol 
2008;1:19-47. 
 (15)  Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development 
of liver tumors in the absence of the bile acid receptor farnesoid X receptor. 
Cancer Res 2007;67:863-7. 
 (16)  Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, Stellaard F, Shan B, 
Schwarz M, Kuipers F. Enterohepatic circulation of bile salts in farnesoid X 
receptor-deficient mice: efficient intestinal bile salt absorption in the absence of 
ileal bile acid-binding protein. J Biol Chem 2003;278:41930-7. 
 (17)  van de Winkel A, Menke V, Capello A, Moons LM, Pot RG, van DH, Siersema 
PD, Kusters JG, van der Laan LJ, Kuipers EJ. Expression, localization and 
polymorphisms of the nuclear receptor PXR in Barrett's esophagus and 
esophageal adenocarcinoma. BMC Gastroenterol 2011;11:108. 
 (18)  van de Winkel A, van Zoest KP, van DH, Moons LM, Kuipers EJ, van der Laan 
LJ. Differential expression of the nuclear receptors farnesoid X receptor (FXR) 
and pregnane X receptor (PXR) for grading dysplasia in patients with Barrett's 
oesophagus. Histopathology 2011;58:246-53. 
 (19)  Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D, Gao X, Zhang Y, 
Ganapathy V, Gonzalez FJ, Guo GL. Farnesoid X receptor deficiency in mice 
leads to increased intestinal epithelial cell proliferation and tumor development. J 
Pharmacol Exp Ther 2009;328:469-77. 
 (20)  Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A. Nuclear bile acid 
receptor FXR protects against intestinal tumorigenesis. Cancer Res 
2008;68:9589-94. 
 (21)  Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, 
Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor for 
bile acids (M-BAR). Biochem Biophys Res Commun 2002;298:714-9. 
 (22)  Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from 
basic research to clinical application. Dig Liver Dis 2014;46:302-12. 
 (23)  Hong J, Behar J, Wands J, Resnick M, Wang LJ, DeLellis RA, Lambeth D, Souza 
RF, Spechler SJ, Cao W. Role of a novel bile acid receptor TGR5 in the 
development of oesophageal adenocarcinoma. Gut 2010;59:170-80. 
 (24)  Tatsugami M, Ito M, Tanaka S, Yoshihara M, Matsui H, Haruma K, Chayama K. 
Bile acid promotes intestinal metaplasia and gastric carcinogenesis. Cancer 
Epidemiol Biomarkers Prev 2012;21:2101-7. 
56 
 
 (25)  Cao W, Tian W, Hong J, Li D, Tavares R, Noble L, Moss SF, Resnick MB. 
Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol 
Gastrointest Liver Physiol 2013;304:G322-G327. 
 (26)  Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of 
colon cancer? Int J Epidemiol 1980;9:227-31. 
 (27)  Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of 
gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am 
2010;39:255-69, table. 
 (28)  Newmark HL, Yang K, Kurihara N, Fan K, Augenlicht LH, Lipkin M. Western-style 
diet-induced colonic tumors and their modulation by calcium and vitamin D in 
C57Bl/6 mice: a preclinical model for human sporadic colon cancer. 
Carcinogenesis 2009;30:88-92. 
 (29)  Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, 
Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science 
2002;296:1313-6. 
 (30)  Zhang B, Xie W, Krasowski MD. PXR: a xenobiotic receptor of diverse function 
implicated in pharmacogenetics. Pharmacogenomics 2008;9:1695-709. 
 (31)  Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour 
A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer 
SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against 
liver toxicity. Proc Natl Acad Sci U S A 2001;98:3369-74. 
 (32)  Klinkspoor JH, Kuver R, Savard CE, Oda D, Azzouz H, Tytgat GN, Groen AK, 
Lee SP. Model bile and bile salts accelerate mucin secretion by cultured dog 
gallbladder epithelial cells. Gastroenterology 1995;109:264-74. 
 (33)  Dray-Charier N, Paul A, Combettes L, Bouin M, Mergey M, Balladur P, Capeau J, 
Housset C. Regulation of mucin secretion in human gallbladder epithelial cells: 
predominant role of calcium and protein kinase C. Gastroenterology 
1997;112:978-90. 
 (34)  Mariette C, Perrais M, Leteurtre E, Jonckheere N, Hemon B, Pigny P, Batra S, 
Aubert JP, Triboulet JP, Van S, I. Transcriptional regulation of human mucin 
MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and 
involves activation of the phosphatidylinositol 3-kinase signalling pathway. 
Biochem J 2004;377:701-8. 
 (35)  Piessen G, Jonckheere N, Vincent A, Hemon B, Ducourouble MP, Copin MC, 
Mariette C, Van S, I. Regulation of the human mucin MUC4 by taurodeoxycholic 
and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by 
hepatocyte nuclear factor 1alpha. Biochem J 2007;402:81-91. 
 (36)  Debruyne PR, Bruyneel EA, Li X, Zimber A, Gespach C, Mareel MM. The role of 
bile acids in carcinogenesis. Mutat Res 2001;480-481:359-69. 
57 
 
 (37)  Jankowski J. Gene expression in Barrett's mucosa: acute and chronic adaptive 
responses in the oesophagus. Gut 1993;34:1649-50. 
 (38)  Szachnowicz S, Cecconello I, Ribeiro U, Iriya K, El IR, Takeda FR, Corbett CE, 
Vaz Safatle-Ribeiro A. Mucin pattern reflects the origin of the adenocarcinoma in 
Barrett's esophagus: a retrospective clinical and laboratorial study. World J Surg 
Oncol 2009;7:27. 
 (39)  Song S, Byrd JC, Guha S, Liu KF, Koul D, Bresalier RS. Induction of MUC5AC 
mucin by conjugated bile acids in the esophagus involves the 
phosphatidylinositol 3-kinase/protein kinase C/activator protein-1 pathway. 
Cancer 2011;117:2386-97. 
 (40)  Wu J, Gong J, Geng J, Song Y. Deoxycholic acid induces the overexpression of 
intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal 
adenocarcinoma cells. BMC Cancer 2008;8:333. 
 (41)  Pyo JS, Ko YS, Kang G, Kim DH, Kim WH, Lee BL, Sohn JH. Bile acid induces 
MUC2 expression and inhibits tumor invasion in gastric carcinomas. J Cancer 
Res Clin Oncol 2015;141:1181-8. 
 (42)  Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon 
cancer: Solving the puzzle with nuclear receptors. Trends Mol Med 2011;17:564-
72. 
 
 
58 
 
 
 
 
 
 
 
 
 
CHAPTER IC 
 
Novel mechanisms implicated in MUC4-mediated increase in the 
stability of EGFR-family members in PC 
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1C.1 General introduction of altered mucins expression and localization under 
disease condition 
Mucins (MUC) are high molecular weight O-glycoproteins, predominantly expressed at 
the apical surface of the epithelial cells, and are classified into membrane bound MUC 
and secreted MUC (1-4). Tissue specific expressions of MUC have essential functions to 
provide protection, lubrication to epithelial cells, maintenance of epithelial characteristics, 
cellular adhesion, differentiation, and immunity (1-5). The expression of MUC is 
significantly altered during tumorigenesis and other pathological conditions. For 
example, MUC4 is not expressed in the normal pancreas, but the early pancreatic 
intraepithelial neoplasia (PanINs) precursor lesions have been shown to express MUC4, 
which further increases as the disease progresses (4-6). In addition, MUC4 is also 
overexpressed in breast cancer, gastric cancer and ovarian cancer (7-9), and its 
overexpression has also been associated with the poor prognosis of pancreatic cancer 
and cholangiocarcinoma (10, 11). However, MUC4 expression is down-regulated during 
prostate carcinomas (12) and urothelial cancer (13), suggesting the complicated context-
dependent role of mucins. Another example, MUC1 is overexpressed in various 
malignancies and inflammatory conditions (1, 14-16). Besides the aberrant expression of 
mucins, emerging evidence suggests that anomalies in their subcellular localization and 
resultant changes in their endocytic trafficking play critical roles under pathological 
conditions (17). 
In a cell, the majority of proteins are not pre-set to any single location and are in 
a steady-state distribution due to opposing egress (exocytosis) and entrance 
(endocytosis) pathways (18). These two pathways are extremely dynamic and are 
regulated by highly sensitive cross talks between different subcellular compartments. 
Endocytic pathways have always been considered as enduring mechanisms for 
60 
 
recycling molecules from the plasma membrane to different intracellular compartments, 
and reduce receptor density at the cell surface resulting in signal attenuation. Proteins 
could be endocytosed by utilizing; clathrin-mediated pathway, caveolae-mediated 
pathway, macropinocytosis, and phagocytosis (19). The MUC1 utilizes these pathways 
for endocytosis and cell surface localization (20-22) (Fig. 1C.1). Like other glycoproteins, 
MUC are also sorted after their internalization in the early or sorting endosome, where 
their fates are decided including, their recycling, transportation to the Golgi (retrograde), 
and proteosomal or lysosomal degradation. This is not only responsible for efficient and 
regulated cellular metabolism and signal transduction, but is also required for 
coordinating the functions of each intracellular compartment by maintaining their specific 
compositions. Intriguingly, the trafficking of MUC and other glycoproteins is mainly 
regulated by post-translational modifications, including phosphorylation, glycosylation, 
palmitoylation and ubiquitylation. In this chapter, we provide a perspective on MUC 
trafficking and its pertinence to pathological conditions. 
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Figure 1C.1 Diagrammatical representation of the intracellular transport of 
glycoproteins along endocytic and exocytic pathways. Internalization of cell surface 
glycoproteins occurs by clathrin-mediated, caveolin-mediated, or clathrin- & caveolin-
independent pathways, followed by the fusion of internalized vesicles with early 
endosomes (EE) where the cargo is sorted and targeted for either recycling (from trans-
Golgi, late endosome and recycling endosome) or for degradation (in lysosomes). The 
other exocytic route are representative of the secretory pathways, where glycoproteins 
are first synthesized and processed in the rough ER followed by their entry into the Golgi, 
where they are further modified, packaged and either targeted to the plasma membrane 
or secreted by the exocytic machinery. 
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Figure 1C.1 
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1C.2 Altered localization of MUC and its association with cancer condition 
 
In 1992, Ceriani and colleagues conducted immunohistochemistry (IHC) analysis of 
MUC1 cytoplasmic and membranous expression/localization on 227 breast cancer 
patients. They found that low cytoplasmic intensity and high cell surface localization of 
MUC1 correlated with better prognosis of breast cancer patients and survival (23). This 
observation was further validated by Rahn et al., who found that increased cell surface 
MUC1 expression in lower grade and estrogen receptor (ER)-positive tumors have better 
prognosis, whereas aberrant MUC1 cytoplasmic localization in tumors correlated with 
worse prognosis (24). Aberrant cytoplasmic MUC1 localization has also been correlated 
with high-risk papillary thyroid carcinoma (25). In breast ductal adenocarcinomas, MUC2 
and MUC5AC are localized in cytoplasm with granular staining pattern (14, 26, 27), 
whereas distribution of MUC5B expression changes from apical localization in non-
malignant breast cells to cytoplasmic and non-apical localization in malignant ductal 
breast carcinoma (28). Similarly, MUC3 cell surface expression has been correlated with 
poor prognosis, higher grade and negative ER expression in breast carcinoma (29). 
These studies clearly demonstrate that, aberrant localization of MUC is associated with 
cancer pathology (14, 23, 25, 26), and therefore, it is essential to investigate the 
mechanisms that alter trafficking of MUC among different subcellular compartments. So 
far, no definite mechanism has been established to understand the elevated intracellular 
presence of MUC in cancer, but different postulations, specifically for MUC1, have been 
put forth including; its impaired recycling, altered glycosylation, altered endocytosis and 
other presumed changes in MUC dynamics (Fig. 1C.2), which will be discussed in detail 
in the next sections.  
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Figure 1C.2: Mechanisms of intracellular transport and sorting of MUC1. MUC1 has 
demonstrated to be internalization by using clathrin and caveolin-mediated pathway, 
which is dependent on Rab5a, an early endosome marker. MUC1 has many interacting 
partners including EGFR family proteins, AP-2, Grb2 and β-catenin. MUC1 possess a γ-
secretase cleavage site and cleaved by the same enzyme in early endosome. Cleaved 
MUC1-C, which is still in contact with β-catenin travels to nucleus to increase the 
transcription of various genes that are regulated by the TCF promoter. MUC1, like other 
glycoproteins, undergoes multiple rounds of sialylation and glycosylation while continuing 
on the itinerary to the Golgi. MUC1 also has a CQCRRK sequence motif, which 
undergoes palmitoylation. These post-translational modifications and interacting protein 
partners play important roles in deciding the fate of MUC1.  
65 
 
 
 
 
 
Figure 1C.2 
66 
 
1C.3 EGFR family receptors  
Sustained proliferative signaling is the fundamental trait of cancer hallmarks (30) 
Normal cells regulate their growth by modulating the expression of growth factors and 
their receptors at an optimal time and concentration. On the other hand, cancer cells 
abrupt this crucial regulation in order to grow unrestrictedly (30). Role of aberrant 
glycoprotein trafficking in this sustained proliferative signaling can be exemplified by the 
understanding of Epidermal growth factor receptor (EGFR) family of receptor tyrosine 
kinases (RTKs) which constitute four receptors; epidermal growth factor receptor 
(EGFR), erbB2/HER2, erbB3/HER3 and erbB4/HER4 (31). Structurally, these receptors 
have a glycosylated extracellular N-terminal ligand-binding domain, a transmembrane 
region, and a C-terminal intracellular domain, which includes the kinase domain and 
multiple phosphorylation sites. EGFR and erbB4 are considered to be fully functional 
receptors due to their ability to bind ligands and autophosphorylate C-terminal tails 
through functional intracellular tyrosine kinase domains (32, 33). On the other hand, 
erbB2 is unique in that it does not have ligand binding domain, therefore, it has to 
heterodimerize with other EGFR family members in order to execute active signal 
transductions. Similar to erbB2, erbB3 needs to heterodimerize, but due to different 
reason, which is the lack of intrinsic tyrosine kinase activity (32). Interestingly, erbB4 is 
known for its established ability to transduce direct nuclear signaling by releasing its 
intracellular fragment that is cleaved by ligand-dependent dual protease (34). 
Upon ligand binding (EGF, transforming growth factor-alpha (TGF-α) or 
amphiregulin), receptors undergo homo- or hetero-dimerization, which is subsequently 
followed by the autophosphorylation of the receptor in specific tyrosine kinase residues 
within the cytoplasmic tail (35). The activated receptor recruits signaling complexes and 
activates the Ras/mitogen-activated protein kinase (MAPK), extracellular signal-
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regulated kinase, phosphatidylinositol 3-kinase (PI3K)/Akt, signal transducers and 
activators of transcription, and phospholipase C gamma pathways (31, 36). These 
pathways are potent oncogenic regulators of tumor cell growth, invasion, transformation, 
and survival. Moreover, EGFR-mediated signaling has also been implicated in 
angiogenesis, promotes invasiveness through matrix metalloproteinases, and stimulates 
tumor-cell motility that furthers metastasis (37, 38). 
1C.4 General mechanism involved in the regulation of EGFR trafficking and 
signaling 
Multiple studies have led us to know that fate of EGFR is dependent on 
various parameters comprising; the phosphorylation and ubiquitination status of the 
receptor and pH sensitivity of the ligand bound receptor (39). All these regulatory 
mechanisms are crucial for EGFR signaling. It is well established that binding of EGF to 
EGFR is followed by receptor internalization and multi-ubiquitylation by Cbl E3 ligase 
inside the endosomes while it is concomitantly participating in active cellular signal 
transductions (40). This multi-ubiquitination facilitates the sorting of EGFR towards the 
degradative route to lysosomes. Unlike EGF ligand, binding of EGFR to transforming 
growth factor-alpha (TGF-α) ligand leads to different outcome by avoiding prolonged 
ubiquitination, and thus hypo-ubiquitylated form would be prevented to take entry into 
the degradative lysosomal pathway, and prefer its routing directly to the recycling route 
back to the cell surface which helps cancer cells to accomplish sustain growth and 
proliferation (41). Interestingly, ubiquitination of the receptor is reliant on pH tolerance of 
ligand bound receptor. For example; EGF-EGFR binary complex is comparatively stable 
at low pH of endosomes, and can undergo polyubiquitination by Cbl ubiquitin ligases, 
followed by their targeting to the lysosomes for degradation (41). On the contrary, 
increased pH sensitivity of TGF-α, makes it to disassociate rapidly from the receptor and 
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prevents its polyubiquitination, and finally, facilitates its recycling back to the plasma 
membrane (41).  
Besides ligands, Cbl ubiquitin ligases are also among the primary 
regulators of RTKs (42). As they act as a negative regulator of RTKs, cancer cells have 
to come up with different strategies to inhibit their function. For instance, by facilitating its 
degradation or by the presence of inactivating mutations in the RING domain of Cbl. 
Approximately, 5% of human myeloid neoplasms have missense mutations, frameshift 
mutations or deletion in the E3 activity in the RING domain of Cbl resulting in the loss of 
its activity (43). Overexpression and mutational activation of Src along with 
overexpressed EGFR, found very frequently in cancers, which constitute one of the 
mechanisms that lead to Cbl degradation. Src is a non-receptor tyrosine kinase which is 
known to be activated by various stimuli including, EGFR. Bao and colleagues have 
reported the involvement of active Src in the obliteration of Cbl functions by inducing its 
tyrosine phosphorylation and polyubiquitination, with subsequent proteasomal 
degradation of Cbl (44). This decrease in Cbl protein expression leads to increased 
EGFR localization on the cell surface, which further facilitates Src activation, and 
therefore, promotes sustained cell proliferation. Receptor recycling and disintegration of 
the degradative mechanisms make cells to undergo repeated rounds of EGFR 
activation. Similar mechanisms have further been explored in other RTKs as well under 
tumorigenic condition. 
 
1C.5 Role of EGFR family members in PC development and progression 
The phosphorylation of protein kinases leads to the activation of multiple signal-
transduction pathways, which have a critical role in a many cellular processes, including 
cell growth, differentiation, and death. In PC, many tyrosine kinases were found to be 
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degregulated and overexpressed, such as EGFR (ErbB1), HER2/neu (ErbB2), VEGFR2, 
platelet-derived growth factor-α, FGF-1, CSF- 1 receptor, steroid receptor co-activator, 
and others. Interestingly, studies have shown that >70% of the known oncogenes and 
proto-oncogenes in cancer are tyrosine kinases (45). Therefore, blocking tyrosine kinase 
activity signifies a highly rationale and potential approach to treat cancer. 
Among multiple tyrosine kinases which are overexpressed in PC, EGFR axis is 
known to play the most important role in PC development and progression. EGFR 
overexpression has been observed in human PDAC and PDAC spontaneous mouse 
models (46). Primarily, its functions have been associated with increased proliferation 
and invasiveness of PC. The expression of activated EGFR was undetectable in WT-
mice, however, in the KrasLSL-G12D/+; Ptf1aCre/+ mouse model, at ∼8 weeks of age, 
when these mice exhibit metaplasia and mPanIN formation, had detectable expression 
of activated EGFR (46). In addition to EGFR, levels of transcripts for both EGFR and 
TGF-α, an EGFR ligand, were significantly upregulated by ∼2-fold. Amphiregulin 
(AREG), another EGFR ligand, was also upregulated relative to WT controls (46). Due to 
the observed highly prominent immunofluorescence staining of EGFR in larger acinar 
clusters of KrasG12D pancreata, especially near areas of metaplasia and mPanIN, it 
seems that activation of EGFR pathway is plausibly an early event in pancreatic 
tumorigenesis. Additionally, EGFR is found to be critical for acinar cell proliferation and 
its stimulation of MEK is necessary for trans-differentiation and transformation of acinar 
cells to a progenitor cell-like, metaplastic ductal epithelial cells. Thereby, EGFR controls 
the differentiation of neoplastic precursors and participates in pancreatic tumorigenesis 
(46). 
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Chronic activation of EGFR alone is sufficient to cause acinar to ducal 
metaplasia (ADM) both in vitro and in vivo. Importantly, blocking EGFR activity 
effectively eradicates KRAS-initiated pancreatic tumorigenesis, with or without 
pancreatitis induction, due to its critical role in amplifying ERK activation within the 
pancreas. Although subgroups of patients with defined molecular subtypes did respond 
to EGFR targeting, overall, the effect of anti-EGFR therapy on the survival of metastatic 
PDA patients was quite modest (47). Interestingly, KrasG12D; p53KO mice exhibited no 
added survival benefit in response to erlotinib treatment, suggesting towards the 
involvement of EGFR-independent mechanisms on the development and progression to 
fully developed PDAC in this spontaneous mouse model. Interestingly, increased MET 
activity has been observed in minority of EGFR negative tumors, suggesting that MET 
activation is plausibly required to circumvent EGFR deficiency. Altogether, these studies 
encourage us to define the essential molecular signals and the exact role of p53 
inactivation in order to improve the efficiency and efficacy of EGFR-targeted therapies 
for the better clinical outcome of PC patients. 
1C.6 Modulation of sub-cellular protein trafficking of EGFR family members by 
mucins 
Due to the loss of polarity in cancer, MUC1 and MUC4 localize all over the cell surface, 
instead of restricted confinement at the apical surface. This allows them to interact with 
cell surface proteins such as the EGFR family members, which normally exist at the 
basolateral sides of polarized cells (48, 49). MUC4 has shown to interact with 
HER2/ErbB2 in ovarian and pancreatic cancers (48, 50). MUC4-ErbB2 complex lead to 
the activation of various signaling pathways leading to cell proliferation and survival 
through stimulation of p38 MAPK phosphorylation (51). In the absence of the soluble 
ligand, the MUC4-ErbB2 complex leads to ErbB2 phosphorylation, which in turn, leads to 
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the phosphorylation of the ErbB2-ErbB3 heterodimer in the presence of neuregulin (52). 
MUC4 did not demonstrate interaction with ErbB3 in polarized cells, but loss of polarity 
also leads to MUC4-ErbB3 interaction. 
The tradeoff between phosphorylation and glycosylation (O-GlcNAc) is known to 
regulate intracellular trafficking of EGFR (53). MUC1 is known to interact with EGFR at 
plasma membranes of non-polarized breast epithelia which resulted in increased EGFR 
internalization, reduced lysosomal degradation and increased EGFR recycling back to 
the plasma membrane (49). Likewise, MUC4 has also shown to interact with the other 
EGFR family member, HER2, via its EGF-like motifs located at the juxtamembrane 
domains (54). The EGF-like motif is also present in other MUC like MUC17, and has 
been implicated in the pathogenesis of colonic inflammation and cancer, can presumably 
initiates EGFR mediated oncogenic signaling. Interestingly, activated EGFR 
phosphorylates YEKV motif in MUC1-CT to induce MUC1 interaction with c-Src and β-
catenin. MUC1-CT also has a γ-secretase cleavage motif and the cleavage by γ-
secretase results in the release of intracellular MUC1-CT to regulate MUC1 mediated 
cellular proliferation (55). The MUC1-CT and E-cadherin both compete for β-catenin 
binding due to the loss of the cellular polarity (56, 57). In breast cancer, silencing of 
galectin-3 strongly enhanced the interaction between MUC1 and EGFR in response to 
EGF stimulation and the reduced rate of their endocytosis, which leads to the noticeable 
cell surface localization of MUC1 and EGFR (58). Therefore, possibly galectin-3 
overexpression in cancer may be related to the frequently observed intracellular 
retention of MUC1.  
Despite of the absence of a classical mitochondrial localization signal, 
MUC1-C gets localized to the outer membrane of mitochondria by its interaction with 
cytosolic chaperones such as HSP70 and HSP90 (59). MUC1-C mitochondrial 
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localization has been correlated with the diminished cell death response to the DNA 
damage and other cellular stress by inhibiting the release of cell-death causing factors. 
Cytosolic sequestration of MUC1 exposes its hydrophobic TM domains that facilitate 
their binding with chaperones, and thus targeting to the mitochondria. Interestingly, 
Heregulin (HRG), a ligand of EGFR family receptor family, enhances the association 
between MUC1-C and HSP90 due to autophosphorylation and activation of c-Src in 
HCT116/MUC1 cells (60) and facilitates the translocation of MUC1-C to the 
mitochondria. In breast cancer cells, FGF1 plays similar role in the mitochondrial 
localization of MUC1 using similar molecular mechanism (56).  
Like EGFR family members, β-catenin also resides at the lateral side of the cell. 
The loss of polarity allows β-catenin to interact with the SAGNGGSSL motif present in 
MUC1-C and the loss of E-cadherin-mediated cell-to-cell interaction at MUC1 positive 
sites. Under normal conditions, β-catenin interacts with the similar SXXXXXSSL motif of 
E-cadherin, which is required for the maintenance of the adherent junction. This 
interaction between β-catenin and MUC1 is regulated by EGFR mediated 
phosphorylation of the crucial tyrosine residues present on MUC1-CT (61). Additionally, 
phosphorylation of the serine residue in SPYEKV sequence by glycogen synthase 
kinase 3β (GSK3β), a site adjacent to the β-catenin binding motif inhibits the interaction 
between MUC1 and β-catenin (62); whereas c-Src mediated phosphorylation of the 
tyrosine residue in that same SPYEKV site enhances this interaction (63). MUC1 shows 
binding affinity to the Armadillo repeats and the non-repetitive COOH-terminal region of 
β-catenin (64). MUC1 and β-catenin, once in complex, mitigates GSK-3β 
phosphorylation of β-catenin and translocate to the nucleus to transcriptional activation 
of various genes implicated in increased carcinogenic potential and metastasis (65). In 
breast and colon cancers, HRG stimulation facilitates the binding between MUC1-CT 
73 
 
and γ-catenin, allowing MUC1 to function as a vehicle for γ-catenin nuclear translocation 
(66). These findings indicate that MUC1-CD has crucial functions in integrating signals 
from the EGFR and Wnt signaling pathways. Unlike in MUC1 and MUC4, the RTK 
binding motif is not present in MUC16-CT (67). MUC16 secretion is influenced by EGF 
stimulation through phosphorylation of MUC16-CT (68). MUC16 knockdown in ovarian 
cancer cell lines caused increased cytoplasmic localization of β-catenin and E-cadherin, 
and was linked with greater cellular motility and invasiveness (67). In agreement, 
reduction of MUC16 expression has been related with advanced ovarian cancer (69). 
Taken together, these studies pointed towards the possibility that the interactions 
between MUC16, E-cadherin and/or β-catenin permit MUC16 to modulate various 
signaling pathways.  
Bitler et al. found evidence that MUC1 has regulatory functions in the trafficking 
and nuclear activity of EGFR (61). Presence of MUC1 showed enhance interaction 
between EGFR and phosphorylated RNA polymerase II, which implies that MUC1 can 
impact the association of EGFR with transcriptional machinery at the promoter region as 
the loss of MUC1 reduces the occupancy of EGFR at the cyclin D promoter region (61). 
Besides controlling such inter-molecular interactions, MUC1-C also regulates Rab31 
expression, which is an early endosome protein belonging to the subfamily of small 
GTPase Rab5 (70). MUC1-C and estrogen receptor form a complex at the Rab31 
promoter and are responsible for the transcriptional activation of Rab31. According to 
this study, patients who express MUC1-C and Rab31 are resistant to tamoxifen 
treatment indicating the possible involvement of these two molecules in determining the 
efficacy of tamoxifen therapy (70). 
 
 
74 
 
1C.7 Summary and Conclusions 
MUC are the chief macromolecular components of epithelial mucus and have been 
incriminated in the pathogenesis of various diseases. Their mislocalization has been well 
associated with the pathobiology of several cancers such as, breast and colorectal 
cancer.  Under normal condition, MUC are localized predominantly on the apical surface, 
but loss of polarity allows them to extend all over the cell. It favors multiple MUC-protein 
interactions that suppose not to occur in a polarized cell. Several unique domains 
present in MUC play crucial important role in determining these interactions. 
Mislocalization of MUC also facilitates MUC interactions with other novel proteins, which 
further help MUC as well as other proteins (Y-catenin) to translocate to the different 
subcellular compartments. Though many postulations have been kept forth to attribute 
the altered localization of MUC including altered glycosylation, sialylation, and differential 
protein-protein interactions, still the exact mechanism behind it has not been explored 
and need immediate attention to make better therapeutic interventions. 
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General Hypothesis and Objectives 
 
Over the past few decades, multiple studies have established key roles of mucins in 
malignant diseases. The expression of mucins is significantly altered during 
tumorigenesis and other pathological conditions. In this dissertation, I have primarily 
focused on MUC4, which is one of the most differentially expressed proteins in PC and 
has strongly been implicated in the progression, metastasis and chemoresistance of PC. 
MUC4 is not expressed in the normal pancreas, but the early pancreatic intraepithelial 
neoplasia (PanINs) precursor lesions have been shown to express MUC4, which further 
increases as the disease progresses. The ability of NIH3T3 fibroblasts cells to form 
tumors in nude mice upon ectopic expression of MUC4 was the first evidence which has 
experimentally proved its oncogenic function. Considering the significant role of MUC4 in 
tumor biology, additional studies are required to highlight its novel functions and 
regulatory mechanisms. Although studies have associated extrinsic (cytokines) and 
intrinsic factors (NCOA3) with the regulation of MUC4, there is no study which has 
addressed the role of PC microenvironmental stress (hypoxia and oxidative stress) on 
MUC4 expression. Both Hypoxia and MUC4 has been associated with PC 
aggressiveness and chemoresistance. Moreover, hypoxia has been shown to regulate 
mucins expression in solid tumors. All these studied led me to hypothesize that hypoxia 
has a significant impact on MUC4 expression in PC, which aggravate the PC conditions. 
Besides PC microenvironment, the critical anatomical position of pancreas can influence 
the growth of pancreatic tumors. However, these mechanisms are unexplored. The 
majority of tumors (about 75%) arise at the head of the pancreas. Most of the PC 
patients develop extrahepatic cholestasis due to common bile duct obstruction by 
increasing tumor size which results in hyperbilirubinemia and elevated circulatory levels 
of bile acids (BA). Multiple studies have implicated BA as tumor promoter for various 
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cancers. A recently performed meta-analysis has shown that patients with the history of 
cholecystectomy have significantly higher risk to develop PDAC. These studies incited 
me to hypothesize that BA play important role in PC tumorigenesis by regulating the 
expression MUC4 oncogene.  
In addition to regulation, I have also focused to elucidate the novel functional 
properties of MUC4 in PC. MUC4 is known to regulate the fate of EGFR family proteins 
in several cancers including PC. However the precise mechanism involved is still 
ascertain. Emerging reports have shown altered expression of RAB proteins in various 
cancers. Additionally, a recent study has shown that mucins can also regulate the 
expression of RABs to influence the trafficking of oncogenic proteins in cancer. It 
brought me to my next hypothesis that MUC4 determines the fate of EGFR family 
members by modulating the expression and activity of RAB GTPases in PC. In addition 
to PC cells, MUC4 expression has recently been detected in activated PaSC. 
Interestingly, our preliminary studies have shown reduction of MUC4 expression upon 
treatment with RA, which is known to change the status of activated PaSC to quiescent, 
suggesting a plausible link between MUC4 expression and activation status of PaSC. It 
led me to hypothesize that MUC4 regulates the activation status of PaSC and thereby, 
promotes desmoplastic reactions in PC microenvironment, which is known to exacerbate 
PC condition. 
Broadly, the aims for my dissertation research were as follows: 
1. To elucidate the role of microenvironment stress (hypoxia and oxidative stress) on 
MUC4 regulation in PC. 
2. To investigate the impact of bile acids (BA) on MUC4 expression in PC. 
3. To identify the novel functions of MUC4 in epithelial (ductal tumor) and nonepithelial 
(PaSC) cells under PC condition. 
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CHAPTER II 
Materials and methods 
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II.1 Cell culture: All PC (CAPAN1, Colo357, HPAC, AsPC1, MIA PaCa-2, and Panc1) 
and LS180 colon cancer cell lines were obtained from American Type Culture Collection 
[ATCC] (Manassas, VA, USA) and cultured in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin, 
and streptomycin (100 µg/ml)) at 37°C with 5% CO2 and were tested mycoplasma-free 
before conducting the experiments. CD18/HPAF is a metastatic clone derived from the 
HPAF cell line (1), whereas T3M4 cell line is derived from lymph node metastasis of 
pancreatic exocrine adenocarcinoma (2). T3M4 PC cell line was a gift from Dr. RS 
Metzgar (Duke University, Durham, NC) and cultured in 10% DMEM media. UMSCC1 
and UMSCC10B (head & neck cancer) cell lines were a kind gift from Dr. Thomas Carey 
(University of Michigan, Ann Arbor, MI, USA) and cultured in 10% minimal essential 
medium (Invitrogen, Carlsbad, CA). Human ductal pancreatic epithelial (HDPE) cells 
were a kind gift of Dr. Thiru Arumugam (MD Anderson, Houston, Texas) and cultured in 
keratinocyte serum-free (KSF) medium supplemented with epidermal growth factor and 
bovine pituitary extract. The method of generation and maintenance of stable clones of 
MiniMUC4 expressing MIA PaCa-2 and MUC4 kd CAPAN1 cells have been described 
previously (3, 4). Pancreatic stellate cells (PaSC) derived from PC patient and 
immortalized with E6/E7 were obtained from Dr. Pankaj K. Singh (UNMC) and were 
cultured in 10% DMEM.  
II.2 Procurement of human and murine PDAC samples: Formalin-fixed and paraffin-
embedded PC Whipple tissue specimen and Rapid Autopsy (IRB-091-01) tissue array 
(consisting of 3 normal pancreas, 25 primary PC with 1 colon and 1 kidney as controls) 
were obtained from University of Nebraska Medical Center and used for 
immunohistoflorescence analysis. For mRNA expression profiling, frozen PC tissues 
were obtained from cooperative human tumor network (CHTN) and UNMC. 
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The detailed information for pancreatic juice collection from PC patients has been 
provided in our previous publication (5). Plasma samples were collected using an 
Institutional Review Board (IRB number PRO07030072) approved protocol at University 
of Pittsburgh (Pittsburgh, PA) from PC patients. Further details of the study design 
(including exclusion and inclusion criteria) have been mentioned earlier (6). A written 
informed consent was obtained from all patients and controls prior to entrance into the 
study. From triple-transgenic animals, KrasG12D/+; p53R172H/+; Pdx1-Cre (KPC), and their 
contemporary littermates, mice were sacrificed and blood collection was done at 5, 7, 
10, 15, 20 and 25 weeks (wk) of age. The mouse model was maintained at UNMC by 
crossing LSL-KrasG12D with LSL-Trp53R172H/+ transgenic mice as described 
previously (7, 8). Whipple tissue specimens were obtained from UNMC and used for 
immunohistoflorescence analysis. For mRNA expression profiling, frozen PC tissues 
were obtained from cooperative human tumor network (CHTN) and UNMC (IRB- 491-
97). For tissues obtained through UNMC, a written informed consent was obtained for all 
non-archival tissue before their collection. 
II.3 Treatment of cells with hypoxia and pharmacological reagents 
Chapter 3  
Hypoxic exposure was carried out at 37°C in a humidified incubator (CoyLab, MI, USA) 
with 94% N2, 5% CO2, and 1% O2. For inhibition studies, before hypoxia or H2O2 
exposure, cells were treated with pharmacologic inhibitors: MG132 (Sigma Aldrich, St. 
Louis, MO), CHX (Sigma), YC-1 (Sigma), NAC (Sigma), α-TS (Sigma), VB (Sigma) and 
RAP (Sigma). 
Chapter 4  
Deoxycholic (DCA) and chenodeoxycholic acid (CDCA) were dissolved in sterile ethanol. 
For inhibition studies, wortamannin (phosphoinositide 3-kinase (PI3K) inhibitor, 1 μM, 
Cell Signaling Technology), SP100625 (JNK inhibitor; 35 μM, Merck Millipore), FAK 
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inhibitor 14 (FAK inhibitor, 15 μM, Cayman’s chemical), U1026 (MAPK inhibitor, 10 μM, 
Promega) and actinomycin-D (2 μg/ml, Sigma) were given 1h prior to BA treatment.  
Chapter 5 
CBP: CREB interaction was prevented by using 20 µM of selective pharmacological 
inhibitor (CAS 92-78-4-Calbiochem) to block CREB-mediated upregulation of Rab5A 
gene. CAPAN1 and CD18/HPAF cells were cultured in serum free media 12h prior to 
treatment. Following, cells were treated with 200 nM of insulin (CAS Number 11061-68-
0, Sigma) for 4h and RNA isolation was performed.  
Chapter 6 
PaSC cells were serum starved for 8h and then overnight RA (Sigma) treatment was 
given at indicated concentrations. 
II.4 Knocked down and overexpression experiments: Transient knocked down of 
HIF-1α and ATG7 in PC cell lines was done by established targeted ShRNA sequence 
and commercially available siRNA oligonucleotides (Cell Signaling Technology, 
Catalogue no. 6604 S), respectively, by using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer's instructions. To transiently knockdown FXR, commercially 
available FXR siRNA (Santa Cruz biotechnologies (SCB), Dallas, TX, USA) were used. 
For transient overexpression of RAB5A in PC cells, we used commercially available 
mRFP-Rab5A construct (addgene). For transfection purposes, lipofectamine 2000 (Life 
Technologies; Carlsbad, CA, USA) was used, according to the manufacturer’s protocol. 
MUC4 was stably knockdown in PaSC using targeted sh-RNA constructs: 
Shmuc4-1(referred as Sh-1 MUC4):5’AGCTTAAAAAGGAGATGGCTATTTCGAAATCTC 
TTGAATTTCGAAATAGCCATCTCCGGG-3’and shmuc4-31 (referred as Sh-3 MUC4 on 
chapter 6) 5’AGCTTAAAAAGCATGAAACTCGACGCGTTTCTCTTGAAAACGCGTCGA 
GTTTCATGCGGG-3’ construct (pSUPER-Retro-sh-MUC4) in PaSC. Scramble control 
(sh-control) and pSUPER-Retro-sh-MUC4 has been transfected into packaging cell 
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Phoenix using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 48h post 
transfection, viral particles were collected and used to infect PaSC cells. Pooled 
population of MUC4 kd cells were obtained using antibiotic selection (Puromycin 4 
μg/ml), and were further expanded to confluent levels to obtain stably transfected cells.  
II.5 Immunoblotting: Immunoblot analysis was performed as described previously (9). 
Briefly, cells were lysed with radioimmunoprecipitation buffer (50 mM Tris-HCl pH-7.5, 
150 mM NaCl, 1% Nonidet P- 40, 0.5% sodium deoxycholate, and 0.1% SDS) 
supplemented with complete protease inhibitor mixture (Roche), 2mM Na3VO4, 10mM 
NaF and 1mM PMSF on ice. Cell lysates were cleared by centrifugation and quantified 
using the bicinchoninic acid method. Due to high-molecular weights of MUC4 (~ 950 
kDa) and MUC1 (~ 250 kDa), electrophoresis was performed on 2% SDS-agarose gel, 
whereas molecules less than 250 kDa were resolved by SDS–PAGE under reducing 
conditions and blotted onto a polyvinylidene difluoride membrane membrane (Millipore). 
Membranes were incubated overnight at 40C with primary antibodies (Table 2A). Blots 
were washed and probed with peroxidase-conjugated secondary antibodies, and the 
bands were visualized using enhanced chemiluminescence (ECL) method 
(Thermoscientific).  
II.6 Isolation of cytoplasmic and nuclear fractions: Briefly, after 4h of 50 µM of DCA 
or CDCA treatment, CD18/HPAF cells were washed with ice-cold PBS and incubated 
with a cytoplasmic extraction buffer (10 mM HEPES, pH 7.4, 10 mM KCl, 0.2% NP-40, 
0.1 mM EDTA, 10% glycerol, 1.5 mM MgCl2, supplemented with protease inhibitor, 1  
mM DTT, 1  mM PMSF, 5  mM Na3VO4, 5  mM NaF) for 1h at 4
0C. Cells were centrifuged 
at 800 × g and the supernatant was labeled as cytoplasmic extract, and the remaining 
pellet was washed with PBS and then incubated for 1h with the nuclear extraction buffer 
(20  mM HEPES (pH 7.6), 420  mM NaCl, 1  mM EDTA, 20% glycerol, 1.5  mM MgCl2, 1  
mM DTT, 1 mM PMSF, 5 mM Na3VO4, 5  mM NaF). Following incubation, the pellet was 
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sonicated for 10 s at 60% amplitude, and then subjected to centrifugation at 13,000 xg 
for 10 min. The obtained supernatant was collected as a nuclear extract. The purity of 
the fractions were checked by analyzing the expression of SP1 (nuclear protein) and 
GAPDH (cytoplasmic protein) in collected lysates (Table 2.A). 
II.7 Confocal Immunofluorescence microscopy: PC cells (1X105) were grown on 
sterilized cover slips for 24h and treated with appropriate vehicle control (media or 
DMSO), CoCl2 (150 μM), H2O2, hypoxia and VB, and further incubated for 24h. Following 
treatment, cells were fixed with 4% formaldehyde, permeabilized (0.2% saponin), 
blocked (with normal goat serum) and incubated with the primary antibodies. For 
immunohistofluorescence, we deparaffinized tissue sections with xylene, rehydrated with 
decreasing concentrations of ethanol and incubated tissues for 30 min. with 3% H2O2: 
methanol solution. Tissues sections were blocked in 2.5% horse serum for 2h and 
incubated with primary antibodies (Table 2A). Following primary antibody incubation, 
cells were washed and incubated with FITC and Texas red conjugated secondary 
antibodies.  
To label autophagic vacuoles, hypoxia and H2O2-treated PC cells were incubated 
with 50 μM of MDC (Sigma) at 37°C for 10 minutes (10). After incubation, cells are 
washed four times with PBS; coverslips were mounted and immediately analyzed. All the 
images were taken by using LSM 510 microscope, a laser scanning confocal 
microscope (Carl Zeiss GmbH, Thornwood, NY) in the respective channels. The 
intensity colocalization plot was made by using the Zen lite 2012 software. Image J 
software was used to determine the Pearson correlation coefficient and MFI values for 
both 8-OHG and MUC4. For box plot, the fluorescence intensities (FI) of 8-OHG were 
sorted, according to the median FI of MUC4. Values more than median FI of MUC4 is 
considered as MUC4 high or MUC4H and values lower than median FI was taken as 
MUC4 low or MUC4L.  
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II.8 Immunohistochemical staining: Paraffin embedded mouse and human tissues 
were deparaffinised in xylene for 4 X 10 min washes, followed by rehydration through 
graded ethanol. To block endogenous peroxidase, tissue slides were kept in 3% 
hydrogen peroxide/methanol for 30 min. 0.01 M preheated citrate buffer (pH −6.0, 90°C) 
was used for antigen retrieval for 15 min, and the slides were cooled and then washed 
with PBS. Following, slides were blocked using horse serum (ImmPRESS kit; Vector 
Labs) for 2 h and sections were incubated overnight at 4°C with primary antibodies 
(Table 2A) diluted in PBS. Slides were washed with PBS, incubated with the secondary 
antibody (peroxidase-labeled universal anti-mouse/anti-rabbit IgG, ImmPRESS kit; 
Vector Labs) for 1h at RT and then washed four times in PBS and were developed using 
DAB as substrate (DAB substrate kit; Vector Labs). The sections were counterstained 
with haematoxylin (Vectors Lab) and washed in tap water, dehydrated in increasing 
grades of alcohol (20–100%), washed with xylene for 5 min and dried overnight at RT. 
Lastly, slides were mounted using paramount mounting medium (Fisher Scientific) and 
images were obtained by using Nikon Eclipse E400 light microscope (Kawasaki, Japan). 
II.9 Measurement of florescence to analyze ROS levels and autophagic vacuoles: 
To analyze ROS production, PC cells were incubated with 1μM 2′-7′-Dichlorofluorescein 
diacetate (DCFDA) (Sigma) for 15 min (11). After three washes with PBS, cells were 
collected in 500 μl of PBS and analyzed (at 488 nm) using flow cytometry. 
For the detection of autophagic vacuoles (positive for MDC) (Suppl. Fig 4A), cell 
lines were incubated with 50 μM of MDC at 37°C for 10 minutes. Following, cells were 
washed thrice with PBS and florescence was measured immediately at 300 nm using 
florescence reader (Biotek, SMATBLD). To quantify number of apoptotic and necrotic 
cells, PC cells were serum starved for 12h, followed by 48h treatment of CD18/HPAF 
cells with 1% hypoxia, either alone or in the presence of NAC (2.5 mM) or CQ (50 uM). 
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After the completion of treatment, Annexin-V-cy5 and propidium iodide (PI) (BD 
biosciences) staining were performed and analyzed by flow cytometry. 
II.10. RT- PCR: RNA was isolated using QIAGEN RNeasy mini kit (Qiagen, Valenica, 
CA, U.S.A.) and cDNA was synthesized using 2 μg RNA, random hexamer primers, and 
Super Script II RNase reverse transcriptase (Invitrogen) and quantitative real-time PCR 
(qRT-PCR) was performed using gene specific primers (Table 2B) using the 
standardized protocol established in our lab, using SYBR Green chemistry. β-actin was 
used as an internal control. The relative fold differences in gene expression were 
calculated using the ΔΔCt method with β-actin as a normalization control (12). For 
reverse transcriptase-PCR (RT-PCR), RNA was isolated and cDNA was prepared as 
mentioned earlier for qRT-PCR, using the following steps: initial denaturation at 95°C for 
5 min., followed by 35 programmed cycles at 95°C for 1 min., 58°C for 1.5 min. and 
72°C for 1 min., with a final incubation at 72°C for 10 min. The amplified product was 
detected by electrophoresis on 2% agarose gels.  
II.11 Quantitative chromatin immunoprecipitation (ChIP): PC cells (CD18/HPAF) 
were starved of serum for 8h and treated with DCA or CDCA for 4h. Afterward, the ChIP 
experiment was performed as described previously (13) and has been repeated more 
than three times. In detail, 1% formaldehyde was used to cross-linked chromatin, which 
was isolated and sheared into 500–1000 bp fragments by sonication (Bioruptor UCD-
200, Diagenode; New York, NY, USA). As an input, 1% of the sonicated DNA was used. 
The remaining sonicated DNA fraction was used for the pull down experiment. The 
concentrations of antibodies used for overnight incubation at 4°C were as follows: 5 μg 
of anti-c-Jun (SCB#1694X) and IgG (negative control). MUC4 promoter targeted primers 
were used to amplify and study the enrichment of the fragmented DNA using real-time 
qPCR. The details of the primers are given in Table 2C. Immunoprecipitated qPCR Ct 
(cycle threshold) values were normalized to input Ct values. 
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II.12 Total BA estimation method: To analyze total BA concentration in pancreatic 
juice and plasma samples, we used a highly sensitive bile acid estimation assay kit 
(Diazyme, NBT, DZO92A-k). To increase the precision of the test, each sample was 
analyzed in triplicates. We used deoxycholic acid for making the reference plot and were 
serially diluted from 1.25 µ mol/L to 150 µ mol/L. After completing the BA estimation 
assay according to the manufacturer’s protocol, ELISA plates were read at 405 nm and 
the collected data was analyzed using SOFTMAX PRO software (Molecular Devices 
Corp., Sunnyvale, CA). 
II.13 Growth inhibition and growth kinetics assay 
Chapter 3 
For the growth inhibition assay, 5 X 103 PC cells were plated onto flat-bottomed 96-well 
plates (Costar, Corning, NY). After 24h, cells were treated with 1% hypoxia and 
indicated concentrations of H2O2, NAC and VB for an additional 24h. Subsequently, MTT 
assay was performed as per the standard procedure.  
For growth kinetics assay, 50 X 103 PC cells were plated in triplicates into six-well 
plates in triplicates and cultured in serum-free DMEM media for 12h. Following, cells 
were first pre-treated with NAC (2.5 mM)  for 30 mins and then incubated with 1% 
hypoxia or oxidative stress condition (H2O2). Cells were counted at indicated time-points 
by using automated cell counter (Invitrogen, CountessTM).  
Chapter 5 
20 x 103 scr and MUC4 kd CAPAN1 cells were plated in triplicates into six-well and 
cultured in serum-free DMEM media for 12h. Following, cells were treated with EGF 
(20ng/ml) containing DMEM media supplemented with 2% FBS. Cells were counted at 
indicated time-points by using automated cell counter (Invitrogen, CountessTM). 
Chapter 6 
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For growth kinetics assay, 50 X 103 PaSC cells were plated in triplicates into six-well 
plates in triplicates and cultured in serum-free DMEM media for 12h. Following, cells 
were cultured in 2% serum containing DMEM media and counted at indicated time-
points by using automated cell counter (Invitrogen, CountessTM).  
II.14 Anchorage-dependent colony formation assay: Briefly, PaSC cells were plated 
at densities of 2000 cells per well in 6-well plates and cultured in regular DMEM medium. 
After overnight incubation, unattached cells were removed and attached cells were fed 
with fresh regular medium every three days for 2 weeks. At the end of the experiment, 
the colonies were stained with 0.2% crystal violet solution (Sigma-Aldrich) containing 
50% methanol. At least two independent experiments were performed in triplicate. 
II.15 Luciferase promoter assay: To perform this assay, previously designed and 
established pGL3-MUC4 deletion constructs were used (14). PC cell lines were plated in 
six-wells in triplicates and repeated thrice. Transient transfection was performed with 
MUC4 deletion constructs using lipofectamine 2000 (Life Technologies; Carlsbad, CA, 
USA). Next day, the media was first changed to 10% FBS containing DMEM for 12h (to 
alleviate cellular stress of transfected cells) and then to serum free media for additional 
8h. Subsequently, transfected cells were treated with BA for 4h in serum free condition. 
Following treatment, cells were lysed using reporter lysis buffer (Promega; Madison, WI) 
and subsequently, the activity of luciferase and beta-galactosidase activity was 
measured using Steady-Glo Luciferase assay system (Promega, E2510) and β-
galactosidase assay kit (Promega, E2000). Fold activation of luciferase activity in BA-
treated cells were calculated and compared with untreated cells. Putative transcription 
binding sites on MUC4 distal promoter were determined by ALGGEN PROMO software 
(where similarity score of >0.85 was used to screen transcription factor binding sites). 
II.16 Plasmids and cloning strategy: Standard PCR and molecular cloning 
techniqueswere used to make constructs. For expression in the mammalian system, 
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p3X-FLAGCMV9 (vector contain N-terminal plasma membrane targeted sequence, 
Sigma) plasmids were used to make various constructs. DNA fragments encoding the 
carboxyl-terminal region of MUC4 (150 amino acids) with deletion of first EGF-L, second 
and third EGF-L, all three EGF-L motifs, cytoplasmic tail (of 21 amino acids) and 
truncated constructs (expressing only MUC4-EGF and CT in different combinations) as 
depicted in Fig. 2A were amplified using specific primers from synthesized cDNA.  In 
frame GFP was placed upstream of MUC4 fragment for the live cell imaging (as our EGF 
ligand is tagged with Rhodamine). The protein expressions of the designed 
3XFLAG.GFP.MUC4 truncated constructs were confirmed in the AsPC1 PC cell line by 
performing transfection, using lipofectamine 2000 according to manufacturer’s protocol 
(Fig. 2B). All the constructs were verified by sequencing. 
II.17 Internalization experiment via different approaches 
Live Imaging by Time-Lapse Fluorescence Microscopy: Cells seeded on a Lab-Tek 
chambered coverglass system (Nunc, Rochester, NY). Live images of the cells were 
obtained a Zeiss LSM 5 Pascal confocal microscope (Zeiss). Temperature was 
maintained at 37°C with a water heated stage and lens warmer (Zeiss). The laser 
excitation setting was maintained at 543 nm for Rhodamine-tagged EGF (Invitrogen), 
with emission detected by appropriate filter sets as supplied by the manufacturer. For 
live pulse chase, cells were starved for 8h followed by a 15 min. binding of the EGF 
ligand at 40C. Cells were then washed three times with PBS followed by incubation in 
complete media, and then the movement of EGF bound EGFR was monitored for the 
indicated time-points. 
Flow cytometry: PC cells were seeded in triplicates on six-well plate. After cells 
confluency reach to 60-70%, cells were serum starved for 8h followed by EGF 
stimulation at 370C for indicated time points which leads to EGFR internalization. 
Following internalization, we replaced the media to 10% serum containing media for 
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recycling purpose for 30 to 60 mins. Subsequently, cells will be washed 3 times with cold 
PBS and fixed with 4% paraformaldehyde. The mean florescence intensity will be 
measured by using flow cytometry approach at 568 nm as the ligand is labeled with 
Rhodamine.  
Confocal microscopy: PC cells were seeded on coverslips. After cells confluency 
reach to 60-70%, cells were serum starved for 8h followed by EGF stimulation 
(unlabeled) at 370C for indicated time points which leads to EGFR internalization. 
Following internalization, we replaced the media to 10% serum containing media for 
recycling purpose for indicated time-points. Subsequently, cells will be washed 3 times 
with cold PBS and fixed with 4% paraformaldehyde. To pinpoint EGFR localization, 
colocalization experiment of EGFR with Rab5A (early endosome marker) and Rab7 (late 
endosome marker) was performed using the similar above mentioned protocol (section 
II.7) 
II.18 Cell motility assay: A six-well chamber insert containing polyethylene 
teraphthalate membranes with a pore size of 8 μM (Becton Dickinson, Franklin Lakes, 
NJ, USA) was used for motility assay. The PC (CD18/HPAF) and PaSC cells were 
seeded at 1 × 106 and 0.5 x 106 in serum free media. After 48 h, cells reached to the 
lower chamber (serum containing media) were stained with Quick-Diff kit staining 
solution, while cells still present on the upper chamber were removed. Stained migrated 
cells were counted in 8 different random fields and the average number of motile cells 
per representative field was calculated.  
II.19 GTP-loaded Rab5 pull-down assay: Protein A+ G-Sepharose beads (Sigma-
Aldrich Corp., St Louis, MO, USA) were coated with anti-Rab5-GTP mouse monoclonal 
antibody (Cat No. 26911, NewEast Biosciences). Beads were then incubated with 
protein lysates obtained from scr and MUC4 kd PC cells for 2h at 4oC. Precipitated 
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active Rab5 was detected by immunoblotting using anti-Rab5A polyclonal antibody (SC-
309, Santa Cruz Biotech (SCB), Dallas, Texas, USA). 
II.20 Statistical analysis: All results are representative of at least three independent 
experiments. The in vitro data are expressed as the mean±standard deviation (S.D.), 
whereas the in vivo data are represented as mean±standard error (S.E.). Statistical 
comparisons of the two groups were made using a student’s t-test (two-tailed, unpaired) 
using Microsoft Excel 2010, where a p value of less than 0.05 was considered 
statistically significant. For correlation analysis, the Pearson and regression coefficients 
were determined between two groups. 
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Figure 2. Strategy to design deletion constructs for MUC4 cytoplasmic domain 
and their confirmation at protein level. A. Pictorial representation of the proposed 
construct designs for MUC4 cytoplasmic domain which consists of 3-EGF-L domains, 
transmembrane domain and cytoplasmic tail. The overall MUC4 structure consist of 
large tandem repeat (TR) domain at N-terminal end and NIDO, AMOP, vWD, EGF-like 
and Trans-membrane (TM) domain towards 3’extermities. MUC4 also consist of short 
(22aa) cytoplasmic tail (CT) and one putative cleavage site (GDPH) supposed to 
generate mucin like MUC4-α and growth factor like MUC4-β subunits. DNA fragments 
encoding the carboxyl-terminal region of MUC4 (150 amino acids) with deletion of first 
EGF-L, second and third EGF-L, all three EGF-L motifs, cytoplasmic tail (of 21 amino 
acids) and truncated constructs (expressing only MUC4-EGF and CT in different 
combinations) were amplified using specific primers from synthesized cDNA.  In frame 
GFP was placed upstream of MUC4 fragment for the live cell imaging (as our EGF 
ligand is tagged with Rhodamine). B. IB confirming the protein expression of synthesized 
MUC4 deletional constructs in transfected AsPC1 cell line. Here, NO-CT represents 
MUC4-CD without CT; N-EGF represents MUC4-CD without any EGF domain; 1-EGF 
represents MUC4-CD without 2nd and 3rd EGF; 2-EGF represents MUC4-CD without 1st 
EGF and 3-EGF is the construct which has the full intact MUC4-CD. 
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Table 2A Primary antibodies used in the study for Immunoblotting (IB) and 
Immunofluorescence (IF) and ChIP purposes  
 
Serial 
no. 
Antibody Company Dilution 
Analysis 
performed 
1 β-Actin Sigma 1:5000 IB 
2. HIF-1α 
NB100-479, Novus 
Biologicals 
1:500 IB 
3. EGFR SC-03, SCB 1:1500 IB 
4. 
phospho-EGFR 
(Ser1046) 
SC-101665 1:500 IB 
5. LC3 2775, Cell Signaling 1:3000 IB 
6. LC3 AP1802a, Abgent 1:200 IF 
7. p62 PAB1750, Abnova 1:3000 IB 
8. p70 S6Kinase 2708, Cell Signaling 1:1000 IB 
9. 
phospho-p70 
S6Kinase (Thr389) 
9234, Cell Signaling 1:1000 IB 
10. p53 SC-126, SCB 1:1000 IB 
11. p21 SC-6246, SCB 1:1000 IB 
12. MDM2 SC-965, SCB 1:500 IB 
13.  Akt 4691. Cell signaling 1:1000 IB 
14.  
phospho-Akt 
(Ser473) 
4060, Cell signaling 1:1000 IB 
15.  LAMP1 ab24170, Abcam 1:200 IF 
16. ATG7 2054-1, Epitomics 1:5000 WB 
17. 8-OHG ab10802, Abcam 1:150 IF 
18.  MUC4 (8G7) In-house generated 
1:1000 
1:400 
1:800 
IB 
IF 
IHC 
19. MUC4 (2175) In-house generated 
1:1000 
1:500 
IB 
IF 
20. 
Muc4 (4A-rabbit 
polyclonal against 
mice) 
Designed by us and 
developed by 
GenScript 
(Piscataway, NJ, 
USA) 
1:400 IHC 
21. MUC1 (HMFG2) 
In-house generated 
(Gifted by Dr. 
Hollingsworth) 
1:5 
1:5 
IB 
IF 
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Serial 
no. 
Antibody Company Dilution 
Analysis 
performed 
22.           c-Jun 
 
SC-1694,SCB 
 
1:500 
1:500 
5 µg 
IB 
IF 
ChIP 
23. p-c-Jun 9261, Cell Signaling 1:1000 IB 
24. FAK SC-558, SCB 1:500 IB 
25. FXR SC-134481, SCB 
1:500 
1:200 
IB 
IF 
26. src SC-18, SCB 1:500 IB 
27. p-src 6943, Cell Signaling (1:1000 IB 
28. SP1 9389S, Cell Signaling 1:1000 IB 
29. GAPDH 5174S, Cell Signaling 1:3000 IB 
30. 
RAB5A SC-309, SCB 
1:500 
1:50 
IB 
IF 
31. RAB11 SC-6565, SCB 1:500 IB 
32. EEA1 SC-6415, SCB 
1:700 
1:50 
IB 
IF 
33. RAB7 2094, Cell Signaling 
1:1000 
1:200 
IB 
IF 
34. RIN1 
bs-6094R, Bioss 
antibodies 
1:1000 IB 
35.  Alpha-SMA ab7817, abcam 
1:500 
1:200 
IB 
IF 
36.  GFAP   SC-9065,SCB 
1:1000 
1:500 
IB 
IF 
37.  MUC16 Clone M11, Dako 1:1000 IB 
38. Alpha-tubulin 
236-10501, 
Thermofisher 
scientific 
1:400 IF 
39.     β-catenin  C2206, Sigma 1:300 IF 
40. Calnexin C5C9,Cell Signaling 1:300 IF 
41. Giantin ab37266, abcam 1:1000 IF 
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Table 2B Human primers sequences used for PCR 
 
(qRT:quantitative real-time) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Primers sequence 
FXR_ qRT_F 5′-GCGCGTCAGCAGGGAGGATC-3′ 
FXR_ qRT_R 5′-CACACAGTTGCCCCCGTTTTTAC-3’ 
MUC4_ qRT_F 5’-GCAGAGAGCCAGTGTTTGTACAATCAG-3’ 
MUC4_ qRT_R      5’-AGGCCTCGCAGCCCTTCCCAGGAA-3’ 
c-Jun_ qRT_F 5’- TCCACGGCCAACATGCT -3’ 
c-Jun_ qRT_R 5′- CCACTGTTAACGTGGTTCATGAC-3’ 
β-actin_ qRT_F 5′- GACCTGTACGCCAACACAGT -3 
β-actin_ qRT_R 5′- AGTACTTGCGCTCAGGAGGA -3′ 
EGFR_ qRT_F 5’-AGGCAC AAGTAA CAGGCTCAC-3’ 
EGFR_ qRT_R 5’-AAGGTCGTAATTCCTTTGCAC-3’ 
TGF-α_ qRT_F 
 
5'- AGATAGACAGCAGCCAACCCTGA-3' 
TGF-α_ qRT_R 
 
5'- CTAGGGCCATTCTGCCCATC-3’ 
EGF_ qRT_F 
 
5'-CCTGCCTAGTCTGCGTCTTT-3'  
EGF_ qRT_R 
 
5'-CACAATACCCAGAGCGAACA-3' 
Cyclin D1_ qRT_F 5’-CCTCTGTGCCACAGATG-3’ 
Cyclin D1_ qRT_R 5’-GGGTCACACTTGATCACTC-3’ 
Rab5A_ qRT_F 5’-ACTTCTGGGAGAGTCCGCTGTT-3’ 
Rab5A_ qRT_R 5’- GTGTCATCAAGACATACAGTTTGG-3’ 
Twist_ qRT_F 5’ CGGGTCATGGCTAACGTG -3’ 
Twist_ qRT_R 5’-CAGCTTGCCATCTTGGAGTC -3’ 
Vimentin_ qRT_F 5’-GACAATGCGTCTCTGGCACGTCTT-3’ 
Vimentin_ qRT_R 5’-TCCTCCGCCTCCTGCAGGTTCTT-3’ 
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Gene Primers sequence 
MUC4_Intron1_F 5'-GTCTATGTCCTGAATGGTATTGCCTA-3' 
MUC4_Ex-2_R     5’-GAGGAGCTGTCTCCATCACATTGT-3’ 
MUC4-5’UTR_F 5’- CTTCGGAGAAACGCACTTGGTTCG-3’ 
MUC4_Ex-1_F 5’- CTGGAGGAGGGTCCCCTGGGTG-3’ 
MUC4_Ex-2_R 5'-GTCACACAACCCAGTCAACAACCGA-3' 
MUC4_Ex-3_F 5’-GACAACACCGTCACTGAAGACAGACG-3’ 
MUC4_Ex-7_R 5’- GAGAAGCCCATGAGCACCGGGTTG-3’ 
MUC4_Ex-8_F 5’- GATGGCTATTTCGAAAACAGCCCACTG-3’ 
MUC4_Ex-12_R 5’- TGGAGCGGTACTGAGCCGCAAA-3’ 
MUC4_Ex-16_F 5’- CTGCGCAACGCAAGCATCGGACT-3’ 
MUC4_Ex-22_F 5’- TTGCTGTGGACACCCAAGTCGC-3’ 
MUC4_Ex-23_F 5’- CCAACACTGGATGGTCATCTCGGAG-3’ 
MUC4_Ex-26_R 5’- CAGCTGAGTTCAGGAAATAGGAGAACCTG-3’ 
MUC4_qRT_Int-1_F 5’-ATTCTATTTGTAGCAATTGTGA-3’ 
MUC4_qRT_Ex-2_R 5’-TTGAAGAAGCTGCAGTTGATTGTC-3’ 
MUC4_qRT_5’UTRF 
 
5’-CTCTTTTGTCCTCTTCCCAGGTTCCCT-3’ 
MUC4_qRT_EX-1R 5’-ACATGCGGAAGGAGGCAGAGACACA-3’ 
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Table 2C CHIP primer sequence for MUC4 distal promoter 
 
 
 
Gene Primers sequence 
hmuc4Promo_c-jun2s 
(Comprising two c-Jun 
sites) 
5’-TCCCGTGGAATATTAACTTACA-3’ 
hmuc4Promo_c-jun1s 
(Comprising one c-Jun 
site) 
5’-ATCGGATGCCTTGGGAGGAGAGAA -3’ 
hmuc4Promo_c-jun_R 
(Common reverse 
primer) 
5’- AAATGGCTCTGTCTTCATCTGGGT -3’ 
hmuc4Promo_c-jun0s_F 
(No c-Jun binding sites) 
5’-ACTCTGGAAAATGGGCATATTGA-3’ 
hmuc4Promo_c-jun0s_R 
(No c-Jun binding sites) 
5’-CGTGCGCACTCCTGTTCACCTCTT-3’ 
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III.1 Synopsis 
Pancreatic cancer (PC) and associated pre-neoplastic lesions have been reported to be 
hypoxic, primarily due to hypovascular nature of PC. Though presence of hypoxia under 
cancerous condition has been associated with the overexpression of oncogenic proteins 
(MUC1), multiple emerging reports have also indicated the growth inhibitory effects of 
hypoxia. In spite of being recognized as the top-most differentially expressed and 
established oncogenic protein in PC, MUC4 regulation in terms of micro environmental 
stress has not been determined. Herein, for the first time, we are reporting that MUC4 
protein stability is drastically affected in PC, under hypoxic condition in a HIF-1α 
independent manner. Mechanistically, we have demonstrated that hypoxia-mediated 
induction of reactive oxygen species (ROS) promotes autophagy by inhibiting 
pAkt/mTORC1 pathway, one of the central regulators of autophagy. Clinically, 
immunohistoflorescence analyses revealed significant negative correlation (p value = 
0.017) between 8-hydroxy Guanosine (8-OHG) and MUC4 in primary tumors (n=25). 
Moreover, we found pronounced colocalization between MUC4 and LAMP1/LC3 in PC 
tissues and also observed their negative relationship in their expression pattern, 
suggesting that areas with high autophagy rate had less MUC4 expression. We also 
found that hypoxia and resultantly arise ROS have negative impact on overall cell growth 
and viability, which was partially, though significantly (p<0.05), rescued in the presence 
of MUC4. Altogether, hypoxia-mediated oxidative stress induces autophagy in PC, 
leading to the MUC4 degradation to enhance survival, possibly by offering required 
metabolites to stressed cells (1).  
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III. 2 Background and rationale 
Pancreatic cancer (PC) is the fourth leading cause of cancer related mortalities in United 
States with an overall survival rate of only 6% (2). Currently gemcitabine is used as a 
standard therapy for advanced PC; however, its clinical outcome is quite modest due to 
development of acquired and inherent chemo-resistance. One of the prominent features 
of PC which contributes to this chemoresistance and cancer progression is the presence 
of extreme hypoxia. Unlike other solid tumors, PC is hypovascular and characterized by 
enormous desmoplastic reactions (3, 4). Tumor hypoxia is a condition when cancer cells 
are deprived of oxygen and is primarily found in regions that are distant from the tumor 
blood vessels, particularly, center of the tumor. Therefore, these microenvironments 
suffer from low nutrient availability and production of waste products (acidosis). 
Ultimately, it results in the development of a stressful environment which adversely 
affects tumor cell proliferation and survival, and leads to the clonogenic selections of 
only those cells who can withstand hostile environment (5). In order to survive and 
remain viable, cancer cells induce both HIF-1α dependent and independent 
mechanisms.  
PC is characterized by aberrant mucins expressions, such as MUC1, MUC4 and 
MUC5AC (6-9). Under normal condition, the expressions of these mucins are low or 
undetectable, but under disease conditions, their expression increases. Studies have 
established that MUC1, a transmembrane protein, is positively regulated by hypoxia and 
has been linked with increase survival, angiogenesis and altered metabolomics in PC 
(10-12). Similar to MUC1, MUC4 is also a transmembrane protein, but it does not 
express in normal pancreas (13). MUC4 appears quite early in preneoplastic stage 
(PanIN-I) and its expression increases with the severity of the disease (8). We have 
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previously established that aberrant overexpression of MUC4 leads to increased tumor 
growth, survival, metastasis and therapy-resistance in PC (14-16). So far, various 
intrinsic and extrinsic factors have been associated with its aberrant expression during 
PC progression (17). However, how environmental stimuli such as hypoxia can regulate 
MUC4 expression is still not clear.  
Therefore, in the present study, we investigated the regulation of MUC4 
expression by hypoxia, and examined the clinical significance of this association in PC. 
Our findings indicate that hypoxia negatively regulates MUC4 expression in PC, and also 
provided evidence for a novel regulatory mechanism which leads to MUC4 degradation 
due to hypoxia-induced oxidative stress.  
III.3 Results 
A. MUC4 expression is down-regulated in PC cell lines in response to hypoxia 
To understand the effect of hypoxia in MUC4 expression, we treated MUC4 expressing 
PC cell lines, CAPAN1, CD18/HPAF and T3M4, with 1% of hypoxia for 24 hours (h). 
There was significant downregulation of MUC4 at the protein level in all three PC cell 
lines (Fig.3.1A), with concomitant increase in HIF-1α levels. Substantially, we observed 
similar decrease in MUC4 levels in hypoxia treated Colo357 cells (Fig.3.1B). 
Immunofluorescence analysis also validated reduction in MUC4 expression, whereas 
MUC1, an established HIF-1α target, was significantly increased in CD18/HPAF cells 
(Fig.3.1C). To further substantiate our findings, we gave prolong (or chronic) hypoxia to 
CD18/HPAF cells for 72h and 96h. Consistently, we observed significant downregulation 
of MUC4, whereas MUC1 expression remains persistently high (Fig.3.1D). The qRT-
PCR analysis showed insignificant reduction in MUC4 expression at transcript levels in 
all tested PC cell lines (Fig.3.1E), suggesting that hypoxia may affect the stability of 
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MUC4 protein. Altogether, the results indicate that MUC4 expression reduces under 
hypoxic condition due to modulation in MUC4 protein stability. 
B. Decrease in MUC4 expression under hypoxia is HIF-1α independent 
Previous studies have linked hypoxia-mediated alterations in mucins expression with 
induced HIF-1α expression (10-12, 18, 19), which led us to ask whether hypoxia-
mediated downregulation of MUC4 expression is HIF-1α dependent. To ascertain the 
role of HIF-1α transcription factor in MUC4 reduction, we silenced HIF-1α expression by 
utilizing ShRNA approach and by pharmacological inhibitor, YC-1. Under both normoxic 
and hypoxia conditions, HIF-1α knocked down (kd) led to MUC4 downregulation in 
CAPAN1, as compared to its respective control (Fig. 3.2A). Furthermore, treatment of 
both CD18/HPAF and CAPAN1 cells with YC-1 inhibited the expression of MUC4 in a 
dose-dependent manner (Fig.3.2B), suggesting the role of HIF-1α in the upregulation of 
MUC4 expression. Additionally, inhibition of HIF-1α degradation upon MG132 (ubiquitin-
proteasome inhibitor) treatment of CD18/HPAF cells did not rescue MUC4 degradation, 
in fact further downregulation in MUC4 expression was observed (Fig.3.2C), possibly 
due to MG132-mediated induction of autophagy (20-22). This data further strengthened 
the fact that reduced MUC4 protein expression under hypoxia is HIF-1α independent, 
and it is the stability of MUC4 which is primarily affected under hypoxia. To further prove 
our conjecture, we treated CD18/HPAF cells with cycloheximide (CHX, protein 
translation inhibitor) for indicated time-points and observed significant decrease in MUC4 
expression under hypoxic condition as compared to normoxia (Fig.3.2D), establishing 
that MUC4 protein stability is reduced under hypoxic conditions. Immunofluorescence 
analysis in PC tissues (n=25) also revealed 56% (14/25) and 68% (17/25) expression of 
MUC4 and HIF-1α, respectively. MUC4 and HIF-1α were co-expressed in 44% (11/25) 
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of patients, however, were simultaneously absent in 20% (5/25) of PC patients 
(Fig.3.2E-F). Altogether, the results indicate that MUC4 expression is positively 
associated with HIF-1α; therefore, hypoxia-mediated downregulation of MUC4 is HIF-1α 
independent. 
C. Decrease in MUC4 expression under hypoxia is ROS-dependent 
Because hypoxia-mediated reduction in MUC4 is HIF-1α independent, therefore, our 
next question was to explore the mechanism responsible for significant downregulation 
of MUC4 expression under hypoxia. It is already known that hypoxia has various HIF-1α 
dependent and independent functions (23). Recent studies have shown that mucins 
expression is regulated by reactive oxygen species (ROS) (24), and induction of ROS 
under hypoxia, is an established feature. It prompted us to ask whether hypoxia-
mediated ROS induction is responsible for MUC4 reduction. To address this question, 
we treated CD18/HPAF cells with 5 mM of ROS scavenger; N-acetyl cysteine (NAC), for 
24h in the presence and absence of hypoxia. Interestingly, we observed attenuation of 
MUC4 reduction under hypoxic condition in NAC treated cells (Fig.3.3A). Notably, NAC 
treatment alone was sufficient for MUC4 upregulation (Fig.3.3B), by attenuating basal 
levels of ROS already present in cancer cell lines (Fig 3C). The measurement of 2′,7′-
Dichlorofluorescin diacetate (DCFDA) florescence showed 41% and 63% reduction in 
ROS levels upon NAC treatment under both normoxic and hypoxic condition, 
respectively, further strengthening that NAC-mediated neutralization of ROS is 
responsible for MUC4 upregulation (Fig. 3D). Treatment of both CD18/HPAF and 
CAPAN1 PC cells with another antioxidant, α-tocopherol succinate (α-TS), also showed 
similar increase in MUC4 expression (Fig. 3E). Additionally, treatment of CAPAN1 with 
exogenous hydrogen peroxide (H2O2), a form of non-ionic ROS, resulted in concomitant 
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reduction in MUC4 expression in a dose-dependent manner (Fig.3F), which was further 
confirmed in CD18/HPAF cells (Fig. 3G). Immunofluorescence experiment also 
exhibited that the negative impact of hypoxia and ROS on MUC4 expression was 
abolished in the presence of NAC (Fig. 3H). Altogether, these data suggests that ROS is 
playing a key role in hypoxia-mediated negative regulation of MUC4 in PC.  
D. Hypoxia-mediated autophagy induction leads to reduced MUC4 stability 
As demonstrated earlier, inhibition of ubiquitin-proteasome pathway was failed to rescue 
MUC4 suppression under hypoxic condition (Fig.3.2C). Multiple studies have 
established that autophagy and ubiquitin proteasome systems (UPS) are functionally 
coupled, and inhibition of UPS system by MG132 induces autophagy (20-22). 
Furthermore, the link between ROS and autophagy is also well established (25, 26). 
Altogether, these studies incited us to propose that HIF-1α independent hypoxia-
mediated induction of oxidative stress promotes autophagy which reduces the protein 
stability of MUC4. Therefore, we first evaluated the status of autophagy in PC cells, 
under hypoxic and oxidative stress conditions. Interestingly, the levels of LC3-I and II 
were significantly increased in hypoxia treated CAPAN1 and CD18/HPAF cells 
compared to normoxic controls (Fig.3.4A). Further, treatment of CAPAN1 cells with 
H2O2 showed increased LC3-I and LC3-II expression levels in a dose-dependent manner 
(Fig.3.4B). The results were verified in CD18/HPAF cells where increase in LC3 was 
accompanied with the concomitant reduction in p62 expression (Fig.3.4C), further 
emphasizing autophagy induction under oxidative stress conditions. Increased 
autophagosome formation in oxidative stress and hypoxic condition was also confirmed 
by monodansylcadaverine (MDC) staining in CAPAN1 cells (Fig.3.4D). Further, 
treatment of CAPAN1 cells with increasing doses of rapamycin (RAP), an autophagy 
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inducer by inhibiting mTORC1 complex, resulted in reduction in MUC4 expression in a 
dose-dependent manner, with concomitant increase in LC3-I and II levels (Fig.3.4E). 
These results were substantiated by treatment of CAPAN1 cells with autophagy inhibitor, 
vinblastine (VB) (27, 28) in the presence and absence of ROS. Consistent to our 
premise, the suppression of MUC4 expression by ROS was significantly abolished by 
VB treatment, as compared to H2O2 treated CAPAN1 cells (Fig.3.4F). VB inhibits the 
fusion of LC3 carrying autophagosome vesicles with lysosomes, and thus, prevents the 
degradation of proteins, causing accumulation of LC3. Immunofluorescence experiment 
further confirmed increase in MUC4 expression and colocalization with accumulated LC3 
positive vesicles in VB-treated CD18/HPAF and CAPAN1 cells (Fig.3.4G and H). To 
further substantiate our findings, we did immunofluorescence staining for MUC4 and 
LAMP1+ lysosomal vesicles in CAPAN1 and observed their colocalization (Fig.3.4I). 
Moreover, significant increase in MUC4 expression upon ATG7 kd in CD18/HPAF cell 
line, establish the involvement of autophagy in MUC4 degradation (Fig.3.4J). Altogether, 
we have demonstrated that hypoxia-mediated ROS stimulation causes induction of 
autophagy process, which leads to MUC4 degradation and reduced stability. 
E. Hypoxia inhibits Akt/mTORC1 pathway to induce autophagy  
Recent report by Wang et al has demonstrated the involvement of Akt activation in 
mTORC1 regulated autophagy process (29). Additionally, chronic hypoxia has also 
shown to suppress Akt activation in hypoxia treated PC cells (30). Similarly, we also 
observed that levels of phosphorylated Akt and mTORC1 effector, pS6 kinase, were 
consistently reduced in hypoxia-treated PC cells, whereas expression of EGFR, pEGFR, 
Akt and S6 kinase remained unchanged (Fig.3.5A). We observed significant reduction in 
p53 expression in hypoxia-treated cells lines, suggesting the possible accumulation of 
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genomic and cellular defects in stressed PC cells. We also observed increase in p21 
expression in hypoxia-treated T3M4 and CD18/HPAF cells, suggestive of growth arrest 
of PC cells (Fig.3.5B), which was corroborated by our growth kinetics analysis in 
hypoxia-treated and untreated CD18/HPAF cells (Fig.3.5C) and by a recent study where 
hypoxia has shown to cause growth inhibition in PC cell lines (31). To assess the role of 
ROS on pAkt reduction, we analyzed its expression in the presence and absence of 
NAC. Interestingly, hypoxia-mediated downregulation of pAkt in CD18/HPAF cells was 
abolished upon NAC administration, further emphasizing that the reduction in pAkt levels 
under hypoxia is ROS-dependent (Fig.3.5D). From this data, we were also able to 
reasoned that p53 downregulation under hypoxia is occurring due to induced expression 
of MDM2 (ubiquitin ligase), though we did not see any change in their levels after NAC 
treatment, implying the involvement of ROS-independent mechanisms in these 
alterations. Further, treatment with NAC attenuates the growth inhibitory effects of 
hypoxia (Fig.3.5E) and H2O2 (ROS stress) on PC cells (Fig.3.5F). These results were 
further supported by performed MTT assay as significant loss in cell viability (p<0.05) 
was noticed in H2O2 treated PC cells (Fig.3.5G). In order to know the effect of hypoxia 
on cell viability and death, MTT assay was performed. CD18/HPAF cells exhibited 
significant loss of viability under hypoxia, which was partially rescued in the presence of 
ROS scavenger (NAC) and further augmented upon autophagy inhibitor chloroquinone 
treatment (CQ) (Fig.3.5H). Similar to cell growth results, under normoxia, NAC did not 
demonstrate any change in cell viability, whereas, CQ significantly reduces the cell 
viability. Interestingly, PC cell lines demonstrate high autophagy rate even at basal 
levels (Fig. 3.5I), affirming protumorigenic role of autophagy in PC (32). Consistent to 
cell viability results, we observed increased cellular apoptosis and necrosis upon 
hypoxia treatment (p<0.05), which was significantly (p<0.05) suppressed by NAC and 
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augmented by CQ treatment (Fig. 3.5I), suggesting that reduction in PC cell viability and 
death under hypoxic condition is oxidative stress-dependent, and induction of autophagy 
is a survival mechanism.  
F. MUC4 gives survival advantage to hypoxia-stressed PC cells 
To determine the role of MUC4 in the survival of PC cells under hypoxia and oxidative 
stress, we gave 1% hypoxia treatment to MUC4 kd and scrambled (Scr) CAPAN1 cells 
(Fig.3.6A). Noticeably, under hypoxia, MUC4 scr CAPAN1 cells exhibited 6%, 21% and 
53% reduction in cell viability on day 1, 3 and 5, respectively, compared to normoxic 
cells. On the other hand, MUC4 kd cells exhibited 10%, 27% and 64% loss in cell 
viability on day 1, 3 and 5, respectively, compared to normoxic kd cells, suggesting the 
role of MUC4 in maintaining the viability of PC cells under stressed condition (Fig. 3.6B). 
Similar results were obtained when MiniMUC4 overexpressing MIA PaCa-2 cell model 
was used (33). In this model, MUC4 non-expressing MIA PaCa-2 cell lines ectopically 
express MiniMUC4, which consists only 10% of the total VNTR of wild-type MUC4 (Fig. 
3.6C). Growth kinetics was performed in these cells for 24 and 48h after H202 treatment 
in the presence and absence of NAC. Intriguingly, we observed 85% and 63% reduction 
in cell viability in H2O2 treated vector and MiniMUC4 expressing MIA PaCa-2 cells, upon 
24h of H2O2 treatment (Fig. 3.6D). At 48h, we observed 71% and 55% reduction in cell 
numbers in H2O2 treated vector and MiniMUC4 expressing MIA PaCa-2 cells, 
respectively. Administration of NAC was able to rescue H2O2-mediated decrease in cells 
numbers in vector and MiniMUC4 expressing MIA PaCa-2 (Fig. 3.6D). These results 
indicate that presence of MUC4 alone cannot completely abolish oxidative stress-
facilitated PC death. However, presence of MUC4 does offer better survival and viability 
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advantage to PC cells under hypoxic and oxidative stress conditions than MUC4 kd or 
null cells. 
G. Clinical validation of MUC4 association with oxidative stress and degradation 
via lysosomal pathway  
To validate the link between MUC4 and hypoxia-induced autophagy, we performed 
immunofluorescence analysis for MUC4 and LAMP1 in PC tissues, and observed 
significant co-localization between them (Fig.3.7A). One of the consistent and intriguing 
finding was the inverse relationship between LAMP1 and MUC4 expression. Ducts 
having high MUC4 expression exhibited low expression of LAMP1 and vice versa, as 
demonstrated in the intensity plot diagram (Fig.3.7A). Due to the established association 
of increased expression of LAMPs with increased lysosomal function and autophagy 
involvement (34), their inverse expression pattern may indicate that MUC4 does enter to 
the lysosomes, and may undergo degradation. Additionally, presence of MUC4 in LC3-
positive vesicles in PC tissues, confirmed the association between MUC4 with 
autophagy (Fig.3.7B). 
To know the clinical association between MUC4 and oxidative stress, we 
performed immunofluorescence analysis by staining PC tissues for MUC4 and 8-hydroxy 
guanosine (8-OHG, commonly used marker for oxidative stress) (35, 36). We observed 
8-OHG and MUC4 expression in 64% and 56% of PC patients, respectively. Validating 
our in vitro data, MUC4 and 8-OHG exhibited significantly inverse expression status 
under in vivo condition, as shown in representative images (Fig.3.7C). It was further 
established by quantifying the mean florescence intensities (MFI) of 8-OHG in MUC4 low 
(MUC4L) and MUC4 high (MUC4H) regions, and the difference was found to be 
statistically significant (p=0.017) (Fig.3.7C). In our analysis, we also observed that 
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oxidative stress does not always correlate with increase HIF-1α expression (Fig.3.7D). 
The statistical analysis of MFI of different spots/fields (n=40) of RAPID autopsy tissue 
array (having 25 PC patients tissues) revealed their Pearson correlation of 0.56 with an 
R2 value of 0.31 (Fig.3.7E). Altogether, we can conclude that MUC4 expression is 
differentially regulated by HIF-1α and oxidative stress, which is possible in varied PC 
microenvironment.  
III. 4  Discussion 
By far, PC has one of the most complicated microenvironment among other solid 
cancers due to its myriad of unique properties (4). Unlike most of the solid tumors, PC is 
characterized by hypo-vascularization due to the deposition of extracellular matrix, which 
causes extreme hypoxia and oxidative stress (4). Chronic and severe hypoxia has been 
shown to inhibit tumor cell proliferation, which ultimately led to cell death (37). 
Nevertheless, tumor hypoxia is also the predict marker for the worse clinical outcome. 
To resolve these two opposite observations, hypoxia has been projected to create a 
selection pressure which causes the survival of only those clones which are highly 
aggressive and resistant towards fluctuating microenvironmental stress (38). 
Alike, aberrant overexpression of mucins has been implicated in PC survival, 
aggressiveness, drug resistance and maintenance of stem cell phenotype (3, 13-15). 
Most of these attributes are frequently assign to their interaction with receptor tyrosine 
kinases, cell surface proteins and components of extracellular matrix (39, 40). Present 
study provides an additional oncogenic mechanism by which MUC4 contributes to the 
survival of PC cells under hypoxic conditions through its degradation via autophagy. 
Among cancers, such as renal and pancreatic cancer, the hypoxia-mediated induction of 
MUC1 has been associated with HIF-1α (10-12). Nevertheless, we observed significant 
reduction in MUC4 expression under hypoxia in multiple PC cell lines. Intriguingly, we 
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observed that similar to MUC1, MUC4 is also positively regulated by HIF-1α, however, in 
spite of increased HIF-1α stability (by inhibiting its proteasomal degradation); MUC4 was 
degraded persistently under hypoxic condition. Therefore, downregulation of MUC4 
expression under hypoxia, even in the presence of induced HIF-1α expression, signifies 
the presence of other predominant pathways independent of HIF-1α. 
Studies have demonstrated that ROS induction is one of the most common HIF-
1α independent mechanism activated under hypoxic conditions (41). Moreover, 
established role of ROS in autophagy induction (42) and emerging data linking mucins 
regulation by ROS (24), prompted us to postulate that ROS induced autophagy plays 
crucial role in MUC4 downregulation. Consistent to our proposition, we did observe 
MUC4 downregulation under hypoxic, oxygen-deficient or chemically-induced 
(rapamycin) autophagy, which was attenuated upon inhibition of ROS and autophagy. 
So far, studies have not demonstrated the involvement of autophagy in mucins 
degradation. The apparent presence of MUC4 in LAMP1 and LC3-positive vesicles in 
PC tissue, imply that MUC4 does enter to autophagy/lysosomal pathway under in vivo, 
and provided the first evidence of mucins degradation by autophagy pathway. Despite of 
both cancer promoting and suppressing role of autophagy, majority of the available data 
hints toward its role in promoting survival and proliferation of PC cells (26, 43). Our study 
also suggests that MUC4 degradation via ROS-mediated autophagy might be a survival 
mechanism in PC, as MUC4 kd CAPAN1 and MUC4-null MIA PaCa-2 cell lines were 
less viable under microenvironmental stress conditions compared to CAPAN1/Scr and 
MiniMUC4 expressing MIA PaCa-2 cells, respectively. Recent studies have clearly 
established that pancreatic tumors are nutrient deprived and heavily-dependent on 
macropinocytosis, leading to uptake of small extracellular proteins by cancer cells (44, 
45). These internalized proteins then undergo autophagy process and provides 
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necessary metabolites to ensure the survival of highly stressed PC cells. Due to 
reportedly reduced levels of extracellular proteins concentration under clinical settings 
(46, 47), we anticipate that requirement or dependency to internalize and degrade 
overexpressed membrane proteins (such as MUC4) by hypoxic/oxidatively 
stressed/nutrient deprived PC cells is conceivably more than extracellular proteins and 
needs further investigations.  
Mechanistically, we observed significant downregulation of phospho-Akt in 
hypoxia treated PC cells. Attenuation of ROS level by NAC treatment, suppresses the 
hypoxia facilitated Akt activation, which was further related with the resumption of cell 
proliferation. These data were further supported by a recent report by Sayin VI et al. 
where in vivo administration of NAC and vitamin-E have demonstrated to increase the 
tumorigenicity of lung cancer by downregulating the levels of ROS, DNA damage, and 
p53 (48). We also observed downregulation of p53 under hypoxia, which further reduces 
upon ROS attenuation, and therefore, questioned the utility of antioxidant-based 
therapies in PC. Looking into earlier clinical trials on dietary antioxidants in cancer 
condition, we have not received encouraging results (49, 50). Moreover, NAC treatment 
leads to the attenuation of apoptotic functions of ROS-inducers, further emphasizing 
towards the optimization of antioxidant therapies against PC (51). However, due to 
observed overexpression of HIF-1α even under normoxic condition, current study 
encourages HIF-1α targeting, which will led to the downregulation of multiple oncogenic 
proteins, including mucins. It will definitely be our future interest to observe how HIF-1α 
inhibition leads to MUC4 downregulation. Our in silico analysis has clearly shown that 
MUC4 promoter does not contain HIF-1α bindings sites, indicating the involvement of 
other protein mediators in HIF-1α facilitated MUC4 regulation. One of the possible 
mechanisms could be EGFR downregulation upon HIF-1α inhibition, as recent study 
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from our lab has shown that inhibition of EGFR leads to MUC4 downregulation in PC 
cells, and need to be investigated (52).  
In conclusion, the present study provides evidence that hypoxia negatively 
regulates MUC4 expression in PC by affecting its stability. Moreover, we found that 
hypoxia-mediated reduction of MUC4 is HIF-1α independent, and further investigation 
directed us to know the involvement of ROS induced autophagy in MUC4 degradation 
(Fig.3.8). Similar to cytokines, we observe functional redundancy in mucins, implying 
that induction in MUC1 expression under hypoxia may be sufficient to compensate for 
MUC4 downregulation, and need to be addressed. Lastly, due to the diverse effect of 
hypoxia and highly complicated PC microenvironment, we can speculate that MUC4 
expression could be differentially regulated by HIF-1α and oxidative stress, which leads 
to differential expression and regulation of MUC4 within the same tumor due to the 
different local microenvironment. 
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Figures and Figure legends 
Figure 3.1. MUC4 is negatively regulated by hypoxia in PC cell lines. A. CAPAN1, 
CD18/HPAF and T3M4 cells were cultured under normoxia or hypoxic (1% O2) 
conditions for 24 h. Following treatment, lysates were collected and western blots were 
performed. Protein expression of MUC4 and HIF-1α was analyzed by 2% agarose and 
10% polyacrylamide gel-based electrophoresis, respectively. B. MUC4 expressing PC 
cell line, Colo357, was exposed to 1% hypoxia for 24 h. As anticipated, upon hypoxia 
treatment, HIF-1a expression was significantly induced, whereas MUC4 protein showed 
significant reduction, as compared to untreated controls. C. CD18/HPAF cells were 
grown on coverslips followed by 24 h incubation under normoxia or hypoxia. After the 
completion of treatment, cells were fixed, permeabilized and then subjected to 
immunofluorescence experiment to observe changes in the expression of MUC1 and 
MUC4. D. Prolong hypoxia treatment was given to CD18/HPAF cells for 72 h and 96 h 
and the expression of MUC4 and MUC1 was analyzed. E. qRT-PCR experiment was 
performed to detect changes in the mRNA expression levels of MUC4 in hypoxia treated 
and untreated CD18/HPAF, T3M4 and CAPAN1 PC cell lines.  
(ns stands for no significant difference, Scale bar = 20 μM). 
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Figure 3.2. HIF-1α independent mechanisms play predominant role in hypoxia-
mediated suppression of MUC4. A. After transiently knocking down HIF-1α, CAPAN1 
cells were incubated under 1% hypoxic conditions for 24 h. Following treatment, total 
protein was isolated and western blot was performed to observe the effect of HIF-1α 
silencing on MUC4 expression under both hypoxic and normoxic conditions. B. 
CD18/HPAF and CAPAN1 cells were exposed to different concentration of YC-1 (10 or 
20 μM), an inhibitor of HIF-1α, for 16 h. Immunoblotting was performed to detect 
changes in MUC4 and HIF-1α expression. C. CD18/HPAF cells were first pre-treated 
with MG132 (10 μM) for 30 mins. Following pre-treatment, cells were incubated under 
1% hypoxic conditions for 4, 6 and 8 h in the presence of MG132. Even after inhibition of 
ubiquitin-proteasome pathway, MUC4 degradation did not prevent, whereas, HIF-1α 
protein which is known to be degraded solely by proteasome pathway was stabilized 
upon MG132 treatment under both normoxic and hypoxic condition. D. Similar to 
MG132, CD18/HPAF cells were pre-treated with CHX (50 μg/ml) for 30 mins followed by 
1% hypoxia treatment for 2, 4 and 6 h in the presence and absence of CHX. 2% agarose 
gel electrophoresis was performed to see the effect of these inhibitor treatments on 
MUC4 expression in the presence or absence of hypoxia. We observed that CHX-
treatment significantly reduces the levels of MUC4 under hypoxic condition, compared to 
CHX treated cells alone, confirming the negative effect of hypoxia on MUC4 protein 
stability. E. Representative images obtained from normal colon and PC tissues (from 
three different patients) showing MUC4 and HIF-1α co-expression at same tissue spots. 
F. The bar graph showing the percentage positive and negative expression for MUC4 
and HIF-1α in stained PC tissue arrays. (Scale bar = 20 μM). 
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Figure 3.3. MUC4 expression is negatively regulated by hypoxia induced ROS. A. 
CD18/HPAF cells were treated with NAC in the presence and absence of hypoxia for 24 
h. Western blot was performed to analyze alteration in the expression of MUC4 and HIF-
1α. B. MUC4 expression was analyzed in lysates obtained from CD18/HPAF cell line 
treated with different concentrations of NAC for 24 h. C. Flow cytometry was performed 
to measure DCFDA florescence in order to detect changes in ROS levels in CD18/HPAF 
cells upon NAC treatment in the presence and absence of hypoxia. D. The bar graph 
showing mean florescence intensity (MFI) measured for DCFDA dye in indicated 
immortalized normal pancreatic and cancer cell lines. (E). After 12 h of serum starvation, 
CD18/HPAF and CAPAN1 cells were treated with α-tocopherol succinate (α-TS) for 24 h 
at indicated concentrations. Following treatment, MUC4 expression was analyzed by 2% 
agarose gel electrophoresis. F and G. CAPAN1 cells and CD18/HPAF cells were treated 
with H2O2 followed by MUC4 expression analysis. H. Immunofluorescence experiment 
was performed to further confirm the effect of hypoxia and exogenous ROS on MUC4 at 
protein level in the presence and absence of ROS neutralizer, NAC. 
(Scale bar = 20 μM). 
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Figure 3.4. Hypoxia-mediated ROS production induces autophagy, which leads to 
reduced MUC4 stability. A. Cell lysates of CD18/HPAF and CAPAN1 were collected 
after 24 h incubation with or without 1% hypoxia to analyze the expression of LC3-I and 
II by western blot. B. CAPAN1 cells were treated with increasing concentrations of H2O2 
to observe the effect of oxidative stress on autophagy. C. To further substantiate that 
presence of oxidative stress induces autophagy, CD18/HPAF cell line was treated with 
40 and 80 μM of H2O2 followed by the analysis of LC3 and p62 levels, using 
immunoblotting. D. Representative image showing increased autophagosome formation 
in H2O2 and CoCl2 (hypoxia mimetic) treated CAPAN1 cells. For the detection of 
autophagy vacuoles, MDC staining was performed (Scale bar = 10 μM). E. CAPAN1 
cells were treated with 10, 20 and 50 nM of rapamycin (RAP), an autophagy inducer, for 
24 h. Cell lysates were prepared to analyze the expression of MUC4 and LC3. F. 
CD18/HPAF cells were treated with VB (10 μg/ml) for 24 h under hypoxic conditions to 
observe the effect of autophagy inhibition on MUC4 expression. G. Additionally, confocal 
microscopy revealed that inhibition of autophagy due to VB treatment leads to increased 
expression and retention of MUC4 in LC3-positive vesicles. The bar graph is showing 
the person correlation coefficient between MUC4 and LC3 colocalization in VB-treated 
and untreated CD18/HPAF cells. (Scale bar = 20 μM). H. To confirm an association 
between MUC4 and autophagy, autophagy was blocked in CAPAN1 cells (plated on the 
coverslips) by treating them with VB (10 µM) for 8 h. Cells were fixed and 
immunofluorescence staining was performed to look for the colocalization between 
MUC4 and LC3 (Scale bar = 20 μM). VB treated PC cells exhibited increased expression 
and retention of MUC4 in accumulated LC3-positive vesicles. I. Confocal image 
demonstrating significant co-localization between MUC4 and LAMP1 in CAPAN1 cell 
line. J. To specifically pinpoint the role of autophagy in MUC4 degradation, we used 
130 
 
targeted siRNA oligonucleotides to transiently knock down ATG7 in CD18/HPAF PC 
cells to inhibit autophagy. Consistently, we observed significant increase in MUC4 
expression upon ATG7 silencing. (**p<0.01: statistically highly significant, Scale bar = 20 
μM). 
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Figure 3.5. Hypoxia-mediated oxidative stress promotes autophagy by inhibiting 
pAkt/mTORC1 axis and reduces cell viability. (A) T3M4, CD18/HPAF and CAPAN1 
cells were incubated under 1% hypoxic conditions for 24 h. Following treatment, cell 
lysates were collected and used for western blotting to observe changes in the proteins 
expression of HIF-1α, EGFR, pEGFR (Ser1046), Akt, pAkt (Ser473), S6kinase, 
pS6kinase (Thr389) and p53. B. Immunoblots showing changes in the expression of p21 
in hypoxia (1% O2) treated T3M4 and CD18/HPAF cell lines. C. Growth kinetics was 
performed for CD18/HPAF for 24 and 48 hrs in the presence and absence of 1% 
hypoxia. D. To know whether hypoxia-mediated suppression of pAkt and p53 is ROS-
dependent, CD18/HPAF cells were first pre-treated with NAC (5 mM) for 30 mins. 
Following pre-treatment, cells were incubated under 1% hypoxia. Cell lysates were 
subsequently collected and immunoblot experiment was performed for Akt, pAkt 
(Ser473), p53, and MDM2 expression levels. E. The graphical representation to 
demonstrate the effect of hypoxia and neutralization of consequently produced ROS (by 
concomitant treatment with 2.5 mM of NAC) on the proliferation of CD18/HPAF and 
CAPAN1 cell lines. F. Cell numbers were quantified after 24 h of H2O2, NAC and 
NAC+H2O2 treatment of CD18/HPAF and CAPAN1 PC cells. G. CD18/HPAF and 
CAPAN1 cell lines were treated with different concentrations of exogenous H2O2. 
Following treatment, MTT assay was performed to analyze the effect of treatment on 
cellular viability. H. To explore the role of hypoxia-induced oxidative stress and 
autophagy on cell death and viability, MTT assay was performed. CD18/HPAF cells 
were exposed to 1% hypoxia in the presence and absence of NAC (2.5 mM) and CQ (50 
µM) for 24 h. Post-treatment, MTT assay was performed and optical density was 
measured at 570 nm. I. The graphical representation of Annexin (indicator of early-
apoptosis) and propidium iodide (PI, indicator of late apoptosis and necrotic cells) 
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staining performed on CD18/HPAF cells treated for 24 h with hypoxia alone, hypoxia 
followed by NAC (2.5 mM) or CQ (50 µM) treatment for further 12 h.  
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Figure 3.6. Hypoxia-mediated reduction in cell viability is rescued by MUC4 
overexpression. A. Immunoblot confirming MUC4 knocked down in CAPAN1 cells. B. 
The graphical representation to demonstrate the effect of 1, 3 and 5 days of hypoxia 
treatment on the proliferation of MUC4 kd and scr CAPAN1 cells. (LE: Low exposure; 
p<0.05: statistically significant; **p<0.01: statistically highly significant; ns: no significant 
difference). C. Immunoblot representing the ectopic expression of MiniMUC4 in MUC4 
non-expressing MIA PaCa-2 cell line. D. The graphical representation to demonstrate the 
effect of 24 h and 48 h of combinatorial or individual treatment of H2O2 and NAC on the 
proliferation of MIA PaCa-2/psectag and MIA PaCa-2/MiniMUC4 expressing cell lines. 
(*p<0.05 signifies statistically significant results; ns means insignificant changes; Scale bar 
=20 μM) 
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Figure 3.7. In vivo validation of MUC4 association with oxidative stress and 
degradation via lysosomal pathway. A. Confocal images showing colocalization 
between MUC4 and lysosomal marker (LAMP1), and thus clearly indicate that MUC4 
does enter to lysosomal compartment. In spite of significant colocalization between 
MUC4 and LAMP1, similar to CAPAN1 cell line, MUC4 and LAMP1 expression pattern 
was inversely associated under in vivo settings. Tumor cells having more LAMP1 
expression exhibited reduce MUC4 expression in stained Whipple tissue samples. 
Histogram representation of the intensities plots for MUC4 and LAMP1 is further 
confirming our observation. B. Immunofluorescence staining was performed in PC tissue 
section to observe the colocalization between MUC4 and LC3 molecules by confocal 
microscopy. C. Representative images of PC tissues stained with MUC4 and oxidative 
stress marker (or high ROS indicator; 8-OHG). Box-plot showing the significant 
difference between the MFI observed for 8-OHG in MUC4L (n=20) and MUCH (n=16) 
fields. D. Representative images obtained from confocal microscopy showing that 
presence of oxidative stress does not always correlate with HIF-1α expression, as PC 
tissue spots demonstrating high 8-OHG expression had less HIF-1α expression and vice 
versa. E. Scatter graph showing relationship between the MFI levels of HIF-1α and 8-
OHG in clinical samples. 
   (Scale bar = 10 μM). 
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Figure 3.8. Schematic presentation of the summary of the paper. Hypoxia is induced 
collaboratively by hypovascularization, desmoplastic reactions and continuous 
proliferation of tumor cells, which further leads to increase ROS production and generate 
oxidative stress condition. Produced ROS inhibits the activation of Akt which further 
leads to mTORC1 inhibition and induction of autophagy. Induce autophagy facilitates 
MUC4 degradation. The inhibitors used in this study suppress the activity of different 
proteins. For example, NAC and α-TOS act as ROS scavenger, rapamycin inhibits 
mTORC1 and VB inhibits the fusion of autophagosomes (AP) with lysosomes (L) and 
thus, prevent the formation of autophagolysosomes (APL) which causes MUC4 
accumulation. 
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             IV. 1 Synopsis 
The majority of pancreatic cancer (PC) patients are clinically presented with 
obstructive jaundice with elevated levels of circulatory bilirubin and alkaline 
phosphatases. In the current study, we examined the implications of bile acids 
(BA), an important component of bile, on the pathophysiology of PC and 
investigated their mechanistic association in tumor-promoting functions. 
Integration of results from patient samples and autochthonous mouse models 
showed an elevation in BA levels (p<0.05) in PC serum samples compared to 
healthy controls. Similarly, an elevated BA levels was observed in pancreatic 
juice derived from PC patients (p<0.05) than non-pancreatic non-healthy 
(NPNH) controls, further establishing the clinical association of BA with the 
pathogenesis of PC. The tumor-promoting functions of BA were established by 
observed transcriptional upregulation of oncogenic MUC4 expression. 
Luciferase assay revealed distal MUC4 promoter as the primary responsive site 
for BA. In silico analysis recognized two c-Jun binding sites on MUC4 distal 
promoter, which was biochemically established using ChIP assay. Interestingly, 
BA treatment led to an increased transcription and activation of c-Jun in a FAK-
dependent manner. Additionally, BA receptor, namely FXR, which is also 
upregulated at transcriptional level in PC patient samples, was demonstrated as 
an upstream molecule in BA-mediated FAK activation, plausibly by regulating 
Src activation. Altogether, these results demonstrate that elevated levels of BA 
increase the tumorigenic potential of PC cells by inducing FXR/FAK/c-Jun axis 
to upregulate MUC4 expression, which is overexpressed in pancreatic tumors 
and is known to be associated with progression and metastasis of PC. 
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IV.2 Background and rationale 
In 2014, about 45,000 new cases of pancreatic cancer (PC) were diagnosed in 
the United States, of which pancreatic ductal adenocarcinoma represents the 
major histological type (1). The majority of tumors (about 75%) arise at the head 
of the pancreas (2). Anatomically, the pancreatic duct is placed close to the 
common bile duct, which both unite at the point known as the ampulla of Vater, 
and secrete their contents into the duodenum, which is the proximal site of the 
intestine (3). Approximately, 70% of PC patients develop extrahepatic 
cholestasis due to blockage of the common bile duct by increasing tumor size 
and results in multiple organ failure and early death (4). Due to this bile duct 
obstruction, extrahepatic cholestasis exhibits obstructive jaundice, and 
indication of both hyperbilirubinemia and the increased circulatory levels of BA.  
BA are amphiphilic molecules and are the main component of bile along with 
cholesterol, phospholipids, and bilirubin (5). By utilizing a series of enzymatic 
modifications, BA are synthesized in the liver using cholesterol as a precursor. 
Even after their synthesis, they are further modified by bacterial species present 
in the colon and form secondary BA (5). Dietary fat is a stimulus for BA 
secretion into the intestine, which is required for the proper digestion of fatty 
foods (5). Though bile-reflux has been associated with esophageal and gastric 
cancers, BA association with PC pathogenesis has not been investigated (6, 7). 
A recently performed meta-analysis has revealed increased risk of PDAC with 
patients having the history of cholecystectomy (8). It has been proposed that the 
mechanism attributed to this is the increased levels of cholecystokinin, which is 
known to stimulate the growth of human PC cell lines and promote pancreatic 
carcinogenesis in hamsters (9).  
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BA have been shown to participate in the progression of tumors using 
multiple mechanisms including, alteration in the expression of oncogenic mucins 
(10, 11). Interestingly, PC is characterized by aberrant mucins expression (12-
14). Among multiple mucins expressed in PC, MUC4 is one of the top-
differentially expressed protein (15). We and others have established the 
oncogenic functions of MUC4 in PC, and inhibition of MUC4 expression has been 
associated with reduced PC cell proliferation, migration, and chemoresistance 
(16-18). MUC4 is one of the most differentially expressed proteins in PC; 
therefore, comprehending the mode of its regulation will give us an opportunity to 
develop novel therapeutic strategies. In the present study, we have evaluated the 
role of BA in the regulation of MUC4 expression in PC. The findings from the 
current study, for the first time, have demonstrated that BA levels are significantly 
high in the serum and pancreatic juice samples obtained from PC patients. Using 
highly defined spontaneous mouse model of PC, we found that BA levels 
increase with the severity of PC disease condition, which led us to propose its 
tumor-promoting functions, which we have mechanistically explained by BA-
mediated induced expression of oncogenic MUC4 mucin. Mechanistically, BA-
mediated upregulation of MUC4 was found to be primarily dependent on FAK-
dependent c-Jun activation. Further studies led us to establish the role of FXR as 
the upstream molecule in this FAK/c-Jun/MUC4 axis. 
           IV.3 Results 
A. BA levels are elevated in serum and pancreatic juice during pancreatic 
cancer 
According to our hypothesis, BA play important roles in PC development by 
regulating the expression of oncogenic proteins, including MUC4. Therefore, we 
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first analyzed the in vivo levels of BA under PC disease condition. We observed 
that PC patients had significantly (p<0.05) higher circulatory bile acid levels as 
compared to the control group (Fig.4.1A). Additionally, we observed a significant 
increase in circulatory BA levels in 10-15-wk- and 20-25-wk-old (fully developed 
PC tumor) of KPC mice compared to their littermate controls (Fig.4.1B), 
strengthening the association of BA with the pathobiology of PC disease. We 
included controls from different age group for BA estimation and did not observe 
any noticeable change in their serum BA levels, which is also evident from the 
demonstrated standard errors (Fig.4.1B). Additionally, earlier report by Uchida K 
et al. have demonstrated that circulatory BA levels when expressed in terms of 
units per rat did not ostensibly change, regardless of their age (19). Consistently, 
pancreatic juice obtained from PC patients (n=18) had significantly high BA levels 
(p =0.048) of 65 μM,  compared to the non-pancreatic non-healthy (NPNH, 
patients with symptoms mimicking pancreatic disease but found to be free of 
pancreatic pathology) subjects (n=5), where the mean concentration of BA was 
13.65 μM (Fig.4.1C). Taken together, high BA levels in PC condition suggest 
their possible involvement in the pathobiology of PC. 
B. BA up-regulate MUC4 expression in PC cells 
BA are known to execute their oncogenic functions by altering the expression 
levels of mucins such as MUC1, MUC2, MUC4 and MUC5AC in oesophageal, 
gastric and colon cancers (10, 11, 20-23). Interestingly, PC is characterized by 
altered mucins expression. We along with others have clearly established that 
mucins play important role in the pathogenesis of PC (12-14). In order to analyze 
the effect of BA on MUC4 expression, we treated PC cell lines with different 
concentrations of DCA and CDCA for 24 h. We observed a significant increase in 
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MUC4 expression in CD18/HPAF cells at all concentrations, ranging from 5-100 
μM with the maximal increase at 50 μM concentration for both DCA and CDCA 
(Fig.4.2A). Corrobortively, our time course experiment in DCA and CDCA treated 
CD18/HPAF cells revealed increase in MUC4 expression starting from 6h 
treatment with maximum increase at 24h (Fig. 4.2B). BA-mediated increase in 
MUC4 expression was further confirmed in T3M4 (Fig.4.2C) and CAPAN1 cell 
lines (Fig.4.2D). Unlike CD18/HPAF, presence of two bands for MUC4 protein in 
T3M4 and CAPAN1 cells indicates the presence of allelic VNTR polymorphism in 
MUC4 genes in these cell lines (24). Furthermore, immunofluorescence 
experiment revealed significant increase in MUC4 expression in DCA or CDCA 
treated CD18/HPAF cell line (Fig.4.2E). Altogether, the results suggest that BA 
may play important role in the pathogenesis of PC by positively regulating MUC4 
expression. 
C. BA transcriptionally upregulates MUC4 expression in PC  
In order to know whether BA-mediated upregulation of MUC4 is at transcriptional 
level, PC cells were treated with DCA or CDCA in conjunction with actinomycin-
D, which inhibits the process of transcription. Intriguingly, we observed a 
significant increase in MUC4 expression by 4.09- and 4.49-fold in DCA and 
CDCA treated CD18/HPAF cells, respectively, which was attenuated to 0.18- and 
0.16-fold in DCA and CDCA treated CD18/HPAF cells when treated in 
combination with actinomycin-D (Fig.4.3A). Similarly, in T3M4 cells, we observed 
a 2.40-fold increase in MUC4 upon DCA treatment, was attenuated to 0.38-fold, 
when given in the presence of actinomycin-D, whereas a 2-fold MUC4 
upregulation in CDCA treated T3M4 cells was reduced to 0.54-fold in the 
presence of CDCA and actinomycin-D treatment (Fig.4.3A).  
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To highlight the DCA and CDCA responsive regions on the MUC4 
promoter, Luciferase reporter assay was performed (Andrianifahanana et al., 
2005). Our results demonstrated that both distal (P-1641) and proximal (P-1809 
and P-2150) constructs were responsive to BA in CD18/HPAF cells (Fig. 4.3B). 
Of particular interest was the deletion construct P-1641, which evidenced a 
statistically significant 2.95- and 3.24-fold upregulation of the reporter gene in 
response to DCA and CDCA treatment, respectively (Fig. 4.3B). A similarly 
enhanced transcriptional activity by 1.93-fold was also noticed in DCA and CDCA 
treated CD18/HPAF cells transfected with P-2150 construct, however, these 
changes were insignificant. P-1809 construct demonstrated increase in luciferase 
activity by 1.21- and 1.91- fold upon DCA and CDCA treatment, respectively (Fig. 
3B), nevertheless, these changes were significant only for CDCA treatment. 
Correspondingly, compared to untreated controls, T3M4 cells transfected with P-
1641 fragments showed 3.04- and 2.55-fold increase (p<0.05), in luciferase 
activity upon DCA and CDCA treatment, respectively (Fig. 4.3C). P-1809 
deletion construct demonstrated 1.53- and 1.78-fold increase in luciferase activity 
upon DCA and CDCA, respectively. Similarly, P-2150 construct exhibited 1.4- 
and 2-fold increase in luciferase activity in the presence of DCA and CDCA, 
respecitively. However, the increase in luciferase activity at proximal promoter 
regions upon BA treament were statistically insignificant in T3M4 cell lines. 
Taken together, our data suggests that the distal promoter region of MUC4 gene 
is mainly responsible for BA-mediated transcriptional upregulation of MUC4 in 
both CD18/HPAF and T3M4 cell lines. 
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D. BA increase the expression and nuclear localization of c-Jun  
Due to an observed maximal increase in the region -2572 to -3135 (present in P-
1641) to BA treatment in PC cell lines, we performed in silico analysis to 
delineate putative transcription factors binding sites for transcription factors on 
this promoter region (Fig. 4.4A). Two c-Jun binding sites were identified on 
MUC4 distal promoter (P-1641), which were absent on the proximal promoter 
fragment (P-1809 sequence) (Singh et al., 2007), and therefore, were suggestive 
of making distal promoter (P-1641) more responsive to BA treatment (Fig. 4.4B). 
It incited us to propose that BA-facilitated upregulation in MUC4 expression in PC 
cell lines is c-Jun dependent. Firstly, we were interested to know whether BA 
itself has any effect on c-Jun expression levels. Intriguingly, in CD18/HPAF cells, 
we observed 1.95-, 2.9-, and 3.46-fold increase (p<0.05) in c-Jun expression at 
10, 50, and 100 μM of DCA treatment over untreated cells. On the other hand, 
1.78-, 2.16-, and 3.87-fold increase (p<0.05) in c-Jun expression was noticed at 
10, 50 and 100 μM concentration of CDCA treatment, respectively (Fig.4.4C). 
The increased expression of c-Jun in response to both DCA and CDCA 
treatments was also confirmed by immunoblot analysis in PC cell lines 
(Fig.4.4D). Immunofluorescence experiments also revealed a significant increase 
in c-Jun expression and nuclear localization in both DCA- and CDCA-treated 
CD18/HPAF cells (Fig.4.4E). Further, nuclear and cytoplasm fractionation after 
BA treatment in CD18/HPAF cells, revealed significant increase in c-Jun 
expression in the nuclear extracts than untreated cells (Fig.4.4F).  
 To investigate the direct involvement of c-Jun in BA-induced MUC4 expression, 
we performed ChIP assay to analyze c-Jun binding on MUC4 distal promoter 
(Fig.4.4G). Using a primer set covering only one c-Jun binding site (or region-II), 
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we observed 4.01- and 1.64-fold enrichment upon DCA and CDCA treatment of 
CD18/HPAF cells, respectively. However, primers encompassing both c-Jun 
binding sites (region-I), showed a significant (<0.05) enrichment of 6.74- and 
2.61-folds, compared to untreated cells after DCA and CDCA treatments in 
CD18/HPAF cells (Fig.4.4G), suggestive of the cumulative effects of both c-Jun 
binding sites in inducing the transcription of MUC4 gene. As a negative control, 
we synthesized primers against the non-c-Jun binding MUC4 promoter fragment 
and found no difference. Taken together, BA increase the expression and 
nuclear localization of c-Jun, which then occupy MUC4 promoter to increase its 
transcription.  
E. BA mediated increase in FAK activation induced c-Jun expression 
To elucidate the signaling pathways responsible for increased MUC4 
transcription to BA treatment, CD18/HPAF cells were treated with a panel of 
inhibitors targeting different signaling pathways prior to BA treatment. 
Interestingly, pharmacological inhibition of both FAK and MAPK pathway showed 
attenuation of DCA- and CDCA-mediated MUC4 upregulation (Fig.4.5A). 
Inhibition of PI3K pathway did not have perceptible effect on MUC4 expression, 
whereas, inhibition of JNK did suppress MUC4 upregulation but only in the 
presence of CDCA (Fig.4. 5A). The attenuation of BA-mediated upregulation of 
MUC4 upon FAK inhibition was further confirmed using an immunofluorescence 
experiment (Fig.4.5B). Earlier JNK and MAPK pathways have been associated 
with BA, however, effects of BA on FAK has not been studied so far, particularly, 
in terms of MUC4 regulation. Moreover, due to observed maximal effect of FAK 
pathway on BA-facilitated MUC4 expression, we decided to focus on FAK 
pathway and analyzed the activation status of FAK in BA-treated PC cells. As 
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anticipated, we observed a high expression of activated FAK or pFAK (Y397) in 
DCA and CDCA-treated CAPAN1 and CD18/HPAF cells (Fig.4.5C), whereas 
expression of total FAK remains constant. As earlier experiments have linked c-
Jun expression with BA-mediated upregulation of MUC4, our next question was 
to explore whether alteration in FAK has any impact on c-Jun expression. 
Interestingly, we observed that selective pharmacological inhibiton of FAK, led to 
significant decline in the expression levels of c-Jun and MUC4 in PC cell lines, 
both at transcript and protein levels (Fig.4.5D and E). To further substantiate our 
results, we performed ChIP experiment and observed significant reduction in 
enrichment for c-Jun binding on MUC4 promoter when BA treatment was 
concomitantly given with FAK inhibitor, as compared to BA alone (Fig.4.5F), 
suggesting that FAK activation is a prerequisite for DCA- and CDCA-mediated 
MUC4 upregulation in PC cells due to its direct involvement in the induction of c-
Jun expression. 
F. FXR activation is a prerequisite for BA-mediated MUC4 upregulation via 
src/FAK/c Jun axis 
Farenosoid-X-receptor (FXR), a well established nuclear receptor, is known to be 
activated by BA. Upon its activation, FXR gets translocated to the nucleus, where 
it alters the trancriptional expression of multiple genes (Fig.4.6A). Interestingly, 
the overall expression of FXR did not get influence by BA treatment, as FXR 
levels were high in the cytoplasmic fraction of untreated cells than DCA and 
CDCA treated cells. Expression profiling of FXR receptor in PC cell lines showed 
its significant overexpression in HPAC, CD18/HPAF; CAPAN1, Panc10.05 and 
Panc1 cell lines (Fig.4.6B-C), compared to immortalized normal pancreatic cells 
(HDPE). Interestingly, significantly high FXR levels in CD18/HPAF cells explains 
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drastic increase in MUC4 expression even at very low concentration of BA 
treatment, compared to T3M4 and CAPAN1 cell lines (Fig.4.1B,C and D). Due to 
observed downregulation of activated FAK expression levels along with c-Jun 
levels upon transient knockdown of FXR in CD18/HPAF and T3M4 PC cell lines, 
it is likely that FXR is acting upstream in this FAK/c-Jun/MUC4 axis 
(Fig.4.6D).The key question which arises is that how FXR expression regulates 
the activity of FAK. It is well-known in the literature that src kinase is one of the 
critical regulator of FAK activity (26). As we have observed thar BA treatment do 
affect the phosphorylation of src (Fig.4.6E), we assumed that FXR-mediated 
phosphorylation of FAK is p-src-dependent, and FXR knocked down PC cells 
indeed showed significant reduction in p-src levels compared to si control 
(Fig.4.6E). To further substantiate our results, we gave BA treatment to FXR 
knockdown CD18/HPAF cells and found significant abrogation of BA-mediated 
MUC4 upregulation (Fig.4.6F). A 2.1-fold increase in MUC4 expression due to 
DCA treatment was reduced to 1.32-fold in FXR silenced CD18/HPAF cells 
(Fig.4.6F). Similarly, a 1.92-fold increase in MUC4 expression upon CDCA 
treatment was reduced to 1.13-fold when CDCA treatment was given to FXR 
knockdown cells (Fig.4.6F). Altogether, the results suggest that FXR activation 
due to BA exposure is responsible for the initiation of FAK/c-Jun/MUC4 axis in 
PC cells, by plausibly regulating the activity of src kinase.  
G. Clinical association between MUC4 and BA receptor FXR 
In clinical samples, we clearly observed that similar to PC cell lines, mRNA 
expression for FXR was higher in 47% of PC tissues (n=15), as compared to the 
tumor adjacent normal pancreatic tissues (n=4) (Fig.4.7A). Though the 
upregulation of FXR in PC patients was not statistically significant (p>0.05), but 
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considering significant increase in the levels of BA, which are activators of FXR 
receptor, both in the circulation and pancreatic juice of PC patients, we can 
speculate that pancreatic tumors have increased activity of FXR receptor, which 
is sufficient to initiate FAK/c-Jun/MUC4 signaling cascade. In order to confirm an 
in vivo association between MUC4 and FXR, we measured the transcript levels 
of MUC4 in same clinical samples and performed regression analysis (Fig.4.7B). 
A fairly positive correlation (R2=0.60) between MUC4 and FXR, further 
substantiated our in vitro findings. Moreover, using confocal microscopy, we 
observed co-expression of both FXR and MUC4 at the same PC tissue spots 
(Fig.4.7C).  
IV.4 Discussion 
Anatomically, the common bile duct and the pancreatic duct are close in 
proximity, and reunite at the ampulla of Vater. This led us to believe that BA can 
reflux to the pancreatic duct under pathological conditions. Growing pancreatic 
tumor often obstruct the  bile ducts, preventing the flow of bile  to the duodenum, 
leading to jaundice, a frequently occuring clinical manifestation in PC patients 
(27). Multiple studies have established BA as tumor-promoting agents in multiple 
cancers, including Barrett's metaplasia and colorectal, biliary, and hepatocellular 
cancers (11, 28-30). However, the role of BA in PC has not been clearly 
understood, which prompted us to study its influence on the tumorigenic 
properties of PC. In order to establish our hypothesis, BA levels were measured 
in the serum and pancreatic juice obtained from PC patients and NPNH 
individuals. Encouragingly, we observed a significant increase in BA 
concentration in those PC patients compared to controls. We also observed 
increased mRNA expression of BA receptor, FXR, in PC tumors compared to a 
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normal pancreas. Due to increased BA levels, which act as FXR agonist, it can 
be speculated that not only its expression, activity of FXR also get increased 
under PC condition, which we have confirmed as well due to increased nuclear 
expression levels of FXR upon BA treatment. Similar to our observation, Lee et 
al. have also observed increased expression of FXR in the PC tissues and 
established its protumorigenic role in PC disease condition (31). Altogether, this 
is a first experimental evidence establishing that BA do enter the pancreatic duct 
and increases the tumorigenic potential of PC cells by altering the expression of 
oncogenic MUC4 mucin.  
Our luciferase promoter assay revealed MUC4 distal promoter as the 
major BA responsive site. Further, in silico analysis demonstrated the presence 
of two activator protein 1  (AP-1) motifs on this region, which has also been 
reported in our earlier publication (32). Consistent with the previous findings 
observed in gastric cells (33), we noticed that BA treatment increase c-Jun 
expression, one of the members of the AP-1 family. Furthermore, ChIP 
experiments confirmed an increase in c-Jun binding on MUC4 distal promoter 
when exposed to BA treatment. Interestingly, by utilizing the same c-Jun 
transcription factor, BA are known to increase the transcription of 
cyclooxygenase gene, by facilitating increased c-Jun binding on COX promoter in 
esophageal adenocarcinoma cells (34). Importantly, c-Jun overexpression has 
already been associated with carcinogenesis and cancer progression in multiple 
cancers (35, 36). Although BA responsiveness was maximally observed at distal 
promoter (P-1641), we also observed increased luciferase activity in proximal 
promoter region, P-1809 transfected CD18/HPAF cells, upon CDCA treatment, 
implying the involvement of other transcription factors in CDCA-mediated 
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upregulation of CD18/HPAF cells due to the absence of c-Jun binding sites on 
this region and requires further investigation (32). Inspite of the presence of c-
Jun bindings sites on MUC4 proximal promoter (P-2150), we observed an 
insignificant increase in luciferase activity upon BA treatment, suggesting that BA 
might be affecting the expression and binding of transcription factors having 
inhibitory effects on proximal promoter region, and therefore, neutralizing the 
positive effects of c-Jun. 
Multiple forms of BA have been previously identified as potent inducers 
of MUC4 expression in esophageal carcinogenesis associated with bile reflux 
(10, 29). Mechanistically, PI3K signaling, protein kinase C and hepatocyte 
nuclear factor-1α were attributed to BA-facilitated increase in MUC4 expression 
(10, 11). However, in the current study, we have established the role of FAK in 
MUC4 regulation in PC cells upon BA treatment. Selective pharmacological 
inhibition of FAK led to the attenuation in BA-mediated MUC4 upregulation. 
Moreover, we observed downregulation of c-Jun expression upon FAK inhibition, 
suggesting that c-Jun activation is a downstream event occurring after FAK 
activation. Nadruz et al. have also established the link between c-Jun and FAK 
molecules in ventricular myocytes (37). Unlike CDCA, the inhibition of the JNK 
pathway had no remarkable effect on DCA-induced MUC4 expression, 
suggesting that different BA transduce differential signaling, and therefore, 
affects the expression of molecules, which is MUC4 in our case, to different 
extent. Moreover, the data also implies differential mode of c-Jun activation in the 
presence of DCA and CDCA. Earlier studies have shown that c-Jun can get 
activated in JNK-independent manner (38, 39). For instance, in neuronal cells, 
DNA damage causing induction of neuronal c-Jun kinase has been shown to 
166 
 
increase c-Jun phosphorylation (Besirli and Johnson, Jr., 2003). Upon injury, c-
Jun is found to be activated in Schwann cells by MAP kinases, which is again 
occurring independent of JNK (Deng et al., 2012). In addition to FAK pathway, 
inhibition of MAPK pathway also led to attenuation of BA-mediated MUC4 
upregulation, which further strengthened our notion that MAPK pathway could be 
involved in c-Jun activation. Future studies will be focused to understand the in-
depth involvement of different signaling pathways in MUC4 regulation after BA 
treatment. 
BA are known to interact with nuclear family receptors including;FXR 
and pregnane X receptor (PXR) in order to influence the transcription of their 
target genes. In the current study, for the first time, we have established the 
direct involvement of FXR protein in MUC4 regulation. In the clinical samples, we 
observed a fair positive correlation between FXR and MUC4 mRNA expression 
profiles. Upon FXR kd, BA-mediated upregulation of MUC4, FAK and c-Jun was 
abrogated, placing FXR as an upstream molecule in this FAK/c-Jun/MUC4 axis 
in PC. Das A et al have shown that FXR promotes the migration of endothelial 
cells by regulating the expression of FAK and MMP9 (40). However, the 
molecular mechanism of FXR-facilitated FAK activation is still unexplored. Due to 
observed increase in src kinase activity upon BA treatment, we assumed its role 
in this FXR-mediated increased FAK activation and found to be plausible as FXR 
silencing led to reduced p-Src levels in PC cell lines, and needs to be further 
validated. Interestingly, previous study in our lab has also shown that 
Guggulsterone, a selective pharmacological FXR inhibitor, also leads to a MUC4 
downregulation at transcriptional level in PC cells by utilizing  src/FAK pathway 
(41). In addition to FXR, other BA receptors could also be implication in BA-
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facilitated MUC4 upregulation. Interestingly, TGR5 has found to be upregulated 
in 67% of PC patients (data not shown) and recent report has shown its 
tumorigenic role in gastrointestinal cancers, including PC (42). Further studies 
will be helpful and required to mechanistically delineate the association between 
TGR5 and PC disease condition.  
Future studies will be directed to get the better insight of BA on the 
pathobiology of PC by bile duct ligation or cholecystectomy using autochthonous 
murine models, which will delineate the role of BA on pancreatic tumor growth 
and metastasis. Moreover, the significantly induced levels of BA indicates their 
possible usefulness for diagnostic purposes, and needs to be validated in more 
number of patient samples to assess and establish its clinical utility.  
Altogether, the current study, for the first time, has established that BA 
levels rises both in the circulation and pancreatic juice in PC, and they exert their 
protumorigenic functions by upregulating oncogenic MUC4 expression. 
Mechanistically, we have demonstrated that BA binding to FXR receptor leads to 
FAK activation, followed by increased c-Jun expression and its nuclear 
translocation, which in turn causes increased transcription of the MUC4 gene 
(Fig. 4.7D). The current study also supports emerging epidemiological data that, 
similar to colorectal cancer, fat-rich diet could be one of the risk factors for PC 
development and progression. Therefore, targeting BA receptors an 
administration of BA antagonists can significantly impact the outcome of PC 
patients. 
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Figures and Figure legends 
Figure 4.1. BA are significantly upregulated in PC condition. A. 
Representation of BA levels in the serum samples obtained from the PC patients 
(n=36) and healthy (n=10) individuals using a commercially available total BA 
estimation kit. The difference in BA levels between normal and PC patients were 
found to be statistically significant. B. To understand the association of BA with 
PC progression, we measured BA levels in established KPC mice model at early 
(5-7 wk), medium (10-15 wk) and advanced stages (20-25 wk). The BA levels 
were found to increase with the severity of the disease. C. Box-plot representing 
the levels of BA in the pancreatic juice obtained from PC patients. We observed 
significant increase in BA concentration in the pancreatic juice obtained from PC 
patients (65 μmol/L) compared to NPNH controls (13 μmol/L). (All values are 
mean ±S.E, ns means non-significant) 
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Figure 4.1 
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Figure 4.2. BA are positive regulators of MUC4 expression. A. CD18/HPAF 
cells were serum starved for 8h prior to BA treatment. Following 24h of BA 
treatment, cell lysates were collected, quantified and resolved using gel 
electrophoresis. Immunoblot showing increase in MUC4 expression upon DCA 
and CDCA treatment of CD18/HPAF cells at indicated concentrations. B. 
CD18/HPAF cells were treated with 50 µM of DCA or CDCA for indicated time 
points. MUC4 protein expression starts increasing at 6 h and maximal increase 
was noticed at 24 h.  C. Immunoblot showing increase expression of MUC4 in 
DCA and CDCA treated T3M4 PC cells cells at indicated concentrations. D. 
Immunoblots confirming MUC4 upregulation by BA treatment in CAPAN1 cells. 
E. Representative confocal images showing the positive effect of BA on MUC4 
expression in CD18/HPAF cells. (LE: Low exposure, scale bar = 20 µM) 
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Figure 4.3. BA-mediated positive regulation of MUC4 is at transcriptional 
level. A. After 8h of serum starvation, both CD18/HPAF and T3M4 cell lines were 
treated for 12h with 50 µM of DCA, CDCA or vehicle control (ethanol) in the 
presence or absence of actinomycin-D (2 µg/ml). Following treatment, cDNA was 
prepared from isolated RNA and used for real-time PCR to analyze the 
quantitative expression of MUC4 gene. The represented graph is demonstrating 
that inhibition of transcription attenuates DCA- and CDCA-mediated increase in 
MUC4 expression in both CD18/HPAF and T3M4 cell lines. B. Luciferase assay 
was performed in CD18/HPAF cell line transfected with MUC4 promoter-
truncated constructs, followed by 4h treatment of 50 µM of DCA and CDCA. A 
significantly elevated luminescence was detected upon BA treatment, primarily at 
the distal promoter region. C. Similar to CD18/HPAF cells, T3M4 cells also 
showed significantly elevated luminescence at the distal promoter region upon 
BA (50 µM) treatment. (*p<0.05, ** p<0.01, *** p<0.001, ns means non-
significant) 
174 
 
Figure 4.3 
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Figure 4.3 
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Figure 4.4. BA affect the expression, activation and nuclear translocation of 
c-Jun, which led to enhanced c-Jun binding on MUC4 distal promoter. A. By 
utilizing PROMO software, we obtained differential transcription factors binding 
sites on the highly responsive region for BA on MUC4 promoter region. B. 
Sequence of the MUC4 distal promoter (P-1641) which has two binding sites for 
c-Jun protein (marked red).  C. Graph showing increase in c-Jun mRNA 
expression in a dose-dependent manner in CD18/HPAF cell line, treated for 2 h 
with DCA and CDCA. C. CD18/HPAF and T3M4 cell lines were treated with BA 
(50 μM) for 4 h and cell lysates were collected. D. Immunoblot was performed to 
observe change in c-Jun expression in DCA- and CDCA-treated CD18/HPAF 
and T3M4 cell lines, compared to their respective untreated controls. E. Confocal 
images showing significant increase in c-Jun and MUC4 protein expression in 
CD18/HPAF cells treated with DCA or CDCA. Graph showing the quantification 
of the c-Jun positive nuclei in DCA and CDCA treated CD18/HPAF cells. F. 
Immunoblot showing significant increase in the expression levels of c-Jun in the 
nuclear fraction obtained from BA (25 μM)-treated CD18/HPAF cells, whereas 
cytoplasmic fraction did not demonstrate any noticeable alteration in c-Jun 
expression. G. ChIP experiment was performed to observe the effect on 
enrichment for c-Jun binding on MUC4 distal promoter in the presence or 
absence of DCA (50 μM) and CDCA (50 μM). We observed a significant increase 
in fold-enrichment at both region-I (containing two c-Jun binding sites) and 
region-II (containing one c-Jun binding sites). (*p<0.05, ** p<0.01, *** p<0.001, 
scale bar = 20 µM) 
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Figure 4.5. BA-mediated upregulation of MUC4 is dependent on FAK 
activation. A. Concomitant treatment of 25 µM of DCA or CDCA in the presence 
or absence of selective pharmacological signaling inhibitors for 12h led us to 
know that the FAK pathway is mainly responsible for MUC4 upregulation upon 
BA exposure, as attenuation of this pathway maximally suppresses the BA-
mediated upregulation of MUC4, compared to the other signaling inhibitors. 
Besides FAK, inhibiton of MAPK pathway also led to reduced MUC4 expression. 
B. Images obtained from immunofluorescence experiment showing MUC4 
upregulation in DCA (25 μM) and CDCA (25 μM) treated CD18/HPAF cells, 
which is attenuated upon inhibiting FAK activity (or phosphorylation). C. Increase 
in FAK activity was confirmed by analyzing pFAK (Tyr397) expression upon BA 
(25 μM) treatment of CD18/HPAF and CAPAN1 cell lines for 4h. D. Graphical 
representation of relative mRNA expression for MUC4 and c-Jun gene altered 
upon inhibition of FAK pathway in both CD18/HPAF and T3M4 cell lines. E. 
Immunoblot showng that inhibition of FAK pathway, using 15 µM of FAK Inhibitor 
14, leads to downregulation of MUC4, pFAK and c-Jun in CD18/HPAF cells. F. 
Graph representing the relative fold enrichment for c-Jun on AP-1 sequence 
motifs present on MUC4 distal promoter when CD18/HPAF cells were 
concomitantly treated with DCA and CDCA in the presence and absence of FAK 
inhibitor for 4 hours. (*p<0.05, scale bar = 20 µM) 
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Figure 4.6. Activation of FXR is required for BA-mediated MUC4 
upregulation via Src/FAK/c-Jun axis. A. Nuclear fraction obtained from 50 µM 
of DCA and CDCA treated CD18/HPAF cells, demonstrated increased levels of 
FXR compared to the untreated control. On the other hand, FXR expression was 
more on the cytoplasmic fraction in untreated cells than DCA and CDCA treated 
cells. B. FXR expression was found to be significantly high in PC cell lines than 
normal pancreatic cells (HDPE).  C. Reverse-transcriptase PCR was performed 
to analyze FXR expression in PC cell lines panel. Following PCR, 2% agarose 
gel was run to detect the bands using ethidium bromide dye.  D. FXR was 
transiently knockdown in CD18/HPAF and T3M4 cell lines using 150 nM of 
siRNA oligos and confirmed using immunoblotting. Interestingly, FXR knockdown 
cells exhibited significant decline in FAK, pFAK (Tyr397), src, p-src (Tyr416), c-
Jun, p-c-Jun (Ser63) and MUC4, suggestive of FXR involvement as the most 
upstream molecule in this BA-mediated FAK/c-Jun/MUC4 axis. E. CD18/HPAF 
cells were treated for 2h with 25 µM of DCA and 50 µM of CDCA. Following 
treatment, the expression of src and p-src (Tyr 416) were analyzed using 10% 
PAGE. (*p<0.05, **p<0.01, ns means non-significant). F. The graphical 
representation of the result obtained from real-time PCR showing that 
knockdown of FXR in CD18/HPAF cell line leads to significant attenuation of both 
DCA (25 µM) or CDCA (25 µM)-mediated MUC4 upregulation.  
185 
 
  DCA (25 µM)      -             +           -             -           +           -        
 CDCA (25 µM)    -              -           +             -           -           +  
FXR 
70 
SP1 
GAPDH 
35 
70 
Cytoplasm Nuclear 
A 
(kDa) 
CD18/HPAF 
1           1.91       1.93         1         0.11      0.10 
0
2
4
6
8
10
12
14
16
B
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
*
*
*
*
**
ns
ns
*
 
Figure 4.6 
H
P
D
E
H
P
A
C
C
D
18
/H
P
A
F
C
A
P
A
N
1
T
3M
4
P
an
c 
10
.0
5
P
an
c1
A
sP
C
1
M
IA
 P
aC
a-
2
FXR
β-actin
250
250
(bp)
B
 
C 
186 
 
D 
Si FXR            -               +                -            + 
CD18/HPAF 
p-Src     
70 
FXR 
70 
(kDa) 
T3M4 
FAK 
130 
Src     
70 
pFAK      
100 
β-actin  
55 
1               0.59              1              0.45            
MUC4      
~950 
1             0.14               1               0.52            
p-c-Jun      
55 
1             0.68               1               0.48            
c-Jun      
   55 
1             0.30               1               0.047            
1               1.08               1               0.59            
1                0.50               1               0.14            
1                1.61               1              0.79            
1                 0.25               1              0.225            
 
Figure 4.6 
CD18/HPAF 
  DCA            -            +              -             
 CDCA           -             -             +           
Src 
p-Src 
β-actin  
70 
70 
55 
(kDa) 
E 
1          1.05      1.06 
1           3.4        3.24 
187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 
188 
 
Figure 4.7. Clinical association between MUC4 and FXR in PC tissues. A. 
Expression profiling of FXR was performed in cDNA samples prepared from 
pancreatic tumor tissues (n=15) and tumor adjacent normal (n=4). Similar to its 
agonists, the levels of FXR was upregulated in tissues obtained from PC patients 
than tumor adjacent tissues. B. Data showing regression analysis which was 
performed to correlate MUC4 and FXR in clinical samples at transcriptional 
levels. C. PC tissues (obtained from Whipple procedure) showed the co-
expression of both MUC4 and FXR at same tissue spots, suggestive of their 
direct association. (scale bar = 20 µM). D. Schematic representation of the 
overall summary of the paper: Treatment with BA leads to the activation of FXR 
receptor, which gets engage in the activation of FAK pathway, possibly by 
activating src kinase. Increase in FAK-mediated signaling leads to an increased 
transcription of c-Jun gene. Increased expression and activation of c-Jun is 
followed by its increased nuclear translocation, leading to increased MUC4 
transcription, which plays an important role in the proliferation, survival, 
metastasis and chemoresistance of pancreatic tumors.  
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CHAPTER V 
 
Multifaceted role of MUC4 in regulating the trafficking of 
RTKs in Pancreatic Cancer
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V.1 Synopsis 
 The importance of EGFR signaling in PC has been acknowledged recently by multiple 
groups. However, the most interesting came in 2013, where Ardito and colleagues have 
clearly shown that EGFR activation is indispensable for the progression and 
development of PC. Interestingly, aberrant expression of MUC has been associated with 
the protein trafficking of EGFR family proteins. For instance, MUC4 expression has been 
linked with the increased protein stability of HER2 in PC cell lines, which was further 
attributed to MUC4-mediated reduced internalization of HER2. In breast cancer, 
modulation of MUC4 expression had significant impact on the expression of EGFR 
family members including, EGFR/HER1 and HER2. In breast cancer, MUC4 silencing 
led to decrease in the expression of Sprouty 2, an intracellular protein with established 
functions in stabilizing EGFR receptor. Besides breast cancer, MUC4 has shown to 
affect EGFR protein expression in glioblastoma. However, the precise mechanism 
involved in MUC4-facilitated impact on EGFR family members in cancer condition is still 
unexplored. In this chapter, I have disseminated the novel mechanisms involved in the 
regulation of the trafficking of EGFR and HER2 proteins by MUC4 mucin in PC. Using 
time-lapse live-cell imaging and confocal microscopy experiments, I have demonstrated 
that presence of MUC4 is increasing both the internalization and recycling rate of RTKs 
in PC cell lines upon ligand stimulation. It has been further associated with MUC4-
mediated regulation of RAB5A, a GTPase which regulates the rate-limiting step in 
protein endocytosis, at the transcriptional as well as protein level. At mRNA level, MUC4 
is inducing the activity of CREB via ERK activation, which is causing increased 
transcriptional activation of RAB5A by binding to the cyclic-AMP response element 
(CRE) present on RAB5A promoter. Moreover, I have observed that MUC4 regulates the 
expression of EGFR ligands, particularly TGF-α, and thereby regulating the receptor 
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recycling. Altogether, in this current chapter, I am presenting the multi-faceted roles of 
MUC4 in regulating the fate and trafficking of EGFR family members. 
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V.2 Background and rationale 
 
PC progression is accompanied by multiple genetic mutations such as, K-ras, p53, 
SMAD4, and so on [1]. Mutations along with inflammation can turned on various genes 
which does not express in normal conditions. MUC4 is one of such aberrantly 
overexpressed protein (~60%-70% of PC patients) in pancreatic cancer condition [2, 3]. 
MUC4 promotes tumorigenicity and has been directly associated with the growth, 
survival and chemoresistance of the PC cells, and its inhibition suppresses pancreatic 
tumor cell growth and metastasis [4-7]. Due to loss of cellular polarity, which is one of 
the hall-marks of cancer, MUC4 spread over the entire cell surface and start interacting 
with various cell-surface RTKs, including EGFR family members [8, 9]. Overexpression 
as well as functional importance of EGFR family members is quite evident in PC [10, 11]. 
Based on numerous experimental approaches, it has been suggested that loss of EGFR 
signaling could decline K-ras activity by 50%, and thus block the process of PC 
tumorigenesis [12]. Though multiple studies have associated MUC4 overexpression with 
the increased stability of RTKs over the cell surface, so far no studies have highlighted 
any mechanism which contributes to this process. Being a well-established model 
system to study receptor trafficking, it is known that EGFR fate is determined and 
decided at multiple steps by myriad of trafficking proteins. Several line of evidence has 
also established that proteins, which are known to participate in prolonging the RTKs-
initiated active signal transductions, overexpress in cancerous condition. One of such 
proteins is Rab GTPases subfamily which has been implicated in the regulation of 
intracellular vesicle transport, such as receptor-mediated endocytosis, exocytosis, 
degradation and recycling [13, 14]. Studies have demonstrated their aberrant expression 
and activity in multiple cancers; for instance, Rab5A has been implicated in the 
progression of multiple cancers, such as, lung, hepatocellular, cervical and ovarian 
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cancers [15-18]. A study by Fukui K et al has clearly shown the involvement of Rab5A in 
potentiating EGFR-mediated signal transductions in hepatocellular carcinoma [19]. 
Moreover, Rab5A is involved in the rate-limiting step of EGFR endocytosis, and 
therefore, acts as a critical link between signal transduction and protein trafficking [20]. 
Considering the importance of MUC4 and Rab5A on the expression of EGFR family 
members, we hypothesized that MUC4 regulates the endocytosis of EGFR by regulating 
Rab5A expression and activity. Therefore, in the current study, for the first time, we have 
addressed the novel role of oncogenic MUC4 protein in determining the fate of RTKs 
endocytosis by Rab5A regulation in PC condition. To address this, we have performed 
biochemical, time-lapse microscopy and qRT-PCR approaches. Our biochemical data 
upon inhibiting protein synthesis and degradation has evidently revealed the involvement 
of MUC4 in increasing the half-life of EGFR family members. Considering the 
importance of RTKs in PC, deeper understanding of its prolonged presence as well as 
activation onto the cell membrane due to MUC4 overexpression, will give us better 
opportunity to therapeutically target PC. 
V.3 Results  
 
A. MUC4 increased the stability of RTKs in PC cells 
 
Studies have evidently shown that MUC4 increase the stability of EGFR family 
members in various cancers [8, 9], which we have also confirmed as significant 
reduction in the EGFR and HER2 levels were noticed in MUC4 knocked down (kd) 
CD18/HPAF and CAPAN1 cells (Fig. 5.1A). Digital merging of confocal microscopic 
images of MUC4 (green) and EGFR (red) exhibited a noticeable colocalization (yellow) 
of these proteins at both membrane (non-permeabilized) and cytoplasmic regions 
(permeabilized) in PC cell lines (Fig. 5.1B). Corroboratively, our clinical data exhibited 
substantial MUC4 and EGFR co-expression and co-localization in PC tissues (n=13) 
than normal pancreas (n=3) and colon (n=1) (Fig. 5.1C), and further establishing their 
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association both under in vivo and in vitro settings. To directly implicate the role of 
MUC4 in EGFR stability, MUC4 scr and kd CD18/HPAF cells were treated with 
cycloheximide, which is an inhibitor of protein translation, for indicated time points. As 
anticipated, we observed significant depletion of EGFR in MUC4 silenced CD18/HPAF 
cells at all time-points compared to their respective scr controls (Fig. 5.1D). Altogether, 
these results indicate that in addition to HER2, MUC4 increases the stability of EGFR in 
PC cells.  
B. MUC4 influences the stability of RTKs by altering their rate of internalization 
Because it is reported earlier that MUC4 modulates the rate of HER2 
internalization and consequently its turnover [8], we hypothesized that MUC4 utilizes the 
same mechanism to regulate EGFR expression. The kinase domain of HER3 shares 
60% and 62% similarity with EGFR and HER2, respectively. However, both EGFR and 
HER2 share 83% identity in their amino acid sequence encoding for kinase domains 
[21]. It suggests that both EGFR and HER2 are more closely related to each other than 
they are to HER3 [21], which further support our hypothesis. To address that, we utilized 
time-lapse live-cell microscopy to monitor the fate of EGFR using rhodamine-tagged 
EGF ligand in MUC4 kd and control CAPAN1 cells. It is well-known in the literature that 
unlike TGF-α, EGF remains bound to EGFR and this EGF-EGFR complex undergoes 
dissociation and degradation in the lysosomes, therefore, movement of labeled vesicles 
from the cell membrane to endosomes actually indicates the levels and status of EGFR 
[22]. At 50 ng/ml of EGF, a concentration which is known to induce receptor degradation 
[23], significantly faster internalization was observed in MUC4 scr compared to MUC4 kd 
cells. As soon as chamber was kept at 370C, scr cells exhibited pronounced punctate 
formation, whereas in MUC4 kd cells, EGF vesicles remain persistently on the 
membrane (Fig. 5.2A). Despite of increased internalization, control cells had 
insignificant loss of EGF vesicles at 60 mins, whereas in MUC4 kd cells, there was 
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significant loss of vesicles, which is highly apparent in the marked (by white box) cells 
(Fig. 5.2A). Similar findings were observed in MUC4 kd CD18/HPAF cells, where control 
cells had significantly higher internalization (after 10 and 30 mins. of pulse) followed by 
insignificant depletion of internalized vesicles when compared to MUC4 kd cells (Fig. 
5.2B).  
To know EGFR localization, internalization experiment followed by colocalization 
experiment was performed. After 15 min. of pulse and 30 min. of chase, most of the 
EGFR vesicles are being recycled back to the plasma membrane in MUC4 scr CAPAN1 
cells, whereas most of the internalized vesicles are depleted in MUC4 silenced cells and 
accumulated in Rab5A and Rab7 positive compartments (Fig. 5.2C). Increased EGFR 
staining on the Rab11-positive compartments at 30 and 60 mins of internalization in 
MUC4 scr CD18/HPAF cells compared to kd cells, further confirms increased receptor 
recycling, whereas more pronounced colocalization between LAMP1 and EGFR in 
MUC4 kd CD18/HPAF cells compared to scr cells, suggests increased degradation of 
EGFR receptor (Fig. 5.2D). 
Earlier studies have implicated MUC4 cytoplasmic domain (MUC4-CD) as an 
interacting partner of HER2. Moreover, CD of mucins have shown to regulate EGFR 
trafficking [24], therefore, our next objective was to see whether overexpression of 
MUC4-CD has any effect on EGFR internalization and stability. Intriguingly, we observed 
increase in EGFR and p-EGFR expression in MUC4-CD overexpressing PC cell lines, 
however, changes in EGFR expression was insubstantial in MUC4-CD overexpressing 
MIA PaCa-2 cell line (Fig. 5.2E). Altogether, the results suggest that cytoplasmic domain 
of MUC4 has stabilizing effect on EGFR expression in PC cells. 
C. MUC4 impacts receptor internalization by altering the expression of Rab5A 
As mentioned earlier, Rab5A catalyzes the rate-limiting step in the internalization 
of RTKs and alterations in its expression have been noticed in various cancers [15-18]. 
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Therefore, we next wanted to analyze the expression status of Rab5A in PC cell lines. 
Intriguingly, it was noticed that MUC4-expressing PC cell lines exhibited high Rab5A 
transcript levels compared to non-expressing PC cells (Fig. 5.3A). Furthermore, 
downregulation in Rab5A mRNA expression in MUC4 kd CAPAN1 cells compared to scr 
cells and upregulation of Rab5A expression in MUC4 expressing MIA PaCa-2 compared 
to MUC4 null MIA PaCa-2 cells (Fig. 5.3B), were enough to directly relate MUC4 with 
Rab5A expression. Similar results were obtained at protein level Fig. 3C). In addition to 
that, active-Rab5A (GTP bound) pull down assay revealed reduced Rab5A activity in 
MUC4 kd CAPAN1 cells compared to control cells (Fig. 5.3D). Further, IF analysis 
revealed co-localization between MUC4 and Rab5A in CD18/HPAF cell line and 
confirmed their concomitant expression and localization in PC cells (Fig. 5.3E). 
Increased Rab5A expression in MUC4-CD overexpressing AsPC1 cells further 
associated the involvement of Rab5A with MUC4-mediated increased RTKs 
internalization (Fig. 5.3F). To solely implicate the role of Rab5A in MUC4-mediated 
regulation of RTKs stability, Rab5A was overexpressed in MUC4 kd and scr CAPAN1 
cells (Fig. 5.3G). Interestingly, we observed that loss of both EGFR and HER2 receptors 
upon MUC4 silencing were attenuated when RAB5A was overexpressed. We also 
validated the positive association between MUC4 and Rab5A expression levels in PC 
tissues using confocal microscopy (Fig.5.3H). Increased RIN1 mRNA expression in PC 
tissues compared to their adjacent controls (Fig. 5.3I); further established increase 
activity of Rab5A in PC patients. Altogether, MUC4 regulates the expression and activity 
of Rab5A and plausibly affects the internalization rate of RTKs in PC. 
D. MUC4-mediated transcriptional regulation of Rab5A is CREB dependent 
Earlier studies have clearly shown that promoter of Rab5A gene has cAMP-
responsive element or CRE [25], which instigated us to propose that MUC4-mediated 
transcriptional regulation is CREB-dependent. To validate the importance of CREB in 
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Rab5A upregulation, we treated PC cell lines with CREB inhibitor to suppress CREB-
mediated transcription by inhibiting its interaction with CBP, and observed 
downregulation in Rab5A expression compared to untreated cells (Fig. 5.4A). Treatment 
of CD18/HPAF cells with CREB activator, insulin, led to increased Rab5A expression at 
mRNA level (Fig. 5.4B), further establishing the involvement of CREB activity on the 
transcription of Rab5A gene.  
Due to observed involvement of MUC4 in the regulation of Rab5A expression, 
our next objective was to determine whether MUC4 expression impacts the expression 
and activation status of CREB molecule. As anticipated, significant downregulation in p-
CREB expression was observed in MUC4 kd PC cell lines compared to the control cells, 
without alteration in the expression of total CREB protein (Fig. 5.4C). ERK signaling has 
established association with the phosphorylation of CREB [26, 27], which was also found 
to be downregulated in MUC4 kd cells [28], and thus, provided the plausible link 
between MUC4 and CREB activation. Expression profiling revealed significant 
overexpression of both CREB and p-CREB in a panel of PC cell lines compared to 
HDPE (immortalized normal pancreatic cells). Moreover, this increase was more 
prominent in MUC4-expressing PC cell lines than MUC4 non-expressing PC cells, 
supporting the role of MUC4 in CREB activation (Fig. 5.4D). Co-expression of MUC4 
and p-CREB in PC tissues further signifies their positive association and validated our in 
vitro results (Fig. 5.4E). Interestingly, p-CREB staining was highly nuclear and 
expressed both in the ductal as well as in the stromal compartments. Taken together, 
the data provides the mechanistic link which leads to MUC4-mediated increase in 
Rab5A transcription via CREB regulation in PC condition. 
E. MUC4-mediated regulation of the expression of EGFR family ligands also 
determine the fate of receptors 
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Although in our study, we have mentioned the role of MUC4 in determining the stability 
of EGFR and HER2, the basal level of EGFR remains unchanged in MUC4-expressing 
and non-expressing PC cell lines, suggesting that PC cell lines do possess some unique 
mechanisms to stabilize the expression of EGFR receptor (Fig.5.5A). Interestingly, 
addition of EGF ligand in these cell lines impacts the fate of EGFR quite differently in 
MUC4 expressing vs. MUC4 non-expressing cell lines. As demonstrated, MUC4 non-
expressing; Panc1 and MIA PaCa-2 cell lines, had significant depletion of EGFR 
receptor at both 60 and 120 mins, compared to MUC4 expressing CD18/HPAF and 
CAPAN1 cell lines (Fig.5.5B). Due to these unique observations and the established 
involvement of EGFR ligands on determining their fate, we decided to analyze the 
expression levels of EGFR ligands in a panel of PC cell lines. Compared to MUC4 non-
expressing cell lines (HPNE, Panc1, AsPC1 and MIA PaCa-2), MUC4-expressing PC 
cell lines exhibited significantly elevated levels of EGF and TGF-α ligands (Fig.5.5C). 
TGF-α has established role in facilitating the recycling of EGFR [22], which can be 
attributed to the observed increased recycling of EGFR receptor in the presence of 
MUC4 and needs to be validated.  Altogether, these results suggest that in the absence 
of MUC4, PC cell lines attempts to stabilize EGFR expression by limiting the 
concentration of ligands.  
G. MUC4 increases the sensitivity of EGF-mediated migration and proliferation by 
increasing oncogenic signaling 
To understand the functional impact of prolonged cell surface localization of 
EGFR in the presence of MUC4, cell-growth kinetics and Boyden chamber migration 
assays were performed in the presence and absence of EGF ligand. CD18/HPAF MUC4 
Scr cells showed significant increase by 39% (p<0.05) in cell growth in ligand treated as 
compared to untreated cells (Fig. 5.6A). Silencing of MUC4 exhibited less impact on cell 
growth as only 18% increase after EGF treatment. CD18/HPAF MUC4 Scr cells showed 
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significant increase in cell migration by 39% (p<0.05) in ligand treated as compared to 
untreated cells. Silencing of MUC4 exhibited less impact on cell migration as only 18% 
increase in cell migration was noticed after EGF treatment in MUC4 kd CD18/HPAF cells 
(Fig. 5.6B). Similar changes were also noticed in CAPAN1 cells, where presence of 
MUC4 increases the responsiveness of EGF-mediated migration by 40%, whereas loss 
of MUC4 attenuate such effects as only 25% increase in cell migration has been noticed. 
Taken together, we can conclude from these results that MUC4 role in providing stability 
to EGFR by preventing its internalization is definitely making cancer cells more sensitive 
for EGF-mediated proliferative and migratory potential. 
V.4 Discussion 
Normal cells regulate their growth by regulating the secretion of growth factors and 
expression of their respective cell surface receptors at the optimal time and 
concentration to maintain their function [30]. On the other hand, cancer cells abrupt this 
crucial regulation in order to grow unrestrictedly [30]. In this study, we have addressed 
the implicated mechanisms by which EGFR and HER2 receptors provide prolong 
proliferative advantage to PC cells. Normal epithelial cells with a well-defined 
morphology with apical, basal, and lateral organization restrict the interaction of proteins 
from one region to another. However, under cancer condition, cells lose its polarity which 
subsequently leads to the disruption of this organization and facilitates novel protein-
protein interactions [31, 32]. For instance, MUC4 which expresses in apical regions in 
normal polarized epithelial cells can interact with basolateral proteins, including 
EGFR/Erbb family receptors in non-polarized cancerous cells, which has been evidently 
shown in multiple cancers such as, pancreatic and ovarian cancers [8, 9]. As a 
consequence, these interactions lead to the induction of multiple downstream signaling 
events such as PI3K and MAPK-mediated signaling [33]. Although earlier studies have 
indicated that presence of MUC4 regulates the stability of RTKs, the exact mechanism 
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which can be attributed to this phenomenon has not been pinpointed. In the current 
study, for the first time, we have indicated that MUC4 regulates the expression of 
Rab5A, a key protein involved in EGFR/HER2 trafficking. Being a critical molecule 
involve in protein endocytosis, alteration in the expression of Rab5A can significantly 
impact the protein trafficking. Nevertheless, we have also shown that MUC4-mediated 
regulation of Rab5A is responsible for the regulation of both HER2 and EGFR. MUC4 
has been demonstrated to increase EGFR expression in triple-negative breast cancer 
and glioblastoma [34, 35], but in the current study, we have clearly shown the 
involvement of MUC4 in EGFR regulation, using both in vivo and in vitro studies. 
Previous studies have shown that MUC1, a well-established mucin, imparts oncogenicity 
in cancerous condition, by influencing EGFR internalization and nuclear translocation 
[24]. Altogether, THE current study along with other studies have suggested that 
upregulation of mucin, one of the characteristics of PC, plays important role in stabilizing 
RTKs to support tumor growth.  
We have demonstrated that MUC4 interaction with EGFR occurs in the 
membranous and cytoplasmic regions under in vitro and in vivo settings [8]. Attenuation 
of EGFR reduction upon MUC4 silencing in CD18/HPAF cells when treated with 
lysosomal inhibitor, chloroquinone (CQ), indicates that MUC4 does regulate EGFR and 
HER2 fate. Under physiological condition as well, MUC4-mediated regulation of EGFR 
plays more significant role than MUC4-mediated HER2 regulation because of 
significantly higher incidence of EGFR overexpression (~70%) than HER2 (`18%) in PC 
condition. Nevertheless, EGFR is expressed primarily on the ductal epithelial cells, 
unlike HER2, which expressed predominantly on stromal cells than pancreatic ducts 
[36]. Though MUC4 interactions with HER2 has been attributed to HER2 increased 
stability on the pancreatic cancer cell surface by our previous study [8], but the general 
mechanism which actually leads to this phenomenon has not been addressed. In the 
  
207 
 
current study, we have established that MUC4-mediated regulation of EGFR family 
members is dependent on Rab5A.  
Rabs family members play critical role in controlling protein trafficking. Change in 
their expression has been observed in multiple cancers [37-39]. Due to established role 
of Rab5A in cancer and EGFR internalization, we focused ourselves on this molecule 
and received intriguing observations. Due to increased expression of Rab5A in PC cell 
lines as compared to normal pancreatic cells (HDPE), we proposed that Rab5A 
negatively regulates EGFR internalization. Indeed, similar to MUC4, overexpression of 
Rab5A leads to an increased rate of internalization and recycling and vice versa. 
Moreover, overexpression of Rab5A in MUC4 kd CAPAN1 cells attenuates the 
downregulation of both EGFR and HER2 compared to their respective controls. 
Interestingly, MUC4 is a critical regulator of transcription of Rab5A gene. Previous study 
has shown that Rab5A has multiple CRE sites [25], suggesting the plausible role of 
CREB in Rab5A transcriptional regulation, which we have established using inhibitors 
approach. Inhibition of CREB causes reduction in Rab5A expression, whereas CREB 
activation by insulin is responsible for Rab5A upregulation at both mRNA and protein 
levels. The connection between ERK and MUC4 signaling is well understood in the 
literature [40]. Similarly, ERK-mediated regulation of CREB phosphorylation is also 
known, which led us to comprehend that MUC4-mediated CREB activation is via ERK 
signaling cascade. Besides regulating the expression of Rab5A, we believe that MUC4 
also regulates its activity by regulating RIN1 expression [41, 42]. Interestingly, frequent 
overexpression of RIN1 at mRNA level was observed in PC patients. Further studies are 
still required to experimentally establish this link.  
As mentioned in the introductory chapter-1c, there is significant increase in the 
levels of EGFR ligands in both PDA spontaneous mouse models and human PC. 
Interestingly, we observed significant influence of MUC4 expression on EGFR ligands, 
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including, EGF and TGF-α. Of particular interest was TGF-α ligand due to its established 
role in facilitating increased recycling of EGFR, which can possibly be attributed to the 
MUC4-mediated increased recycling of both EGFR and HER2 [22]. However, it is still a 
critical question how does MUC4 mechanistically regulate the expression of EGFR 
ligands at transcriptional level? Altogether, from this data, it seems that MUC4 regulates 
the fate of EGFR family members at multiple steps. Our functional studies have shown 
that presence of MUC4 makes cancer cells more responsive to EGF-mediated 
oncogenic effects. We observed significant increase in cell growth and migration upon 
the addition of EGF in MUC4 Scr than the MUC4 kd PC cells. There are myriad of 
evidence suggesting the overexpression of EGF under cancerous condition, including 
PC [12, 43]. EGF overexpression has been linked with increased cancer cell migration 
and proliferation due to its ability to activate multiple downstream signaling elements via 
EGFR receptor.  
Besides regulating the oncogenicity of pancreatic tumor cells, MUC4 mediated 
regulation of EGFR internalization could also affect the therapeutic response, as one of 
the widely accepted mechanisms of action of EGFR based mAbs is to induce receptor 
internalization followed by degradation. We have observed significant attenuation of 
EGFR specific monoclonal antibody (mAb) mediated EGFR degradation in the presence 
of MUC4, suggesting that MUC4-EGFR interaction is not only stimulating the 
proliferation of the cells but also makes cells resistant towards EGFR-based therapies. 
In fact, presence of MUC4 has been associated with herceptin resistance in breast 
cancer [44]. Altogether, these observations led us to think that in spite of having such 
enormous importance of EGFR in PC; EGFR mAbs such as cetuximab, did not deliver 
anticipated clinical benefits to the patients. Physical interaction between MUC4-EGFR 
interactions, which is inhibiting mAbs-mediated internalization and receptor degradation 
to attenuate signaling, could be an important contributing factor in drugs failure and 
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resistance. Therefore, by modulating their interaction, we can possibly achieve increase 
efficacy of EGFR-mediated therapeutic response. Further studies are required to 
understand the relevance of MUC4 domains in terms of EGFR-directed monoclonal 
antibodies. Conclusively, this study has highlighted a novel function of MUC4 in 
regulating the trafficking of EGFR to potentiate EGF-mediated effects. 
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Figure and Figure legends 
 
Figure 5.1 In vitro and In vivo data shows an association between MUC4 and 
EGFR in PC condition. A.  CD18/HPAF and CAPAN1 cells were serum-deprived for 12 
hours, and then cell lysates were collected. IB results showing significant reduction in 
HER2, EGFR and pEGFR protein levels in MUC4 kd CD18/HPAF and CAPAN1 PC cell 
lines, compared to scr control cells. B. IF images showing significant colocalization and 
interaction between MUC4 and EGFR in CD18/HPAF and CAPAN1 cell lines under both 
permeabilized and non-permeabilized conditions. A 0.2% saponin was used with 
antibody solution for permeabilized condition, whereas antibody solution without 
detergent was used for non-permeabilized condition. C. Confocal images demonstrating 
co-expression of MUC4 and EGFR in stained PC tissues. Pearson correlation was 
calculated using Image J software for each field from tissue spots of normal colon (NC), 
normal pancreas (NP) and PC. The graph is clearly showing that colocalization between 
MUC4 and EGFR was significantly high in PC P. D. IB showing significant depletion of 
EGFR protein levels upon cycloheximide (50 µg/ml) treatment in MUC4 kd CD18/HPAF 
cells compared to scr cells, suggesting that MUC4 has significant role in stabilizing 
EGFR expression in PC cancer condition. 
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Figure 5.2 MUC4 significantly impact EGFR trafficking. A. Images obtained from live 
cell imaging experiment have revealed that EGF ligand tagged with Rhodamine (but 
represented as yellow color for more clarity) is internalizing at very faster rate in MUC4 
control cells compared to MUC4 scr cells. However, CAPAN1/scr cells also had 
significant recycling of EGF-vesicles at 45 and 60 mins, compared to MUC4 kd PC cells. 
B. Flow cytometry data revealed that MUC4 scr cells had significantly higher level of 
uptake or internalization of EGF bound EGFR at 30 mins compared to MUC4 scr cells, 
however, the bound receptor is getting depleted in MUC4 kd CD18/HPAF cells than scr 
control cells. C. Confocal images showing the presence of EGFR and Rab5A in scr and 
MUC4 kd CAPAN1 cells. Here, cells were stimulated with unlabeled EGF for 15 min. and 
then EGF bound EGFR was chased after 30 mins at 370C. D. Confocal images showing 
significant colocalization between EGFR and LAMP1 at 60 mins in MUC4 kd CAPAN1 
cells compared to scr cells, suggesting increased degradation of receptor in scr cells. On 
the other hand, increased colocalization between EGFR and RAB11 receptor in MUC4 
scr cells compared to MUC4 kd cells, suggestive of increased recycling. E. Ectopic 
expression of MUC4 cytoplasmic domain (MUC4-CD) in MIA PaCa-2 and AsPC1 cell 
lines led to increased expression of both EGFR and p-EGFR compared to their 
respective vector controls.  
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Figure 5.3 MUC4 regulates the expression and activity of Rab5A. A. Quantitative 
real-time PCR data showing increased expression of Rab5A in MUC4 expressing 
(CAPAN1, CD18/HPAF, Colo357, HPAC, SW1990 and T3M4) PC cell lines, compared 
to MUC4 non-expressing (HPNE, AsPC1, Panc1,MIA PaCa-2) cells. B. MUC4 kd 
CAPAN1 and MUC4 ectopic expression in MIA PaCa-2 cell lines exhibited reduced and 
high expression of Rab5A at mRNA levels, compared to their respective controls. C. 
These results were also confirmed at protein levels. D. Active Rab5A was pulled down in 
MUC4 scr and kd CAPAN1 cells. IB results are clearly showing that Rab5A pull down 
was significantly more in MUC4 kd CAPAN1 cells compared to scr cells. E. Confocal 
images demonstrating Rab5A expression in MUC4 scr and kd CD18/HPAF cells. F. IB 
showing increased expression of Rab5A upon ectopic expression of MUC4-CD in MIA 
PaCa-2 and AsPC1 cell lines. G. IB showing the expression levels of EGFR and HER2 
in Rab5A overexpressing MUC4 kd and scr CAPAN1 cells. H. MUC4 and Rab5A 
colocalization (or co-expression) was determined using immunofluorescence experiment 
in RAPID autopsy tissue samples. I. Increased mRNA expression of RIN1 in PC patients 
compared to tumor adjacent tissues, further confirm increased activity of Rab5A in PC 
tissues than control.  
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Figure 5.4 MUC4-mediated regulation of CREB activity is leading to Rab5A 
regulation. A. Inhibition of CBP:CREB interaction by using pharmacological inhibitor 
significantly reduces Rab5A expression in CAPAN1 and CD18/HPAF cells. B. CAPAN1 
and CD18/HPAF cells were cultured in serum free media 12h prior to treatment. 
Following, cells were treated with insulin (200 nM) for 4h and RNA isolation was 
performed. The graph is showing upregulation of Rab5A mRNA expression upon insulin 
treatment in both the tested cell lines, confirming the positive involvement of activated 
CREB on the transcriptional induction of Rab5A gene C. IB showing reduced expression 
of p-CREB and p-ERK in MUC4 kd PC cells, while total CREB remains constant. D. A 
panel of PC cell lines was screened for p-CREB and CREB molecules using IB analysis. 
Both CREB and p-CREB levels were relatively high in MUC4 expressing than MUC4 
non-expressing PC cell lines, confirming the link between MUC4 and CREB activation. 
E. IF images were taken for p-CREB and MUC4 in stained PC tissues. The significant 
coexpression of both of these molecules on PC tissue spots was validating our in vitro 
results under clinical settings.   
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Figure 5.5 MUC4 regulates the expression of EGFR ligands. A. A panel of PC cell 
lines was screened for EGFR expression using IB. B. PC cell lines were stimulated with 
unlabeled EGF ligand (20ng/ml) for 60 and 120 min. Following stimulation, cells were 
stained with EGFR. Significant depletion of EGFR was noticed in MUC4 non-expressing 
MIA PaCa-2 and Panc1 cell lines, whereas CAPAN1 and CD18/HPAF cells also 
exhibited depletion of the receptor; however it was significantly less than MUC4 non-
expressing cell lines. C. A panel of PC cell lines was screened for EGFR ligands; EGF 
and TGF-α. The data showing the relative mRNA change value normalized with β-actin. 
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Figure 5.6 MUC4 potentiates EGF-mediated proliferative and migratory potential. 
A. 0.5X106 of scr and MUC4 kd CD18/HPAF cells were grown on the surface of Boyden 
Chamber assay in serum free media. After 12h, EGF ligand (20ng/ml) was added on the 
bottom chamber and cells movement was traced. Following 48h of treatment, cells 
reached to the lower chamber were stained, while cells still present on the upper 
chamber were removed. Stained cells were quantified by the use of microscope. Images 
obtained are showing the effect of EGF ligand on the migration of MUC4 scr and kd 
CD18/HPAF cells, and suggesting that presence of MUC4 does make PC cells more 
responsive for EGF-mediated effects on cellular migration. B. Similar to migration, scr 
cells also exhibited higher levels of proliferation upon EGF treatment, compared to 
MUC4 kd cells, as depicted by growth kinetics experiment. 
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Figure 5.7 Schematic diagrams showing that presence of MUC4 determines the 
fate of EGFR. In the presence of MUC4, through the activation of MAPK pathway, 
CREB is getting phosphorylated to p-CREB, which allows it to enter to the nucleus. 
Inside the nucleus, p-CREB binds to the CRE element present on RAB5A promoter, 
which increases the transcription of RAB5A gene. It is followed by increased synthesis of 
RAB5A. Increased RAB5A expression will then leads to increased internalization of 
EGFR receptor. However, internalized EGFR will be redirected to the recycling pathway 
to the plasma membrane, rather than lysosomal degradation pathway. This preference 
of EGFR for recycling route in the presence of MUC4 could be attributed to induce TGF-
α expression. This is one of the mechanism by which aberrant expression or 
overexpression of MUC4 helps cancer cells to proliferate in an unrestricted manner. 
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CHAPTER VI 
 
Identification of MUC4 in Pancreatic stellate cells (PSCs) 
and  putative MUC4 alternate promoter  
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VI.1 Synopsis 
Pancreatic ductal adenocarcinoma (PDAC) is an extremely malignant disease with an 
equally poor prognosis. Till date, no significant improvement has been made to improve 
clinical outcomes of the PDAC patients, primarily due to the limited number of patients 
eligible for surgical resections and the frequently occurring problem of radiation and 
chemotherapy resistance of these tumors. Due to consistent failure of both conventional 
and novel therapies, researchers are forced to re-scrutinize the involvement of tumor 
environment in PDAC. The pancreatic tumor microenvironment is comprised of 
abundant amount of stroma containing many cells types, but the majority of them are 
pancreatic stellate cells (PaSC). It is well established that PaSC are responsible for 
enormous desmoplastic reactions which is apparent in almost 90% of the PC patients. 
These desmoplastic reaction leads to fibrosis which is observed in two major diseases of 
the pancreas—chronic pancreatitis and pancreatic cancer. Considering the importance 
of PaSC in the pathobiology of PC disease, there has been an exponential upsurge in 
research in this field in last few years, with numerous research groups channelizing their 
energies to elucidate the biology and function of these cells. However, the major 
problem that we are currently facing is the lack of consensus among PaSC markers. 
Still, alpha smooth muscle actin (a-SMA) is widely used to detect activate stellate cells in 
PC.  
While studying the role of different cell types on MUC4 expression, I came to this 
very intriguing observation that PaSC does have MUC4 mucin expression, whereas 
other transmembrane mucins such as MUC1 and MUC16 were completely absent. This 
is the first report which has shown MUC4 expression in cells of non-epithelial origin. 
Interestingly, inactivation of PaSC by using retinoic acids (RA) leads to drastic reduction 
in MUC4 expression. Further, confocal microcopy has shown significant expression 
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levels of MUC4 in glial fibrillary acidic protein (GFAP, marker of myofibroblasts) positive 
PaSC. Encouragingly, PC tissue samples have also shown presence of MUC4 in few α-
SMA-positive cells, a marker of activated PaSC. Moreover, MUC4 knocked down (kd) in 
PSC, using two targeted ShRNA constructs, has shown significant reduction (p>0.05) in 
a-SMA expression. We also evidenced decline in the proliferative and migratory 
properties of MUC4 kd PaSC, as compared to the Scr control cells, emphasizing that 
MUC4 plays an important role in determining the activation status of PaSC. This study 
gives us an additional reason to target MUC4, which not only leads to the killing of PC 
cells, but will also inhibits the activation of PaSC. 
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VI.2 Introduction 
Pancreatic cancer (PC) is the fourth leading cause of cancer mortality in United States 
with 5-year survival of only 6% (1). Due to lack of diagnostic markers, early metastasis 
(invasion to local and distant organs), frequently developed chemo-resistance and lack 
of reliable therapies, PC is a very lethal disease. Moreover, PC has expected to become 
the second leading cause of cancer-related deaths in next 15 years (2). Among many 
unique hallmarks, PC is characterized by extreme desmoplastic reactions, which has 
shown to accelerate PC growth and metastasis. One of the major contributors of 
pancreatic desmoplasia is pancreas residing fibroblasts cell population, also known as 
pancreatic stellate cells (PaSC) or myofibroblasts. In normal pancreas, PaSC are 
quiescent in nature, but inflammation, hypoxia and pancreatic injury leads to their 
activation, which is accompanied by the absence of lipid droplets, and their increased 
migratory and proliferative potential (3, 4). Activated PaSC synthesizes and secretes 
excessive extracellular matrix proteins, which reduces the accessibility of chemotherapy 
agents to the cancer site. In addition, activated PaSC are also known to contribute in PC 
metastasis.  
Considering the highly important role of PaSC in PC progression, metastasis and 
chemo-resistance, recent studies have been directed to inhibit their activation (3, 4). Our 
research group from past two decades has established MUC4, a transmembrane 
protein, as one of the critical oncogenic protein because it facilitates survival, growth and 
metastasis of PC (5-7). MUC4 is one of the top differentially expressed proteins in PC 
(8). Earlier, expression of mucins was thought to be confined to epithelial cells. However, 
emerging reports have demonstrated presence of mucins on non-epithelial cells. For 
instance, MUC3 expression has been noticed in synovial lining cells, macrophages and 
fibroblasts derived from rheumatoid arthritis (RA), osteoarthritic (OA) and normal human 
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synovial tissues (ST) (9). Similarly, these cell types also exhibited expression for 
MUC5AC, though at extremely low levels. In addition, MUC1 expression was observed 
in activated human T-cells (10, 11). However, there is no report so far which has shown 
the presence of MUC4 in non-epithelial cells. While studying the role of PC tumor 
microenvironment in MUC4 regulation, we obtained one of the most intriguing findings, 
which was the presence of MUC4 in PaSC. In addition to its expression, we have also 
demonstrated the role of MUC4 protein on the activation status and functional properties 
of PaSC. 
VI.3 Results 
A. Presence of MUC4 mucin on activated cancer associated fibroblast cells 
Normal and healthy pancreas contains less number of fibroblast cells, and they are 
generally inactive until or unless there is any stimulatory signal present. When cultured 
in the presence of tumor (KCT961)-derived conditioned media, inactivated fibroblasts 
cells (ImPaSC, obtained from WT mice) become activated, marked by significant 
increase  in the expression of both α-SMA and Ki67 staining (Fig. 6.1A). Real-time PCR 
experiment led us to know significant increase in MUC4 expression by ~20-fold in 
activated ImPaSC, compared to inactivated ImPaSC (Fig. 6.1B). To further establish 
these findings, we used another PaSC cell lines (immortalized with E6/E7 antigen) 
derived from human PC patients. Similar to CD18/HPAF PC cells, human PaSC cells, 
which are already activated, showed positive expression for MUC4 promoter, though at 
significantly less molecular weight (Fig. 6.1C). However, other transmembrane mucins 
such as MUC1 and MUC16, were absent in PaSC cells (Fig. 6.1C). We further verified 
the presence of MUC4 in PaSC using different anti-MUC4 antibody (2175) (Fig. 6.1D), 
however, difference in its molecular weight in PaSC and CD18/HPAF cells was relatively 
less than our previous observation (Fig. 6.1C). Immunofluorescence staining showed 
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significant colocalization between MUC4 and GFAP (marker of PaSC) which further 
supported our findings (Fig. 6.1E). Confocal microscopy performed for MUC4 and α-
SMA in PC tissue array further validated our in vitro findings (Fig. 6.1F). We observed 
that small fractions of PaSC cells were positive for MUC4 expression in PC tissue spots. 
IHC performed for MUC4 in human PC tissues and KPC mice model also demonstrated 
the presence of MUC4 in cells other than epithelial cells, with morphology similar to 
myofibroblast cells (Fig. 6.1G-H).   
B. Presence of MUC4 determines the activation status of PaSC 
Due to observed MUC4 expression in activated PaSC, we were prompted to 
hypothesize that MUC4 expression is required for the functionality and activation of 
PaSC. To address our hypothesis, we made stable MUC4 kd PaSC using two different 
MUC4 targeting constructs. As depicted in Fig. 6.2A, MUC4 was significantly 
downregulated in PaSC cells at protein levels, which was further confirmed with the help 
of IF and qRT-PCR techniques (Fig. 6.2B-C). In MUC4 kd PaSC cells, we observed 
significant decrease in α-SMA expression, which is a marker of activated cancer 
associated fibroblasts or PaSC, at both mRNA and protein levels (Fig. 6.2D-E), 
suggesting that MUC4 does involve in the maintenance of the activation status of PaSC. 
Alternatively, upon inducing quiescence in PaSC by using RA (12, 13), significant 
decline in MUC4 expression was noticed in RA-treated PaSC at both protein (Fig. 6.2F) 
and mRNA level (Fig. 6.2G). Altogether, our results demonstrate that MUC4 expression 
and activation of PaSC cell are directly associated with each other. 
C. Suppression of MUC4 reduces the proliferation and migration of PaSC 
It is well-established in the literature that activation of PaSC is accompanied by increase 
in their migration and proliferation (3). Therefore, analysis of the migratory and 
proliferative potential upon MUC4 silencing would be another way to prove that MUC4 
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plays important role in the activation status of PaSC cells. Similar to PC cell lines, 
suppression of MUC4 expression led to significant decrease in cell proliferation (p<0.05), 
particularly on day 5 and 6, compared to scr control cells (Fig. 6.3A). Further, we 
observed decrease in number of colonies in our anchorage dependent assay upon 
MUC4 kd PaSC cells compared to control (Fig. 6.3B). At molecular level, we observed 
decrease in the EGFR and cyclin D1 protein expression, without any noticeable effect on 
Akt and ERK activation (Fig. 6.3C). To relate MUC4 kd with the migration of PaSC, we 
did Boyden chamber motility assay and observed that kd of MUC4 led to significant 
reduction in migration of PaSC cells to the lower chamber compared to scr control cells 
(Fig. 6.3D). We observed reduction in the expression and arrangement of the tubulin 
proteins in MUC4 kd PaSC than scr cells (Fig. 6.3E). Further, significant decrease in the 
expression of vimentin protein in MUC4 kd cells than control cells, validate the role of 
MUC4 in the motility of PaSC, however, N-cadherin expression did not change with 
MUC4 silencing (Fig. 6.3F). Similar to their protein data, we observed decline in the 
mRNA expression of twist, vimentin, cyclin d1 and EGFR in MUC4 kd PaSC compared 
to control cells (Fig. 6.3G).  
D. Identification of novel MUC4 promoter  
From earlier results, it is quite apparent that molecular weight of MUC4 is less in PaSC 
cells compared to PC cells; which led us to postulate that the observed difference is 
possibly due to exon deletion, which is quite common among mucins. Screening of 
MUC4 cDNA from exon-1 to exon-26 using RT-PCR revealed that MUC4 in PaSC cells 
does not utilize classical promoters (CP) and has exon-1 deletion (Fig. 6.4A). Using 
promoter prediction V2 software, two highly likely predicted promoter sites on intron-1 
(primarily at the end) were recognized, which we have referred as alternate promoter or 
AP (Fig. 6.4B). Certainly, we did observe amplified expected PCR product in PaSC 
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using forward primer against intron-1 and reverse primer against exon-2, and 
sequencing was done to confirm that the amplified band is MUC4 only. Further, we 
found that this identified AP is present only in MUC4-expressing PC cells and is 
completely absent in MUC4 non-expressing PC cell lines, excluding the possibility of 
DNA contamination in utilized cDNAs obtained from these PC cell lines (Fig. 6.4C). 
These results were further verified using quantitative RT-PCR. We observed that AP is 
maximally expressed by HPAC and Panc10.05 cell lines, whereas CP expression is 
maximal in CAPAN1, Panc10.05, Colo357 and QGP-1 cell lines (Fig. 6.4D). To validate 
the presence of AP in clinical samples, we did RT-PCR in cDNA obtained from PC 
tissues. We observed the presence of MUC4 at transcriptional level in tumor adjacent 
and tumor tissues, whereas AP was found to be utilized by tumor tissues only, 
associating the presence of AP with the aggressiveness of pancreatic tumors (data not 
shown). Using in silico analysis, a putative AUG translation site in-frame codon was 
detected at the beginning of exon 2 of MUC4 gene. It suggested that the protein which is 
being synthesized by utilizing MUC4 AP will have most likely all the MUC4 domains 
present, except leader sequence due to exon-1 deletion. 
E. Differential localization of MUC4 in PaSC and PC cell lines 
As mentioned earlier that MUC4 in PaSC has an exon-1 deletion, which led us to 
assume that MUC4 localized differentially in these two different cell types. For that, we 
utilized confocal microscopy approach. As anticipated, we observed that MUC4 in PaSC 
cells have more surface localization, whereas its localization in early endosomes 
(signified by EEA-1 staining) and Golgi (marked by giantin staining) was significantly less 
compared to PC cell line (Fig. 6.5). In spite of the absence of leader sequence, MUC4 
does enter into endoplasmic reticulum (ER), which is possible and has been observed 
for other proteins that do not possess leader sequence (Fig. 6.5). We observed that 
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MUC4 enters to lysosomes in both PaSC and CD18/HPAF PC cells. Altogether, these 
results suggest that MUC4 localization is different between PaSC and PC cell lines. 
VI.4 Discussion 
In this study, we have analyzed in detail the expression and functions of MUC4 in 
activated PaSC cells. The current study is the first evidence where presence of MUC4 
has been observed in cell type other than epithelial cells. Upon exploring its function, we 
realized that MUC4 increase the activation status of PaSC under both in vitro and in vivo 
settings.  Metastasis is one of the main reasons of PC related deaths, in which activated 
PaSC has shown to play important role. By orthotopic transplantation of a suspension of 
human PC cells (MiaPaCa-2, AsPC-1, BxPC-3), alone or in combination with primary 
human PaSCs, directly onto the mouse pancreas, two separate studies by Vonlaufen et 
al. and Hwang et al. have shown that the combination of human PaSCs and PC cells 
has significantly high degree of desmoplasia, increased primary tumor growth and 
increased regional/distal metastasis compared to PC cells alone (4, 14). Therefore, 
increased activation of PaSC and the implicated role of MUC4 further strengthened the 
rationale to target MUC4, which not only leads to the killing of PC cells, but will also 
inhibits the activation of PSC.  
Moreover, we have also seen that this alternate form of MUC4 is present on 
aggressive PC tissues (n=6), whereas it was completely absent in tumor adjacent 
tumors (data not shown), suggesting that during the course of evolution, PC cells 
undergo many changes in which utilization of MUC4 AP is one of the them. Although in 
this study, we have highlighted the expression and functions of MUC4, it is still not clear 
when and how AP of MUC4 is being regulated and utilized by PC cells, which we would 
like to delineate in future.  
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Importantly, we have identified the usage of AP in MUC4-expressing PC cell 
lines and human PC tissues using RT-PCR approach. The AP of MUC4 was identified 
on intron-1. The concept that intronic sequences can also act as alternate promoters is 
not new. For instance, in a study by Scohy et al., authors have demonstrated the 
presence of a novel, tissue-specific α-fetoprotein mRNA isoform in the yolk sac and fetal 
liver, with a transcription site present on the first intron of the α-fetoprotein gene (15). 
This isoform is synthesized by the usage of an AP located ∼100 bp downstream of the 
enhancer element (15). However, the direct evidence validating the presence of MUC4 
AP is still lacking and needs to be established. Currently, these results are being 
validated using 5’Rapid Amplification cDNA ends (RACE) experiment. With the help of in 
silico analysis, we predicted that MUC4 isoform driven by alternate promoter is using the 
translation site present on exon-2. Further studies also prompted us to assume that 
identified isoform of MUC4 has altered localization in PaSC vs. PC cell lines due to the 
absence of exon-1 which encodes for MUC4 leader sequence. Along with aberrant 
expression, accumulating evidence has associated altered subcellular localization of 
mucins with the poor prognosis and survival of cancer patients (5). Loss of leader 
sequence encoding exon-1 in MUC4 due to alternate promoter usage will definitely 
impact MUC4 subcellular localization. This study has paved the way to initiate 
investigations which will provide us in-depth understanding of MUC4 both at the cellular 
and molecular levels. 
Taken together, this study for the first time has shown the expression of MUC4 in 
non-epithelial cells. Further functional studies established that presence of MUC4 does 
alter the migratory and proliferative potential of PaSC cells and is directly related with the 
activation status of PaSC. Further, studies with more number of activated pancreatic 
248 
 
cancer fibroblast or stellate cells will strengthen our observations and is a part of our 
future investigations. 
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Figure and Figure legends 
Figure 6.1. Identification of MUC4 expression in activated pancreatic stellate cells.  
A. IF experiment revealed that ImPaSC cells obtained from WT mice become activated 
when cultured in tumor-derived (KCT961) conditioned media, as marked by induced 
expression of α-SMA and ki-67, compared to untreated control cells. B. The bar graph is 
showing Muc4 expression at mRNA level in mice PaSC co-cultured with or without tumor 
cells (KCT961). C. The transmembrane mucins; MUC1, MUC4 and MUC16 were 
profiled in CD18/HPAF and PaSC cells by immunoblotting, which did reveal the 
presence of MUC4, whereas other two membranous mucins were absent. D. 
Immunoblotting by using another antibody against MUC4 (2175) is confirming the 
presence of MUC4 in PaSC and CD18/HPAF cells. E. IF analysis revealed noticeable 
co-localization between MUC4 and PaSC cells. GFAP is a marker of stellate/fibroblast 
cells, whereas 8G7 and 2175 antibodies were used to detect MUC4 expression. F. 
Confocal microscopy was utilized to detect MUC4 expression in activated stellate cells 
(marked by positive α-SMA staining) in pancreatic tissues obtained from RAPID autopsy 
program. G. IHC images obtained from stained human PC tissues are showing the 
presence of MUC4 in cells other than ductal epithelial cells. H. In 25-wk age of KPC 
mice, when PC is fully developed, MUC4 was stained using IHC protocol. 
Correspondingly, Muc4 was observed in non-ductal cells, which share a significant 
similarity in the morphology with myofibroblast cells. 
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Figure 6.2. MUC4 kd has significant impact on the activation status of PaSC.  A. 
Stable kd for MUC4 was performed in PaSC cells and immunoblot technique was used 
to confirm MUC4 silencing in PaSC. B. Images obtained from IF experiment further 
confirmed significant kd of MUC4 protein expression in PaSC. C. The graph is 
representing the data obtained from qRT-PCR and showing fold change in MUC4 
expression in scr and MUC4 kd PaSC cells. D. Scr and MUC4 kd PaSC were cultured 
alone or in the presence of CD18/HPAF derived conditioned media (tumor conditioned 
media or TCM). Here, bar graph is showing the effect of MUC4 silencing on the 
expression of α-SMA at transcriptional level. Supportively, MUC4 kd led to significant 
decline in α-SMA mRNA expression in both TCM treated and untreated PaSC cells, 
compared to respective scr control cells. E.  IB showing the effect of MUC4 silencing on 
the protein expression for α-SMA and GFAP in PaSC cells. F. To induce quiescence, 
PaSC were treated with RA (500 nM) which led to significant reduction in MUC4 
expression as shown by immunofluorescence staining. G. Inhibition of MUC4 expression 
was further noticed at transcriptional level in RA treated and untreated PaSC cells.  
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Figure 6.3. MUC4 kd PaSC exhibits negative effects on their proliferative and 
migratory potential.  A. Growth kinetic experiment was performed for indicated time-
points in MUC4 scr and kd PaSC cells, which showed significant reduced cell number at 
day 6 in both MUC4 kd PaSC than scr cells.  B. The bar graph is showing the results 
obtained from anchorage dependent assay which was performed on MUC4 kd and scr 
PaSC cells. C. IB results showing the effect of MUC4 suppression in PaSC on the 
protein expression of EGFR, pEGFR, Akt, pAkt, ERK, pERK and cyclin D1. Reduced 
EGFR and cyclinD1 expression in MUC4 kd PaSC than control cells, signifying that 
aberrant expression of MUC4 does influence the proliferation of PaSC cells. D. Images 
showing the results obtained from Boyden chamber assay, which was performed to 
analyze the effect of MUC4 kd on the motility of PaSC cells. E. IF images showing the 
impact of MUC4 silencing on the intensity and arrangement of α-Tubulin of PaSC cells. 
F. IB showing the impact of MUC4 kd on the protein expression of N-cadherin and 
vimentin molecules. G. The bar graph is showing the influence of MUC4 suppression on 
the mRNA expression of twist, vimentin, cyclinD1, EGFR and MUC4.  
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Figure 6.4. Identification of MUC4 promoter in PaSC cells, PC cell lines and PC 
tissues.  A. 2% Agarose gel was ran to detect the PCR product amplified using RT-PCR 
technique, which was performed to screen PaSC from exon-1 to exon-26 of MUC4 gene. 
B. Promoter V2 software was used to identify the presence of highly likely prediction 
sites for MUC4 promoter on intron-1.  C. Agarose gel showing the expression of 
classical promoter (detected by using 5’UTR+Ex-2) and AP (Intron-1+ex-2) in MUC4 
expressing and non-expressing PC cell lines. D. Quantitative RT-PCR was done to 
measure the levels of both ALP and CLP in PC cell lines.  
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Figure 6.5. Altered MUC4 localization in PaSC and PC cells. Confocal images 
obtained the difference in the localization of MUC4 protein in PaSC and CD18/HPAF 
cells. Here, β-catenin is used as a plasma membrane marker, EEA-1 is used as a 
marker of early endosomes, Lamp1 is used as a marker for lysosomes, calnexin is an 
ER marker and Giantin is a Golgi marker.  
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A. Summary/Conclusions 
 
Aberrant overexpression of various members of the mucin family of proteins (i.e., 
MUC1, MUC4, MUC16, and MUC5AC) is one of the hallmarks of PC. It starts 
appearing in precursor lesions (i.e., pancreatic intraepithelial neoplasia [PanIN]) 
and increases with severity of disease. There are multiple studies which has 
associated the functional significance of mucins in PC pathobiology, and 
recognized their usefulness as diagnostic and therapeutic targets. In terms of 
their regulation, mucin expression is known to be controlled by inflammatory 
cytokines, including TGF-β, interferon-γ (IFN-γ), interleukins, and tumor necrosis 
factor-α (TNF-α) (1-3). MUC4 is one of the most differentially overexpressed 
mucins associated with oncogenic transformation in PC (4-8). It functionally 
contributes to enhanced motility, invasiveness, metastasis, and drug resistance 
of PC cells (9, 10). Earlier, our studies have demonstrated that IFN-γ, an 
inflammatory cytokine, and all-trans retinoic acid (RA) synergistically upregulate 
MUC4 in PC cells (11). The cellular complexity of the PC stoma leads to hypoxia 
due to huge desmoplastic reactions (12, 13). Moreover, as the size of tumor 
grows, metabolic activities expedite which cause increased generation of ROS, 
which prompted us to speculate that microenvironmental stress also has role in 
MUC4 regulation in PC. In this dissertation, I have examined the role of 
microenvironmental stress and bile acids on MUC4 expression. Moreover, I have 
also highlighted the novel mechanism by which MUC4 regulates the expression 
of EGFR family members. Further, I have discussed one of the most intriguing 
finding that MUC4 is expressed by PaSC, where its transcription is facilitated by 
an alternate promoter, which is locate on intron-1 of MUC4 gene. The detailed 
summary of all these observations is as follows 
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a. The role of PC micro-environmental stress on MUC4 regulation: 
Pancreatic cancer (PC) has been reported to be most hypoxic among solid 
tumors, primarily due to its hypovascular nature and extreme desmoplastic 
reactions (14). Emerging evidence demonstrates that HIF1α regulates MUC1 
expression under hypoxia in PC. It enhances hypoxia driven angiogenesis and 
tumor cells survival by regulating the metabolic programming of PC cells. Our 
group has demonstrated that MUC4, which remains undetectable in the normal 
pancreas, is aberrantly overexpressed in the precursor lesions and progressively 
increase with the severity of PC. In this study, for the first time, I have 
demonstrated that under hypoxia, the stability of MUC4 protein is significantly 
affected in PC, in a HIF-1α independent manner. Further, I have demonstrated 
that hypoxia-mediated induction of reactive oxygen species (ROS), promotes 
autophagy by inhibiting pAkt/mTORC1 pathway, one of the central regulators of 
autophagy, leading to MUC4 degradation. Due to established functional 
redundancy in mucins, hypoxia-mediated induction of MUC1 may be sufficient to 
functionally compensate for autophagic degradation of MUC4. Altogether, 
hypoxia-mediated degradation of MUC4 provides necessary metabolites to 
ensure the survival of highly stressed PC cells. 
b. The pathobiological implications of BA in PC: The pancreatic duct is 
placed in close proximity to the common bile duct, and they both unite at the 
point called as the ampulla of Vater. Approximately, 70% of PC patients develop 
extrahepatic cholestasis due to obstruction of common bile duct by gradually 
increasing tumor size, and exhibits obstructive jaundice which is characterized by 
increased circulatory BA levels. Moreover, most of the pancreatic tumors (about 
75%) occur at the head of the pancreas. The tumor-promoting functions of BA 
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are established for multiple cancers such as esophageal, gastric and colorectal 
cancers, which made me inquisitive to comprehend whether BA play tumorigenic 
role in PC development and progression. Interestingly, I observed high 
circulatory BA levels (p<0.05) and its receptor expression, namely FXR, in PC 
patients compared to controls. Moreover, significantly high levels of BA in 
pancreatic juice obtained from PC patients than non-pancreatic non-healthy 
(NPNH) controls, suggest that there is a direct involvement of BA in the 
pathobiology of PC disease. Using defined spontaneous mouse model of PC 
(KPC), BA levels has shown to progressively increase with the severity of PC, 
which supported our postulation that BA do have tumor-promoting functions. 
Mechanistically, I have demonstrated that BA exposure led to induced mRNA 
expression of MUC4, which is primarily dependent on FAK-mediated induced 
expression of c-Jun. Using quantitative ChIP assay, I have shown that c-Jun 
binds to the AP-1 motifs present on MUC4 distal promoter region, a maximal 
responsive region for BA. This is the first study which has shown the direct 
involvement of c-Jun in MUC4 regulation. Further studies established FXR as the 
upstream molecule in this FAK/c-Jun/MUC4 axis. Therefore, targeting BA 
receptors or administration of BA antagonists can significantly impact the disease 
outcome.  
c. MUC4 potentiates EGF-mediated signaling by regulating receptor 
trafficking in PC: Multiple studies have linked aberrant overexpression of MUC4 
in cancer condition with the increased stability of HER2 over the cell surface, 
which facilitates sustained proliferation (15-17), one of the hallmarks of cancers; 
however, no studies have so far highlighted the implicated mechanism. In this 
study, I have highlighted the novel role of oncogenic MUC4 protein in 
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determining the fate of RTKs internalization, particularly EGFR. In PC tissues, 
calculated Pearson colocalization coefficient led me to know that ~60% of 
patients have both MUC4 and EGFR expression. By utilizing time-lapse live-cell 
imaging and confocal microscopy, it became apparent that presence of MUC4 
increases the rate of internalization and recycling of EGFR and HER2 receptors 
to the plasma membrane compared to MUC4 kd PC cells. Mechanistically, the 
altered rate of EGFR and HER2 receptors in MUC4 kd cells was associated with 
the role of MUC4 in regulating the activity of Rab5A, one of the member of Rab 
GTPase family, which is known to catalyze the rate-limiting step of receptor 
internalization. Overexpression of Rab5A in MUC4 kd PC cells was able to 
attenuate the loss of EGFR and HER2 receptors, suggesting that MUC4 utilizes 
the common mechanism to regulate their fate. Besides Rab5A, we have also 
demonstrated that MUC4 regulates the expression of EGFR ligands such as, 
TGF-α and EGF. Altogether, we have found that MUC4 has multifaceted role in 
the regulation of the EGFR family receptors in PC. Considering the importance of 
RTKs in PC, deeper understanding of its prolonged presence as well as 
activation onto the cell membrane due to MUC4 overexpression, will give us 
better opportunity to therapeutically target PC. 
d. Discovery of MUC4 mucin in activated pancreatic stellate cells (PaSC): 
While studying the role of PC tumor microenvironment in the regulation of MUC4, 
I obtained one of the most intriguing findings, which was the presence of MUC4 
in PaSC cells (immortalized with E6/E7), whereas other mucins (MUC1 and 
MUC16) were absent. This was an unexpected finding given that MUC4 is 
normally expressed in the epithelial cells. Using confocal microscopy, these 
results have further confirmed the presence of MUC4 expression in α-SMA 
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(representing active PaSC) positive cells in PC tissue sections. Unlike PC cell 
lines, treatment with RA, which has well-established role in inducing PaSC 
quiescence, leads to reduced transcriptional expression of MUC4 in PaSC. It 
directed us to postulate that MUC4 expression determines the activation status of 
PaSC, which we have addressed by silencing MUC4 expression in PaSC by 
using targeted ShRNA constructs. Suppression of MUC4 expression leads to 
significant reduction (p>0.05) in α-SMA, vimentin and EGFR expression. 
Functionally, significant decline in the proliferative and migratory potential was 
observed in MUC4 kd PaSC cells, compared to the control cells. Altogether, 
these results indicate towards the involvement of MUC4 expression in 
determining the activation status of PaSC. This study has given us an additional 
strong rationale to therapeutically target MUC4, as it will not only kill PC cells, but 
will also inhibit the activation of PaSC cells, which has prominent role in PC 
desmoplasia.  
e. Identification of Alternate promoter for MUC4 gene: MUC4 gene contains a 
GC-rich and TATA-less proximal regulatory region and a distal regulatory region 
flanked by a TATA box (18, 19). In addition to these promoters, I have identified 
a putative alternate promoter (AP), which is located on the intron-1 region of 
MUC4 gene. The size of MUC4 protein in PaSC was significantly smaller than 
PC cell lines, which was indicating a plausible deletion of exon. Screening of 
MUC4 cDNA from exon-1 to exon-26 using RT-PCR revealed that MUC4 in 
PaSC cells does not utilize CP and has deletion of exon-1 which encodes for the 
leader sequence of MUC4. Using promoter prediction V2 software, two highly 
likely predicted promoter sites on intron-1 (primarily at the end) were recognized. 
Certainly, I observed amplified expected PCR product in PaSC using forward 
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primer against intron-1 and reverse primer against exon-2, and further confirmed 
using sequencing. Further, I found that this identified AP is being used by MUC4-
expressing PC cells as well. Supportively, in silico analysis has revealed that 
there is a presence of open reading frame at the beginning of exon-2, from where 
active translation could take place. Along with aberrant expression, accumulating 
evidence has associated altered subcellular localization of mucins with the poor 
prognosis and survival of cancer patients. Loss of leader sequence in MUC4 due 
to AP usage leads to significant change in MUC4 subcellular localization in PaSC 
compared to CD18/HPAF PC cell line (which primarily utilize MUC4 CP). This 
study has paved the way to initiate investigations which will provide us in-depth 
understanding of MUC4 both at the cellular and molecular levels. 
B. Future directions 
a. The role of PC micro-environmental stress on MUC4 regulation 
Similar to cytokines, functional redundancy also exists among mucins, implying 
that hypoxia-mediated induction of MUC1 expression may be sufficient to 
compensate for MUC4 downregulation. We would like to experimentally 
authenticate our assumption by using MUC1 kd CD18/HPAF and CAPAN1 cell 
lines. Being the least molecular weight, it seems logical that nutrient-deprived, 
hypoxic and oxidatively stressed PC cells are inducing MUC1 (~250 kDa) 
expression, while simultaneously facilitating the degradation of high molecular 
weight MUC4 protein to save cellular energy expenditure. It would be interesting 
to study the impact of hypoxia on the expression and stability of other high 
molecular weight mucins, such as MUC16 and MUC5AC in PC condition.  As 
shown in chapter 3, presence of MUC4 provides survival benefits to cancers cells 
residing in highly stress conditions and led us to hypothesize that MUC4 
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degradation in hypoxia may be critical for the viability of PC cells by reducing 
energy consumption, which is an urgent need for the survival of hypoxic cells. To 
directly relate MUC4 with the metabolism of stressed PC cells, we would like to 
do the quantitative measurement of metabolites in MUC4 kd and control PC cells 
with or without hypoxia treatment. Moreover, we have seen that HIF-1α and 
MUC4 has direct relationship both in vitro and in vivo system. One of the possible 
mechanisms could be EGFR downregulation upon HIF-1α inhibition, as recent 
study from our lab has shown that inhibition of EGFR leads to MUC4 
downregulation in PC cells, and need to be investigated. 
b. The pathobiological implications of BA in PC 
In this project, we have associated BA-induced MUC4 expression with FXR 
expression, which is found to be overexpressed in 47% of PC patients. However, 
another BA receptor, TGR5 was upregulated in 67% of PC patients and 
emerging studies have shown its tumorigenic role in GI cancers, including PC. 
Further studies will be helpful and required to mechanistically delineate the 
association between TGR5 and PC disease condition. We would also like to 
study whether TGR5 is involved in mucins regulation. As mentioned earlier, PC 
also has aberrant expression for MUC1, MUC5AC and MUC16; we would like to 
see the impact of BA exposure on these mucins. BA levels have been found to 
be elevated in chronic pancreatitis condition, one of the known risk factor for PC 
development. As mentioned earlier, mucins overexpression appears early and 
increases with the progression of PC. Although in my dissertation research, I 
have primarily focused on the role of BA at the late stages of PC when most of 
the patients exhibit obstructive jaundice, it will be important to study the 
implications of the BA at the initial stages of PC. To get the better insight of BA 
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on the pathobiology of PC, bile duct ligation or cholecystectomy using 
autochthonous murine models could be extremely important to reveal its 
importance at the initial and later stages of pancreatic tumor. Moreover, the 
significantly induced levels of BA indicates their possible usefulness for 
diagnostic purposes, and needs to be validated in more number of patient 
samples to assess and establish its clinical utility. In addition to FAK pathway, 
inhibition of MAPK pathway also led to attenuation of BA-mediated MUC4 
upregulation. Future studies will be focused to understand the in-depth 
involvement of different signaling pathways in MUC4 regulation after BA 
treatment. 
c. MUC4 potentiates EGF-mediated signaling by regulating receptor 
trafficking in PC 
In this project (chapter 5), we have shown that MUC4 is plausibly regulating the 
expression of TGF-α at transcriptional level. TGF-α has known function to direct 
EGFR towards recycling route. Therefore, by delineating the mechanism involved 
in MUC4-mediated regulation of TGF-α ligand, we would be able to explain the 
observed involvement of MUC4 in increased EGFR receptor recycling to the 
plasma membrane. Because we did not see an apparent interaction of MUC4-CD 
either with EGFR or HER2, we believe that the observed interaction between 
these receptors and MUC4 is primarily occurring at the MUC4 N-terminus. We 
would like to study this in-depth using MUC4 N-ter. We already have MiniMUC4 
construct which consists 10% of VNTR of WT-MUC4, from which MUC4 C-ter 
can be detached using restriction enzymes. The remaining MUC4 N-ter could be 
used to do pull down experiments to confirm that this site is mainly interacting 
with EGFR and HER2 proteins. Although recent studies have shown the success 
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of erlotinib therapy in PC, treatment of PC patients with this drug did not lead to 
anticipated improvement on the clinical outcome of PC patients. Interestingly, in 
breast cancer, MUC4 overexpression has been considered as one of the reasons 
for Herceptin failure, which further provide more strength to our rationale to 
address this question. Therefore, our next objective would be to analyze whether 
presence of MUC4 influences the sensitivity and efficacy of EGFR-targeting 
therapies.  
d. Discovery of MUC4 mucin in activated pancreatic stellate cells (PaSC) 
In this research project (chapter-6), I have clearly shown that presence of MUC4 
in PaSC affects its activation status, migration and proliferation. However, how 
does control and MUC4 kd PaSC affect the migration and proliferation of PC 
cells is still need to be explored. For that, we would take the help of 3D co-culture 
technique. Moreover, PaSC are considered to be partner-in-crime with PC cells 
and increase the incidence of both regional and distant metastasis of PC cells. 
Therefore, we would like to address whether expression of MUC4 in PaSC is 
responsible for increasing the metastatic potential of PC cells? Orthotopic 
implantation of the combination of PC cells with MUC4 scr or kd PaSC cells 
would be extremely helpful to delineate the functional importance of MUC4 
expression on PaSC in PC development and progression.  
 Because we have observed that MUC4 cDNA in PaSC have all the exons 
present, except extremely short exon-1. Therefore, the observed difference in the 
molecular weight of MUC4 protein between PaSC and PC cell lines is plausibly 
due to other reasons. One of the most likely reasons could be the presence of 
allelic VNTR polymorphism in MUC4 gene in these cell lines, which also cause 
large variations in the size of MUC4 protein among PC cell lines (20). 
277 
 
Importantly, most of the conducted experiments involve only one PaSC, which is 
one of the biggest limitations of this study. Therefore, we would like to confirm 
MUC4 expression with additional PaSC cell lines, where UNMC rapid autopsy 
program could be of great help. We will obtain PaSC and PC cells from the same 
PC patients and analyze MUC4 expression both at genomic and protein levels. 
e. Identification of Alternate promoter for MUC4 gene 
The identification of alternate promoter of MUC4 gene in PC cell lines, PaSC and 
human PC tissues is primarily done by using RT-PCR technique followed by 
sequencing. Although we have considered all the precautions required to negate 
the possibility of DNA contamination, we will further evidence the presence of AP 
using more confirmatory techniques, such as 5’ rapid amplification of cDNA ends 
(RACE). Moreover, as mentioned earlier, we detected the presence of AP only 
on cDNA derived from PC tissues, whereas tumor adjacent tissues did not 
demonstrate the presence of AP. We correlated the usage of MUC4 AP with the 
aggressiveness of PC cancer, which needs to be studied in details. Additional 
studies focused to delineate the regulation of MUC4 AP would be advantageous 
to understand when and why MUC4 AP usage is preferred over MUC4 CP. For 
that, we would like to perform in silico analysis on MUC4 AP which will highlight 
the putative sites for the binding of transcription factors. Construction of 
luciferase promoter constructs against AP segment will further help us to confirm 
the influence of revealed transcription factors. 
  
278 
 
Reference List 
 (1)  Borchers MT, Carty MP, Leikauf GD. Regulation of human airway mucins by 
acrolein and inflammatory mediators. Am J Physiol 1999;276:L549-L555. 
 (2)  Koo JS, Kim YD, Jetten AM, Belloni P, Nettesheim P. Overexpression of mucin 
genes induced by interleukin-1 beta, tumor necrosis factor-alpha, 
lipopolysaccharide, and neutrophil elastase is inhibited by a retinoic acid receptor 
alpha antagonist. Exp Lung Res 2002;28:315-32. 
 (3)  Li X, Wang L, Nunes DP, Troxler RF, Offner GD. Pro-inflammatory cytokines up-
regulate MUC1 gene expression in oral epithelial cells. J Dent Res 2003;82:883-
7. 
 (4)  Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth 
MA, Buchler MW, Aubert JP, Batra SK. Mucin (MUC) gene expression in human 
pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as 
a tumor marker of diagnostic significance. Clin Cancer Res 2001;7:4033-40. 
 (5)  Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, 
Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH. 
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive 
characterization and comparison of the transcription profiles obtained from three 
major technologies. Cancer Res 2003;63:8614-22. 
 (6)  Joshi S, Kumar S, Choudhury A, Ponnusamy MP, Batra SK. Altered Mucins 
(MUC) trafficking in benign and malignant conditions. Oncotarget 2014;5:7272-
84. 
 (7)  Joshi S, Kumar S, Bafna S, Rachagani S, Wagner KU, Jain M, Batra SK. 
Genetically engineered mucin mouse models for inflammation and cancer. 
Cancer Metastasis Rev 2015. 
279 
 
 (8)  Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer 
and its microenvironment. Nat Rev Gastroenterol Hepatol 2013;10:607-20. 
 (9)  Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, Batra 
SK. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and 
invasive properties and interferes with its interaction to extracellular matrix 
proteins. Mol Cancer Res 2007;5:309-20. 
 (10)  Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 
mucin. FASEB J 2008;22:966-81. 
 (11)  Andrianifahanana M, Agrawal A, Singh AP, Moniaux N, Van S, I, Aubert JP, 
Meza J, Batra SK. Synergistic induction of the MUC4 mucin gene by interferon-
gamma and retinoic acid in human pancreatic tumour cells involves a 
reprogramming of signalling pathways. Oncogene 2005;24:6143-54. 
 (12)  Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ, 
Vierra M. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol 
Phys 2000;48:919-22. 
 (13)  Omary MB, Lugea A, Lowe AW, Pandol SJ. The pancreatic stellate cell: a star on 
the rise in pancreatic diseases. J Clin Invest 2007;117:50-9. 
 (14)  Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, 
Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, 
Combs C, Winter SP, et al. Inhibition of Hedgehog signaling enhances delivery of 
chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-
61. 
 (15)  Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh 
PK, Hollingsworth MA, Mehta PP, Batra SK. MUC4 mucin interacts with and 
280 
 
stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res 
2008;68:2065-70. 
 (16)  Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of 
ErbB1 receptor trafficking. Oncogene 2007;26:1693-701. 
 (17)  Ponnusamy MP, Singh AP, Jain M, Chakraborty S, Moniaux N, Batra SK. MUC4 
activates HER2 signalling and enhances the motility of human ovarian cancer 
cells. Br J Cancer 2008;99:520-6. 
 (18)  Van S, I, Pigny P, Perrais M, Porchet N, Aubert JP. Transcriptional regulation of 
the 11p15 mucin genes. Towards new biological tools in human therapy, in 
inflammatory diseases and cancer? Front Biosci 2001;6:D1216-D1234. 
 (19)  Perrais M, Pigny P, Ducourouble MP, Petitprez D, Porchet N, Aubert JP, Van S, 
I. Characterization of human mucin gene MUC4 promoter: importance of growth 
factors and proinflammatory cytokines for its regulation in pancreatic cancer 
cells. J Biol Chem 2001;276:30923-33. 
 (20)  Choudhury A, Moniaux N, Winpenny JP, Hollingsworth MA, Aubert JP, Batra SK. 
Human MUC4 mucin cDNA and its variants in pancreatic carcinoma. J Biochem 
2000;128:233-43. 
 
 
80 
 
General Hypothesis and Objectives 
 
Over the past few decades, multiple studies have established key roles of mucins in 
malignant diseases. The expression of mucins is significantly altered during 
tumorigenesis and other pathological conditions. In this dissertation, I have primarily 
focused on MUC4, which is one of the most differentially expressed proteins in PC and 
has strongly been implicated in the progression, metastasis and chemoresistance of PC. 
MUC4 is not expressed in the normal pancreas, but the early pancreatic intraepithelial 
neoplasia (PanINs) precursor lesions have been shown to express MUC4, which further 
increases as the disease progresses. The ability of NIH3T3 fibroblasts cells to form 
tumors in nude mice upon ectopic expression of MUC4 was the first evidence which has 
experimentally proved its oncogenic function. Considering the significant role of MUC4 in 
tumor biology, additional studies are required to highlight its novel functions and 
regulatory mechanisms. Although studies have associated extrinsic (cytokines) and 
intrinsic factors (NCOA3) with the regulation of MUC4, there is no study which has 
addressed the role of PC microenvironmental stress (hypoxia and oxidative stress) on 
MUC4 expression. Both Hypoxia and MUC4 has been associated with PC 
aggressiveness and chemoresistance. Moreover, hypoxia has been shown to regulate 
mucins expression in solid tumors. All these studied led me to hypothesize that hypoxia 
has a significant impact on MUC4 expression in PC, which aggravate the PC conditions. 
Besides PC microenvironment, the critical anatomical position of pancreas can influence 
the growth of pancreatic tumors. However, these mechanisms are unexplored. The 
majority of tumors (about 75%) arise at the head of the pancreas. Most of the PC 
patients develop extrahepatic cholestasis due to common bile duct obstruction by 
increasing tumor size which results in hyperbilirubinemia and elevated circulatory levels 
of bile acids (BA). Multiple studies have implicated BA as tumor promoter for various 
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cancers. A recently performed meta-analysis has shown that patients with the history of 
cholecystectomy have significantly higher risk to develop PDAC. These studies incited 
me to hypothesize that BA play important role in PC tumorigenesis by regulating the 
expression MUC4 oncogene.  
In addition to regulation, I have also focused to elucidate the novel functional 
properties of MUC4 in PC. MUC4 is known to regulate the fate of EGFR family proteins 
in several cancers including PC. However the precise mechanism involved is still 
ascertain. Emerging reports have shown altered expression of RAB proteins in various 
cancers. Additionally, a recent study has shown that mucins can also regulate the 
expression of RABs to influence the trafficking of oncogenic proteins in cancer. It 
brought me to my next hypothesis that MUC4 determines the fate of EGFR family 
members by modulating the expression and activity of RAB GTPases in PC. In addition 
to PC cells, MUC4 expression has recently been detected in activated PaSC. 
Interestingly, our preliminary studies have shown reduction of MUC4 expression upon 
treatment with RA, which is known to change the status of activated PaSC to quiescent, 
suggesting a plausible link between MUC4 expression and activation status of PaSC. It 
led me to hypothesize that MUC4 regulates the activation status of PaSC and thereby, 
promotes desmoplastic reactions in PC microenvironment, which is known to exacerbate 
PC condition. 
Broadly, the aims for my dissertation research were as follows: 
1. To elucidate the role of microenvironment stress (hypoxia and oxidative stress) on 
MUC4 regulation in PC. 
2. To investigate the impact of bile acids (BA) on MUC4 expression in PC. 
3. To identify the novel functions of MUC4 in epithelial (ductal tumor) and nonepithelial 
(PaSC) cells under PC condition. 
